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ABSTRACT

Thangamani, Shankar. Ph.D., Purdue University, December 2016. Repurposing NonAntimicrobial Drugs to Treat Multi-Drug Resistant Bacterial and Fungal Infections.
Major Professors: Mohamed. N. Seleem and Kenitra Hammac.

Bacterial and fungal resistance to conventional antimicrobials is a burgeoning global
health epidemic that necessitates urgent action. Even more alarming, the development of
new antimicrobials to treat these multidrug-resistant pathogens has not kept pace with the
rapid emergence of resistance to current antimicrobials. Antimicrobial drug development
through the traditional de novo process is a risky venture given the significant financial and
time investment required by researchers and limited success rate of translating these
compounds to the clinical setting. This has led researchers to mine existing libraries of
clinical molecules in order to repurpose old drugs for new applications (as antimicrobials).
The main aim of this research endeavor was to screen and validate approved drug libraries
and small molecules for their antimicrobial activity against multidrug-resistant bacterial
and fungal pathogens, including Staphylococcus aureus and Candida albicans.
The present study identified four approved drugs (auranofin, ebselen, simvastatin and
celecoxib) that exhibited potent antimicrobial activity against multidrug-resistant bacterial
and fungal pathogens. Notably, auranofin, an FDA-approved anti-rheumatic drug
possessed excellent antibacterial activity against S. aureus and was found to exert its effect

xiv
by inhibiting multiple biosynthetic pathways including DNA, protein and cell wall
synthesis. Furthermore, auranofin was found to be efficacious in a mouse model of S.
aureus systemic infection, as it significantly reduced the bacterial load in murine organs,
including the spleen and liver. Ebselen, an organoselenium compound known to be
clinically safe, exhibited potent anti-staphylococcal activity by inhibiting bacterial protein
synthesis. Other approved drugs including simvastatin (anti-hyperlipedmic drug) and
celecoxib (non-steroidal anti-inflammatory drug) also possessed anti-staphylococcal
activity against various clinical isolates of S. aureus. Our study also revealed that three
drugs (auranofin, ebselen and simvastatin) markedly reduced the production of major
staphylococcal toxins including Panton-Valentine leucocidin (PVL) and α-hemolysin (Hla),
thereby improving the treatment outcome against toxin-producing bacterial pathogens.
Furthermore, all these drugs effectively reduced both the bacterial load and inflammatory
cytokines in a mouse model of S. aureus skin infection.
In addition to their antibacterial activity, auranofin and ebselen were found to possess
potent antifungal activity against two major pathogens, Candida and Cryptococcus; they
exerted their antifungal effect through inhibition of mitochondrial proteins (auranofin) and
glutathione synthesis (ebselen) respectively. Additionally, these two drugs proved superior
to control antifungals, as they reduced the fungal load in a Caenorhabditis elegans animal
model. Taken altogether, the potent in vitro and in vivo antimicrobial activity (against
bacterial and (or) fungal pathogens) of auranofin, ebselen, simvastatin and celecoxib
indicates these four drugs have considerable promise to be successfully repurposed for use
as antimicrobial agents.

1

CHAPTER 1. DRUG REPURPOSING FOR THE DEVELOPMENT OF NOVEL
ANTIMICROBIALS

(Thangamani S, Mohammad H, Younis W, Seleem MN. Drug repurposing for the
treatment of staphylococcal infections. Current Pharmaceutical Design. 2015;21(16):
2089-100)

1.1

Introduction

Bacterial and fungal resistance to conventional antimicrobials is a burgeoning
global health epidemic that necessitates urgent action. Reports by the Centers for Disease
Control and Prevention in the United States and the European Centre for Disease Control
and Prevention indicate more than two million individuals in the United States and nearly
400,000 individuals in Europe are stricken each year with infections caused by multidrugresistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA),
carbapenem-resistant Klebsiella pneumoniae, vancomycin-resistant Enterococcus faecium
and fluconazole-resistant Candida

1,2

. Treatment of these infections are often expensive

costing residents an estimated $55 billion in the United States and €1.5 billion in the
European Union in total costs every year 1,2. Furthermore, the issue of bacterial and fungal
resistance to antimicrobials around the world appears to be getting worse with the
emergence of pathogens exhibiting resistance to agents of last resort 3-5. Even more
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alarming, the development and approval of new antimicrobials capable of being used to
treat infections caused by multidrug-resistant pathogens has not been able to keep pace
with the rapid emergence of bacterial and fungal resistance to currently efficacious
antimicrobials. Drug development of novel compounds is a time-consuming, costly, and
high-risk venture given that few compounds successfully make it through stringent
regulatory requirements to reach the marketplace. Collectively, this points to a critical need
for the identification of novel strategies to develop antibiotics to deal with this challenging
health issue. One strategy which warrants more attention as a unique method for identifying
new antimicrobials is drug repurposing.
Drug repurposing, is a clever strategy to identify new applications (“off” targets) for
drugs approved for other clinical diseases 6. This strategy has been successful employed to
unearth new potential treatment options for different diseases including cancer,
amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and malaria 7. On average, 2030 new drugs receive FDA-approval each year; of these, 30% are repurposed agents

8,9

.

Thus this points to repurposing being a quicker strategy to stock the drug discovery
pipeline, particularly for antibiotics and antifungals, compared to the traditional process of
de novo synthesis of new compounds which can cost pharmaceutical companies $800
million to upwards of $1 billion in research and development expenditures and require 1017 years to attain regulatory approval

10,11

. Repurposing existing approved drugs permits

companies to bypass much of the preclinical work and early stage clinical trials required
for new compounds (particularly toxicological and pharmacological analysis of drugs) thus
cutting into the cost (by nearly 40%) associated with bringing a drug to the marketplace 10.

3
In addition to lower drug discovery-associated costs, repurposing approved drugs
(particularly for identification of new antimicrobials) has several additional benefits. Given
these drugs have already been tested in human patients, valuable information pertaining to
pharmacokinetic and pharmacodynamics parameters are known 7. This permits a better
understanding of the overall pharmacology of the drug, potential routes of administration
(i.e. systemic versus local applications), and establishing an appropriate dosing regimen
for patients. Moreover, as the toxicity profile of these drugs in humans has been extensively
studied, valuable information has already been obtained regarding potential adverse side
effects present with using the drug at certain therapeutic doses. This information is
important as it pertains to antimicrobials as the concentration where toxicity is observed
with host tissues can be correlated with the minimum inhibitory concentration (MIC)
values obtained in standard bacterial susceptibility assays to determine if drugs are viable
candidates for repurposing as antimicrobials.
Interestingly, several antibiotics have been repurposed for other clinical
indications. For example, the third-generation cephalosporin, ceftriaxone, was initially
approved for use in treating bacterial infections, including community-acquired pneumonia
and meningitis 12-14. In bacteria, it interacts with penicillin-binding protein 2 to inhibit cell
wall synthesis

15

. Surprisingly, when tested in a neurodegenerative mice model of ALS,

ceftriaxone was found to reduce the loss of neurons and muscle strength by increasing
expression of glutamate transporter GLT1 thus decreasing the concentration of the toxic
neurochemical glutamate present near motor neurons

16

. This provided hope that this

antibiotic could be repurposed as a novel treatment option for patients suffering from ALS.
Unfortunately, a phase III clinical trial testing ceftriaxone in ALS patients was stopped
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after it was suspected that the drug would not be able to help slow down progression of the
disease or increase the rate of survival in affected patients

17

. A recent study found that

ceftriaxone also possesses antitumor activity and may be an alternative chemotherapeutic
agent for use in lung cancer patients 6. In addition to ceftriaxone, the tetracycline antibiotic,
minocycline, has been shown to slow down the emergence of ALS in mice and enhance
patient survival in an ALS mouse model 18. Another antibiotic, fosmidomycin, that targets
isoprenoid synthesis in bacterial cells, has been shown to have excellent activity against
the parasite Plasmodium falciparum, thus permitting investigation for use as a treatment
for malaria 19. Its mode of action in the malaria parasite involves inhibition of a key enzyme
(1-deoxy-D-xylulose 5-phosphate reductoisomerase) in the non-mevalonate pathway

20

.

Clinical trials performed with fosmidomycin in combination with a second antibiotic
(clindamycin) in malaria-stricken patients have obtained promising results thus far, further
supporting the repackaging of fosmidomycin for use as a new treatment option against
malaria

20,21

. Furthermore, the antibiotic rapamycin (also known as sirolimus) was

approved in 1999 by the FDA for use in patients to prevent organ transplant rejection; it
was later found to have potential use in two other diseases - Autoimmune
Lymphoproliferative Syndrome (ALPS) and the lung disease, lymphangioleiomyomatosis
22-24

.
Though antibiotics have entered clinical trials to be repurposed for other clinical

indications, to date, not a single drug has been successfully repurposed for use as an
antibiotic, particularly for hard-to-treat infections caused by bacteria such as S. aureus. As
stated earlier, there are several approved drugs for different ailments that have been
successfully repurposed as anti-infective agents especially to treat parasitic and protozoal
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diseases (Table 1.1). Hence, given the significant problem posed by pathogenic bacteria
and fungi, more effort and attention needs to be focused on using drug repurposing as a
tool to uncover new treatment options for infections especially caused by multi-drug
resistant pathogens, such as S. aureus. The present review will delve into approved drugs
which have demonstrated promise to be repurposed as agents for S. aureus infections,
discuss alternative applications for drugs possessing antimicrobial activity, and address
current limitations to expedite the discovery and development of approved drugs to be
repurposed for use as antibiotics.

Table 1.1 List of drugs which have been repurposed as anti-infective agents
Drugs
Auranofin
Miltefosine
Amphotericin B
Dapsone
Eflornithine
Doxycycline
Paromomycin

Initial use
Antirheumatic agent
Skin metastases (breast cancer)
Antifungal
Pulmonary tuberculosis
Antitumour agent/P. carinii
infection in AIDS patients
Antibacterial
Antibiotic

Spiramycin
Chloroquine

Antibacterial
Malaria

Atovaquone

Malaria

Repurposed use
Amoebiosis
Vischeral leishmaniasis
Visceral leishmaniasis
Malaria
Human African sleeping
sickness
Malaria
Visceral and cutaneous
leishmaniasis
Toxoplasmosis
Amebiasis and
sarcoidosis
Toxoplasmosis and
P. carinii pneumonia

References
25
26,27
28
29-31
32-36

37
38-40

41
42,43

44-46
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1.2

Approved non-antimicrobial drugs with activity against S. aureus

Several studies have presented approved non-antibiotic drugs that possess
antimicrobial activity, especially against S. aureus, indicating these drugs have potential
alternative use for treatment of staphylococcal infections. However, the major hindrance
for repurposing these drugs pertains to a lack of in vivo studies to confirm these drugs do
possess antibacterial activity in an animal model. The primary criteria for in vivo systemic
studies pertain to the availability of enough free drug in the plasma, when given at the
tolerable dose, to ensure inhibition of bacterial growth. Hence considering the human
plasma concentration of the approved non-antibiotic drugs, hereby we classify the
antimicrobial activity of approved non-antibiotic drugs into two categories (a) drugs with
activity in a clinical range that can be achieved systemically and (b) drugs with activity
that cannot be achieved systemically (Table 1.2).

1.2.1

Drugs with activity in a clinical range that can be achieved systemically

Several of the approved drugs discussed below have antimicrobial activity (denoted
as the minimum inhibitory concentration (MIC) or lowest concentration of drug capable of
inhibiting bacterial growth) several folds lower than the plasma concentration of the drug
in humans. Therefore these particular drugs might be potential candidates to consider for
treatment of systemic staphylococcal infections.

Auranofin
Auranofin, a FDA-approved gold compound has been used for treating rheumatoid
arthritis for almost 30 years

47,48

. However, its exact mechanism of action (MOA) in

7
treating rheumatoid arthritis still remains unclear 49,50. Interestingly, independent of its antirheumatoid action, auranofin has also been shown to have anti-parasitic effects. For
example, auranofin has been shown to be capable of killing Schistosoma mansoni at a
concentration of 5 μM and is also active against bloodstream and procyclic stages of
Trypanosoma brucei with a half-maximal inhibitory concentration, IC50, of 0.5 µM 51,52. It
also inhibits the growth of the malaria parasite, Plasmodium falciparum, in vitro with an
IC50 value of 142 nM

53-55

. Of particular interest, is the recent discovery of auranofin’s

efficacy in treatment of human amebiasis caused by Entamoeba histolytica. Auranofin
exhibited anti-Entamoeba activity with a half-maximal effective concentration (EC50 =
concentration of drug necessary to reduce the culture density to 50%) of 0.5 μM. The EC50
for E. histolytica was seven-fold lower than the clinically achievable blood concentration
of the drug (3.5 μM). Even though auranofin is rapidly metabolized and 60% is bound to
plasma proteins, it was found to be effective in two animal models of amebic colitis and
amebic liver abscess 25,56. Based on these studies, auranofin was granted orphan-drug status
from the FDA for treatment of human amebiasis in 2012 25.
With regards to auranofin’s antibacterial activity, two recent studies have demonstrated
that auranofin also possesses potent antimicrobial activity against S. aureus
vitro MIC reported for this drug ranges from 0.125 to 0.5 mg/L

57,58

57,58

. The in

. More importantly,

auranofin demonstrated bactericidal activity against several multidrug-resistant of S.
aureus within an achievable clinical drug concentration in humans 25,57,58. Based on these
promising preliminary studies, and its recent approval by the FDA as an anti-amoebic drug,
auranofin might be a potential agent to repurpose for the treatment of systemic and topical
staphylococcal infections. However, future studies are needed to reveal its mechanism of
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action against S. aureus and establish its antibacterial activity in vivo in different animal
models of S. aureus infection.

Ebselen
Ebselen, an organoselenium compound also known as PZ51 or DR3305, has been
widely investigated for its anti-inflammatory, anti-atherosclerotic and antioxidative
properties

59-62

. This particular drug has a well-studied toxicology and pharmacology

profile and is currently undergoing clinical trials as a treatment option for different ailments
including arthritis, cardiovascular disease, stroke, atherosclerosis, and cancer

60,63-66

. In

addition to being used as a treatment for multiple diseases, ebselen has also been shown to
possess potent antimicrobial activity in vitro

67,68

. It has activity against yeast and

Escherichia coli and works by interfering with proton-translocation and inhibiting the
thioredoxin reducatse (TrxR) enzyme respectively

68,69

. Another interesting study has

shown that it has potent antimicrobial activity against S. aureus with a MIC of 0.20 µg/ml
67

. This minimum inhibitory concentration is well within the plasma concentration (4-

6µg/ml) which is attained after1 mg/kg bolus injection combined with 1 mg/kg per hour
intravenous infusion in rats 70. Surprisingly, this drug has not been investigated further as
a treatment option for staphylococcal infections in spite of its excellent antibacterial
activity in antimicrobial susceptibility assays.
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Table 1.2 Approved drugs with activity against S. aureus
Drugs
5-fluoro-2'-deoxyuridine
Auranofin
Ebselen
5-fluorouracil
Mitomycin-C
Mithramycin
Disulfiram
Triflupromazine
Dactinomycin
Oxymetazoline
Daunorubicin
Doxorubicin
Levocabastine
Emadastine
Dicyclomine
Prochlorperazine
Simvastatin
Celecoxib
Tetrahydrozoline
Methotrexate
Tegaserol
Amitriptyline hydrochloride
Azelastine hydrochloride
Mitpranolol
Promethazine
Butorphanole
Diclofenac
Tropicamide
Oxyfedrine
Aminopterin
Fluvastatin
Ketamine
Proxymetacaine
Mequitazine
Cyproheptadine
hydrochloride
Ibuprofen
Acetaminophen

Class/type
antineoplastic
anti-rheumatoid
organoselenium compound
antineoplastic
antineoplastic
antineoplastic
alcohol deterrent
antipsychotic
antineoplastic
Vasoconstrictor(decongestant)
antineoplastic
antineoplastic
antihistamines
antihistamines
antispasmodic
antipsychotic
antihyperlipidemic
NSAIDs
vasoconstrictor (decongestant)
antineoplastic
narcotic and analgesic
antidepressant
antihistaminic
antiarrhythmic, antiglucoma
neuroleptic and antihistaminic
narcotic and analgesic
anti-inflammatory
anticholinergic
vasodilator
antineoplastic
antihyperlipidemic
anesthetic
anesthetic
Antihistaminic
and
anticholinergic
antihistaminic

MICs (µg/ml)
0.0007-0.002*
0.125-0.5*
0.2*
0.5 – 0.8
0.25
0.25
1.33
2-5
4
5
8
16
20
20
25
20-25
29-74
32
50
64 – 102
80
100
125- 250
140
125- 250
180
200
200
200-250
256
400
450
500
625-125

References

625-125

83

NSAIDs
NSAIDs

1250
1250

87

71
57,58
67
72
73
73
74
75
73
76
73
73
76
76
77
78
79
80
81
72
76
82
83
84
83
84
85
84
86
73
76
76
76
83

87

10
Table 1.3 continued
Telmisartan
antihypertensive
Perazine
antipsychotic
Amlodipine
antihypertensive
Docusate sodium
laxative
Etodalac
NSAIDs
Alverine
spasmolytic
Fluvoxamine
thymoleptic
Tolfenamic acid
NSAIDs
Temozolomide
antineoplastic
Acepromazine
antiemetic, sedative
Riluzole
anticonvulsive, antiepileptic
Tamoxifen
anti-neoplastic
Solifenacin succinate
spasmolytic
Perphenazine
antipsychotic
Oxaprozin
NSAIDs
Citalopram
antidepressant
Zofenopril
ACE inhibitor
Sertraline
antidepressant
Chlorpromazine
antipsychotic
Acebutolol
antihypertensive
Clopidogrel
anticoagulant
* MICs below the plasma concentration of the drug in humans

2000
2000
3000
3000
4000
4000
4000
5000
5000
5000
5000
6000
7000
8000
13000
13000
15000
16000
20000
23000
24000

76
88
81
89
76
76
88
76
76
81
88
88
89
81
76
89
88
90
81
81
89

Considering its potent in vitro anti-staphylococcal activity, studies on the antibacterial
MOA of ebselen and evaluating its in vivo activity against S. aureus could be useful for
developing ebselen as an antibacterial agent to treat multidrug-resistant staphylococcal
infections 67,68.

5-Flurouracil, 5-fluoro-2'-deoxyuridine, and mitomycin C
Antimetabolites such as 5-flurouracil, 5-fluoro-2'-deoxyuridine (FdUrd), and
mitomycin C belong to a class of antineoplastic drugs which are used for treatment of
various malignant diseases 91. They primarily act by inhibiting DNA and RNA synthesis
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91

. In addition to their anticancer activity, these three drugs also exhibit potent antimicrobial

activity below the concentration that can be achieved in human plasma 72. For example, 5fluorouracil has been shown to inhibit S. aureus at a concentration ranging from 0.5 – 8.0
µg/mL, in vitro; at this concentration, these drugs fall within the mean plasma
concentrations of 13.4 and 8.3 µg/mL, which is attained after a single intravenous (250 mg)
and oral dose (500 mg), respectively72,92,93.
Similarly, FdUrd, an interchangeable metabolite of 5-fluro uracil is capable of
inhibiting S. aureus growth at a MIC ranging from 0.0007-0.002 µg/ml, which is several
hundred folds lower than the mean plasma concentration of 14.1 + 2.7 µg/ml, which is
attained after a continuous infusion of 1000 mg/m2 per 24 hour dose of 5-flurouracil for 5
days

71,94,95

. In addition, 5-fluoro-2'-deoxyuridine is a pro-drug which needs the

deoxyribonucleoside kinase (dNK) enzyme to exert its action; this enzyme is present in S.
aureus 71,95.
Another anticancer drug, mitomycin C, when given at a dose of 60 mg/m2 in humans
has been shown to have a peak plasma concentration of 1.9 µg/ml. This drug inhibits S.
aureus growth at a MIC of 0.06 - 0.25 µg/ml, which is well within the range capable of
being reached in the plasma

72,93,96

. Hence, considering promising in vitro antibacterial

studies conducted this far, these drugs warrant further evaluation as anti-staphylococcal
drugs. Future studies would need to be conducted to test their in vivo antibacterial efficacy
in different animal models.
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1.2.2

Drugs with activity that cannot be achieved systemically

Most of the approved non-antimicrobial drugs that possess anti-staphylococcal
activity have MIC values that are higher than their plasma concentration; thus, using these
drugs for treatment of systemic infections might not be a viable option. However, they can
be potentially used for topical application for treating staphylococcal skin infections.
Community-associated methicillin-resistant S. aureus (CA-MRSA) strains have become a
significant source of staphylococcal skin infections. In particular, the strain MRSA
USA300 has emerged as one of the most highly prevalent isolates in United States
responsible for skin and soft tissue infections 97,98. Additionally, MRSA colonization in the
skin and mucosa is considered an important risk factor for invasive infections

99

. Thus

repurposing approved drugs, with high MIC values that cannot be achieved systemically,
for use to treat MRSA skin infection and as decolonizing agents is a sensible approach
which warrants further investigation. These drugs can be either used as single agents or can
be combined with conventional antimicrobials to enhance the efficacy and extend the life
span of traditional antimicrobials. Furthermore, several of these drugs have additional
benefits that will permit their use as a topical antimicrobial agent. For example, the drugs
simvastatin and celecoxib have been shown to inhibit the pro-inflammatory cytokines
tumor necrosis factor-α (TNF-α) and IL-6

100,101

. Controlling excess inflammation,

particularly by limiting TNF-α and IL-6 production, in chronic wounds plays a beneficial
role in wound healing 102-107. Additionally, simvastatin has been shown to enhance wound
healing and angiogenesis in diabetic mice 108. Hence, taking into account the antimicrobial
activities of these agents combined with their beneficial properties (such as anti-
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inflammatory properties), further investigation is warranted to test these approved drugs in
topical S. aureus infection animal models.

1.3

Novel uses of approved drugs

For the past few decades, the development of new antimicrobials has slowed down
while the evolution of bacterial resistance has continued to rise; hence, there is an urgent
need to identify alternative strategies to combat infections caused by multidrug-resistant S.
aureus 109-111. Emergent approaches that have drawn great interest recently include drugs
with indirect antimicrobial activity which work by (i) targeting virulence factors and toxins
(anti-virulence agents) 110,112,113, (ii) enhancing host immunity (immunomodulators) 111,114,
and (iii) enhancing entrance of other antimicrobials into target cells by increasing the
permeability of the outer membrane or by inhibiting efflux pumps (helper drugs) 115. These
novel approaches can be combined with traditional antibiotics to enhance the efficacy and
extend the life span of antimicrobial drugs and to minimize the evolution of bacterial
resistance to these agents. Here we provide several examples of FDA-approved nonantimicrobial drugs which do not have direct antimicrobial activity or have very high MIC
in vitro that cannot be achieved clinically; though they cannot be used systemically, they
have potential for use to disrupt bacterial pathogenesis or to modulate a host’s immune
response to combat staphylococcal infections.

1.3.1

Targeting virulence factors and toxins

Targeting staphylococcal virulence factors and toxins is an important strategy to
disarm the pathogen in the host. The basic strategy involves inhibiting the mechanisms that
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play a role in promoting S. aureus invasion, pathogenesis, and persistence

110,113

. Even

though, S. aureus is not killed directly in this strategy, it greatly reduces the ability of
bacteria to colonize the host 110.
Several FDA-approved drugs that do not possess direct antimicrobial activity in
vitro have been shown to inhibit important virulence factors and toxins. For example,
salicylic acid, the major metabolite of aspirin, inhibits the global regulators of virulence
genes in S. aureus such as sarA and agr

116

. Repression of these two genes, at a clinical

achievable dose, leads to the down regulation of various exotoxins and exoenzymes, such
as fibronectin protein binding genes (fnbA and fnbB) and α-hemolysin (hla), which are
responsible for S. aureus adhesion and host tissue cytolysis116,117. This may have the
potential to be used as an adjunctive agent for the treatment of multidrug-resistant S. aureus
infections 116.
Other drugs such as cisplatin and chloroquine are also known to protect infected
hosts from the effects of bacterial toxins. Cisplatin is an anticancer drug that acts primarily
by interacting with DNA to form DNA adducts, thereby leading to the activation of
apoptosis

118

. In addition to this, cisplatin also protects macrophages from anthrax lethal

toxin (LT) by inhibiting LT translocation into cells 119. This protective effect has also been
confirmed in murine models 119. Similarly, chloroquine, a well-known anti-malarial drug,
blocks the entry of anthrax toxins and increases animal survival in anthrax-toxin
challenge.120-122. Future studies are needed to gain more insights into the molecular actions
of these drugs with bacterial toxins. Additionally, it will be worthy to investigate the effect
of these FDA-approved drugs on S. aureus toxin production, toxin interaction with host
cells, and the host immune response.
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1.3.2

Efflux pump inhibitors

Efflux mediated resistance towards antibiotics in S. aureus has been gaining more
attention recently and is recognized as the first line of bacterial defense against
antimicrobials 123. Several efflux pumps in staphylococci are associated with resistance to
various antimicrobials. Efflux pumps such as Tet (K) and Tet (L) contribute to tetracycline
resistance, NorA, NorB, NorC, MepA and MdeA are associated with fluoroquinolone
resistance, while Mef(A) and Msr(A) mediate resistance to macrolides 123,124.
FDA-approved drugs have been shown to inhibit important efflux pumps in S. aureus.
For example, the phenothiazine group of drugs such as chlorpromazine, fluphenazine,
prochlorperazine, and thioridazine, which are primarily used for the treatment of
schizophrenia and other psychotic disorders, showed marked inhibitory activity against
efflux pumps in S. aureus

125,126

. All four drugs have also been found to inhibit NorA-

mediated efflux in S. aureus and enhance the activity of norfloxacin several fold

127

.

Chlorpromazine and thioridazine have also been shown to reduce MRSA resistance to
oxacillin 128. Similarly, reserpine, an antipsychotic and antihypertensive drug, also inhibits
an efflux pump in S. aureus that subsequently makes it susceptible to both oxacillin and
norfloxacin 127,128. Another antihypertensive drug, verampil, has also been shown to reduce
fluoroquinolone-resistance in S. aureus 129,130.
Proton pump inhibitors, such as omeprazole and lansoprazole, which are used for the
treatment of gastroesophageal efflux and dyspepsia in humans, have also been proven to
be potent inhibitors of S. aureus efflux pumps 131. These drugs greatly enhance the activity
of fluoroquinolones such as levofloxacin, ciprofloxacin, and norfloxacin in strains of S.
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aureus expressing NorA 131. Therefore, therapeutic development of bacterial efflux pump
inhibitors (in combination with antimicrobials to permit entry of the antimicrobial into the
pathogen) is a useful strategy to consider as a treatment for S. aureus infections. However,
a limitation of the non-antibiotic drugs discussed above is none possess activity at a
concentration lower than those achievable in human serum

131

. Hence, future studies are

needed to focus on making modifications to these drugs to enhance their activity against S.
aureus. Additionally, screening of FDA-approved drug libraries can be done to identify
more potent efflux pump inhibitors within the applicable clinical range in humans.

1.3.3

Immuno-modulatory drugs

S. aureus possesses diverse immune evading mechanisms to alter the host immune
response in such a way that favors their invasion, survival, and replication in the host 132,133.
Hence, modulation of this complex host immune response to the pathogen is another
reasonable approach to target these bacterial infections that has been widely investigated
in recent years 111,114. In general, pathogens develop strategies to become invisible to the
host immune system and in turn the host fails to mount an effective immune response to
clear the pathogen 132-134. On the other hand, there are circumstances where pathogens, such
as S. aureus and its virulence factors, are capable of hyper stimulating the host immune
system, leading to the uncontrolled production of inflammatory markers and other
mediators which result in tissue damage and septic shock 135,136. This happens more often
in acute infections such as in sepsis where the strong inflammatory response and cytokine
storm that follows may lead to shock and death 137-139. In addition, S. aureus is also known
to secrete various exotoxins such as α-hemolysin, leukocidins and toxic shock syndrome
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toxin (TSST-1) which can activate antigen-presenting cells (APCs) and T-cells leading to
the induction of a strong inflammatory cascade reaction

135,136,140

. Superantigens such as

TSST-1 and enterotoxins also bypass normal antigen processing by APCs and induce direct
proliferation of T-cells, even at a picomolar concentration

140,141

. Hence, finding

immunomodulatory agents that can be effectively combined with antibiotics may produce
a better outcome in patients afflicted with a S. aureus infection. 142-145.
Non-antibiotic FDA-approved drugs with immuno-modulatory activity to treat
bacterial infections have been investigated by various researchers. Even though some of
these drugs have no direct antimicrobial activity in vitro, they have been shown to aid in
achieving a better resolution of staphylococcal infections by reducing toxin production or
by modulating host immune response to enhance bacterial clearance.

Statins
Statins are one of the major classes of FDA-approved lipid lowering drugs that act
on HMG-CoA reductase; these drugs have been widely used to prevent cardiovascular
disease in humans

146-148

. In addition to their role in cardiovascular disease, numerous

functions of statins, independent of their lipid lowering property, have been studied
recently 149. The antibacterial activity of statins, particularly simvastatin, has been explored
by several groups

150-157

. However, the high MIC value obtained for statins is a major

concern with using statins directly as antimicrobial agents

158

; this has led to researchers

searching for alternative uses for statins for treating bacterial infections.
Statins act at various cellular and molecular levels and regulate multiple antiinflammatory actions, reduce oxidative stress, and inhibit leukocyte-endothelial
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interactions and leukocyte migration. All these effect are beneficial in treating sepsis

159

.

Furthermore, statins inhibit several different cytokines including TNF-α, IL-1β, IL-6, and
IL-8, thereby lowering the inflammatory activity of neutrophils and macrophages and
dampening the immune response involved in sepsis

159-165

. In addition to the extensive

inflammatory response, the release of several mediators such as C-reactive protein also
plays a major role in sepsis

166

. C-reactive protein promotes thrombus formation by

enhancing endothelial cell–monocyte interaction, increases tissue factor expression, and
activates the complement system leading ultimately to organ dysfunction and death
159,166,167

. However, statins greatly reduce the levels of C-reactive protein and its subsequent

actions in sepsis

168-170

. Statins also inhibit leukocyte migration by reducing various

adhesion molecules such as VLA4, P-selectin, CD11b, CD11a and CD18 171-173. In addition,
a study demonstrated that simvastatin pre-treatment also reduces S. aureus α-toxin induced
leukocyte rolling, adhesion, and transmigration 174. Furthermore, the overall beneficial role
of statins in S. aureus septicemia is supported by a retrospective and clinical study which
demonstrated significant reduction in mortality among patients with statin therapy
compared with patients not taking statins

158,175,176

. Hence, the promising evidence

compiled thus far of statins in limiting the effects of sepsis make it worthwhile to
investigate the exact molecular mechanism by which statins exhibit their action to propel
them into clinical trials in the future, as a novel therapeutic approach for sepsis
management.

19
Nicotinamide
Beyond the use of nicotinamide (vitamin B3) as a supplement, it inhibits
inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α and is used for the treatment
of inflammatory skin disorders such as atopic dermatitis and acne vulgaris

177,178

. In

addition, nicotinamide, in combination with nafcillin, improved the survival outcome of
staphylococcal septic shock in mice 179. However, the exact molecular mechanism behind
this immune modulation activity remains unclear. Another study showed nicotinamide
enhanced S. aureus killing in vivo by modulating host factors

180

. Host factors, such as

phagocytic ability of monocytes and macrophages, greatly influence bacterial clearance. In
particular, a higher expression of anti-staphylococcal peptides such as lactoferrin (LTF)
and cathelicidin in monocytes and macrophages greatly increases their phagocytic ability
and bacterial killing

180-183

. However, the expression of antimicrobial peptides (LTF and

cathelicidin) in phagocytic cells is regulated by CCAAT/enhancer-binding protein ε
(C/EBPε), a myeloid-specific transcription factor

180-183

. Nicotinamide increases the

activity of C/EBPε in neutrophils and enhances the killing of S. aureus up to 1000-fold in
vivo

180

. Hence, by manipulating C/EBPε expression, the phagocytic ability of certain

immune cells can be enhanced, which further increases their bactericidal activity. 180.
Additionally, nicotinamide also reduces staphylococcal enterotoxin (SEB)-induced
responses

184

. Nicotinamide inhibits the SEB-induced T-cell proliferation and

inflammatory cytokines such as IL-2 and IFN-γ, and protects mice from SEB-induced
toxicity

184

. Thus, taken collectively, nicotinamide with potent immuno-modulatory

activities via increased S. aureus killing and damping the SEB-induced inflammatory
response should have therapeutic value for the treatment of staphylococcal infections.
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Dexamethasone
Dexamethasone

is

a

steroid

drug

with

potent

anti-inflammatory

and

immunosuppressive activity that has been used for the treatment of various systemic and
localized skin diseases. Being a potent anti-inflammatory drug, it also inhibits
staphylococcal enterotoxin (SEB)-induced inflammatory cytokines such as TNF-α, IFN-γ,
IL-1α, IL-2, and IL-6 and protects mice from hypothermia and shock 185-188.

Rapamycin
Rapamycin, a FDA-approved immunosuppressive drug is used to prevent graft
rejection in renal transplantation 189; it has also been shown to have a protective effect in a
SEB-induced septic shock mice model by inhibiting cytokines such as TNF-α, IFN-γ, IL2, IL-6, and IL-1α. Additionally, it inhibits production of chemokines such as chemo
attractant protein 1 (MCP-1) and macrophage inflammatory protein 1(MIP-1) in peripheral
blood mononuclear cell PMBC 190,191. When tested in vivo, rapamycin protected all treated
mice from lethal staphylococcal shock even when administrated 24 hours after SEB
challenge 190,191.

Pentoxifylline
Pentoxifylline, a FDA-approved drug used for the treatment of intermittent
claudication resulting from peripheral artery disease, has a protective role on SEB or
TSST-1 induced lethal effects

192,193

. It suppresses T cell activation and inhibits the
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cytokines TNF-α, IFN-γ, and IL-1α 192. Furthermore, pentoxifylline prevents mice lethality
in a SEB-induced shock model 192.
The examples described above demonstrate the great potential of FDA-approved
non-antimicrobial immunomodulators to be combined with traditional antimicrobials to
modulate the host immune response and can be further explored as a novel viable
therapeutic strategy for the treatment of staphylococcal infections.

1.3.4

Anti-biofilm agents

Biofilm-forming S. aureus often cause serious complications leading to lifethreatening infections 194. Studies on staphylococcal biofilm present on indwelling medical
devices such as catheters, implanted devices, and prosthetic heart valves have drawn great
interest over the past few decades

194

. S. aureus biofilm-associated infections are

challenging to treat with conventional antibiotics 194,195. Hence, novel drugs and strategies
are in immediate need to deal with biofilm infections

195

. Several FDA-approved non-

antibiotic drugs have been shown to possess anti-biofilm activity. For example,
nitazoxanide (NTZ), an anti-protozoal agent approved for the treatment of
Cryptosporidium parvum and Giardia intestinalis infections in humans, is shown to have
anti-biofilm activity

196

. Nitazoxanide exhibits anti-staphylococcal activity at a MIC

ranging from 8 to 16 μg/ml. Additionally, at sub inhibitory concentrations (IC50 of 1 to 3
μg/mL), NTZ is shown to inhibit biofilm formation by Staphylococcus epidermidis 197.
Several FDA-approved drugs are known to disrupt adherent microbial biofilms.
Examples include auranofin (anti-rheumatoid drug), benzbromarone (gout drug),
pyrvinium pamoate (antihelminthic), yohimbine hydrochloride (mydriatic vasodilator),
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and zotepine (antipsychotic) which have all been shown to be capable of inhibiting preformed microbial biofilms

198

. Further testing of these drugs against different

staphylococcal biofilms, both alone and with conventional antimicrobials, should be
considered as a new avenues to target multidrug-resistant staphylococcal infections and
associated biofilms.

1.4

Identifying new antibiotic leads from approved drugs which can serve as novel
antibiotics

From 2008-2012, only three new antibiotics received approval from the FDA

199

.

Interestingly, in 2014, thus far the FDA has already approved three new antibiotics
(dalvance, tedizolid phosphate, and oritavancin) indicating the agency is recognizing the
urgent need for new antibiotics to treat difficult bacterial infections; all three approved
drugs are indicated for use in treating acute bacterial skin and skin structure infections
caused by pathogens such as MRSA 200,201. These antibiotics are not new drug classes but
rather modified derivatives of older antibiotics which interfere with the same biochemical
pathways and molecular targets known for many years. For example, dalvance and
oritavancin belong to the glycopeptide class of antibiotics (which interfere with bacterial
cell wall synthesis) while tedizolid phosphate is an oxazolidinone which inhibits bacterial
protein synthesis.
Though numerous new molecular/druggable targets inside bacteria have been
identified in recent years, no compounds have been successfully developed (and received
approval) that interact and bind to these targets. Given that only four new antibiotic classes
have been identified in the past 40 years using the traditional drug discovery approach, new
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techniques need to be considered to discover drugs capable of binding to these unique
targets 202. Drug repurposing presents a new method to screen for existing drugs that can
interact with these critical targets inside pathogens. This could lead to the development of
new antimicrobial classes which interact with different molecular targets compared to
traditional antibiotics. Understanding which moiety on the drug interacts with the
molecular target can also permit medicinal chemists to make rational modifications to the
parent drug to construct analogues with enhanced binding affinity for the target (with the
hope of improved antimicrobial activity), improved pharmacokinetic profile of the drug,
and reduced toxicity to host tissues. Also this could permit the identification of new
bacterial targets which have not been previously known.

1.5

Challenges for repurposing non-antibiotic drugs for S. aureus

Though repurposing approved drugs for use as antimicrobials is an exciting avenue
for discovery of new potential treatments for bacterial infections, there are multiple
obstacles hindering progress in identifying and developing these agents. One of the biggest
challenges in the field of antibiotic drug discovery is the lack of interest by pharmaceutical
companies and industry to invest resources in this area. The reality is that the vast majority
of drugs currently available in the market were discovered by the pharmaceutical industry.
In the United States alone, only 9% of new drugs discovered between the years of 1960
and 1969 came from government agencies, universities, and not-for-profit organizations 8.
This trend continued to hold true in latter parts of the 20th century as over 93% of new
drugs approved in the United States, from 1990 to 1992, were procured from industry;
government agencies and academic institutions each accounted for just over 3% of new
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drugs in this time span 10. Thus industry is a key cog in the identification and development
of drugs which are capable of reaching the healthcare setting. However, given the low
return on investment for antibiotics, companies, particularly Big Pharma, have moved
away from developing new antibiotics. This can be illustrated with a simple example; from
2009-2012, Merck’s leading medication for diabetes (Januvia) outsold its top-selling
antibiotic (Invanz, a carbapenem antibiotic) by US$11 billion

203

. Moreover, a review of

the top 100 best-selling drugs from April 2013 through March 2014 revealed treatments
for chronic diseases such as rheumatoid arthritis (Humira, Enbrel, Remicade), depression
(Cymbalta, Seroquel XR), asthma (Advair), high-cholesterol (Lipitor, Crestor, Zocor),
multiple sclerosis (Copaxone, Tecfidera), Alzheimer’s disease (Namenda), diabetes
(Lantus Solostar, Januvia), AIDS (Atripla, Truvada, {Prezista), high blood pressure
(Diovan, Metoprolol), and cancer (Rituxan, Avastin, Gleevec) generated the most sales for
pharmaceutical companies; interestingly no antimicrobials were found on this list. Given
the associated costs involved with drug discovery, the lack of sales generated by antibiotics
(in comparison to drugs developed for chronic diseases such as asthma, diabetes, and high
blood pressure), and stringent regulations required for new antibiotics to receive regulatory
approval, this significantly reduces the incentive needed by companies to pursue
developing novel antimicrobials

199

. This has led to several major companies, including

Pfizer and Roche, to terminate their antibiotics research & development division; as of
2013, only four major pharmaceutical companies have active antimicrobial drug discovery
programs

202,203

. This leaves government agencies, academic institutions, and small

companies with the burden of filling this gap to generate new antimicrobials. While
repurposing existing drugs is a mechanism for these institutions to curb costs associated
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with the drug discovery process, most of these agencies lack the resources available to
industry for drug discovery. Additionally, these organizations face a second major obstacle
in the path to repurposing drugs as antimicrobials.
A second major challenge to repurposing approved drugs as antimicrobials pertains
to the lack of accessibility to libraries containing clinical drug collections. As highlighted
by Chong and Sullivan, no single collection of the nearly 10,000 known clinical drugs
currently exists 7. Instead these drugs are dispersed throughout several different collections
or are not available to researchers (in part due to existing patents present for certain drugs).
Among the publicly available compound collections include the National Institute of
Neurological Disorders and Stroke (NINDS) collection of 1,040 compounds, the Prestwick
Chemical Library in Washington, DC (containing more than 1,000 approved drugs), and
the Johns Hopkins Clinical Compound Library (consisting of more than 1,500 compounds)
7

. Combined with other drug collections available for commercial purchase, this amounts

to only 40% of the total known approved drugs and clinical molecules which are available
for screening for antimicrobial activity 7. However, redundancy and overlap between these
different libraries presents an additional problem as a compound may be present in more
than one collection making screening these compounds more difficult.
Obtaining access to the remaining 60% of clinical drugs, for screening for
antimicrobial activity, is a significant impediment to identifying new clinical applications
for these drugs. Moreover, it would be valuable to researchers if they can gain access to
libraries of compound metabolites and drugs which entered phase II and III clinical trials
but failed to receive approval for the initial clinical indication. Most drugs fail in phase II
clinical trials because they prove ineffective in treating the disease they were initially
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intended to be used for

11

. Though these compounds may not have succeeded in gaining

approval for their initial clinical application, they may still have promise for alternative
uses, for example as antibiotics for S. aureus infections. Gaining access to these
compounds, clinical data generated for these compounds, and information pertaining to
why they failed in clinical trials will permit researchers to rationally design potential
solutions to overcome these issues in repurposing these compounds for other clinical
applications. However, many of these clinical failures are often not made publicly
accessible by pharmaceutical companies (for competitive and financial reasons);
additionally given these companies often are focused on developing drugs for specific
diseases, they may not have the resources (i.e. models to study infectious diseases in
humans) or personnel to identify new applications for these failed compounds

11

.

Establishing relationships and bridging the gap between industry (who would provide these
compounds and clinical data garnered), academic research institutions (to screen these
compound libraries for hits for antimicrobial activity), and government agencies (to assist
with sponsoring clinical trials to test drugs to be repurposed as antimicrobials) is very
important in order to find new applications for both approved drugs and compounds which
have entered into late stage clinical trials but ultimately failed.

1.6

Conclusion

Development of new antimicrobials is very slow and there are not enough new
antimicrobials in the drug pipeline to keep pace with the emergence of multidrug-resistant
bacterial strains. Moreover, pharmaceutical companies lacking interest in antimicrobial
drug discovery has contributed to the dearth of new and novel antibiotics. Therefore
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alternative strategies are in urgent need to battle against multidrug-resistant infections such
as those caused by S. aureus. Repurposing approved drugs presents an emerging approach
with reduced cost, discovery time, and risk associated with antibiotic development. We
presented several approved drugs that possess potent anti-staphylococcal activity in vitro;
with further mechanistic and in vivo studies, these drugs might be a potential candidate
drugs that can be considered for systemic and (or) topical applications. Independent of
antimicrobial activity, some drugs also have the ability to interfere with S. aureus
pathogenesis and modulate host immune response to enhance bacterial killing and
clearance. This is an additional novel application of the approved drugs which warrants
further exploration. With the promising activity and the past success in drug repurposing,
repositioning existing drugs might form a potential alternative strategy to discover new
antimicrobials and might drive interest of researchers both in academia and the
pharmaceutical industry to invest more research resources in this area.
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CHAPTER 2. DRUG REPURPOSING FOR BACTERIAL INFECTIONS

2.1

Antibacterial activity and mechanism of action of auranofin against multidrug resistant bacterial pathogens

(Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick VE, Paul
LN, Seleem MN. Antibacterial activity and mechanism of action of auranofin against
multi-drug resistant bacterial pathogens. Scientific Reports. 2016 Mar 3;6:22571.)

2.1.1

Introduction

Bacterial resistance to antibiotics is a significant public health challenge, as
infections caused by antibiotic-resistant bacteria claim the lives of nearly 23,000 people
each year in the United States alone

204

. A single pathogen, methicillin-resistant

Staphylococcus aureus (MRSA), is responsible for nearly half of these fatalities. MRSA
has been linked to invasive diseases including pneumonia

205

and sepsis

206

, that affect a

diverse population of patients including individuals with a compromised immune system
207

such as young children 208. While a powerful arsenal of antibiotics was once capable of

treating S. aureus-based infections, clinical isolates of MRSA have emerged to numerous
antibiotics, including agents of last resort such as vancomycin 4 and linezolid 209.
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Most current antibiotics were discovered via the time-consuming and financially
taxing process of de novo synthesis and screening of chemical compounds210. An
alternative approach to unearthing new antibacterials that is garnering more recent attention
is screening libraries of approved drugs (or drugs that made it to clinical trials but
ultimately failed to receive regulatory approval) in order to identify candidates that can be
repurposed as antimicrobials

210

. Recently, we assembled and screened 50% of the

commercially available drugs (~ 2,200 drugs) and small molecules tested in human clinical
trials

7,211

(727-NIH Clinical Collections 1 and 2, 1,600-Pharmakon from Microsource,

Approved Oncology Drugs Set-NIH, and few small libraries) and identified three drugs
that exhibited potent antibacterial activity at a dose that is clinically achievable. One of
these drug, auranofin is capable of inhibiting growth of clinically-pertinent isolates of
MRSA at submicrogram/mL concentrations in vitro. Auranofin is an oral gold-containing
drug initially approved by the U.S. Food and Drug Administration (FDA) for treatment of
rheumatoid arthritis. In a study by Debnath et al, auranofin was found to exhibit potent
anti-parasitic activity against Entamoeba histolytica providing evidence that this drug
could be repurposed as an antimicrobial agent 25. More recent studies have discovered this
drug also possesses potent antibacterial activity including against important pathogens such
as MRSA 25,212-215.
Building upon this seminal work, the goals of the present study were to further
investigate the antibacterial mechanism of action of auranofin and to examine potential
applications of auranofin as an antibacterial agent for systemic MRSA infections. We have
identified that auranofin appears to target multiple biosynthetic pathways in S. aureus,
including inhibition of cell wall, DNA, and protein synthesis; this latter property permits
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auranofin to mitigate specific virulence factors including reducing the production of key
toxins such as α-hemolysin and Panton-Valentine leucocidin, a fact previously unknown.
Auranofin is less effective against Gram-negative pathogens in large part due to the
presence of the outer membrane in these pathogens. Furthermore, in vivo studies
demonstrate that auranofin is capable of treating invasive MRSA infections, thereby
expanding the potential therapeutic applications of this drug for use as a novel antibacterial
agent. The findings presented in this study provide strong evidence that auranofin can be
repurposed as a novel antibacterial agent for treatment of invasive MRSA infections in
humans.

2.1.2 Materials and Methods
Bacterial strains and reagents
Bacterial strains used in this study are presented in Tables 1 and 2. Mueller-Hinton
broth (MHB) was purchased from Sigma-Aldrich while Trypticase soy broth (TSB),
Trypticase soy agar (TSA), and mannitol salt agar (MSA) were purchased from Becton,
Dickinson and Company (Cockeysville, MD). Auranofin (Enzo Life Sciences),
vancomycin hydrochloride (Gold Biotechnology) and linezolid (Selleck Chemicals) were
al purchased from commercial vendors.

Antibacterial assays
The broth microdilution method was employed to determine the MICs of all test
agents (tested in triplicate) as per the Clinical and Laboratory Standards Institute (CLSI)
guidelines

216

. Test agents were incubated with bacteria for 16 hours at 37°C prior to
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determining the MIC. The MIC was classified as the lowest concentration of drug capable
of inhibiting visible growth of bacteria by visual inspection.

Gram-negative bacteria outer membrane permeabilization assay
The MIC of auranofin and control antibiotics, in the presence of polymixin B
nonapeptide (PMBN), against Gram-negative bacteria was measured as described in the
antibacterial assay section above. A subinhibitory concentration of PMBN (10 µg/ml) was
added to TSB to increase the outer membrane permeability and facilitate the entrance of
auranofin, as described elsewhere 217,218.

Macromolecular synthesis assay
S. aureus ATCC 29213 was used for the macromolecular synthesis assay and the
assay was carried out using auranofin and control antibiotics (ciprofloxacin, rifampicin,
linezolid, vancomycin and cerulenin) as described elsewhere 211.

Proteomics analysis
Sample Preparation: An overnight culture of MRSA USA300 cells were treated
with 10 × MIC of auranofin (1.25 µg/ml), linezolid (20 µg/ml) and vancomycin (10 µg/ml)
for one hour at 37°C. Bacterial cells were centrifuged and sequence grade Lys-C/Trypsin
(Promega) was used to enzymatically digest samples. Samples were reduced and alkylated
prior to digestion. All trypsin digestions were carried out in a Barocycler NEP2320 (PBI)
at 50°C under 20 kpsi for two hours. After digestion, samples were cleaned using
MicroSpin C18 columns (Nest Group, Inc.) and the resulting pellets were re-suspended in
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97% H2O/3% ACN/0.1% FA. A small aliquot (5 µL) of sample was analyzed via nanoLCMS/MS.
LC-MS/MS: Samples were run on an Eksigent 425 nanoLC system coupled to the Triple
TOF 5600 plus

219

. The gradient was 120 min at 300 nl/min over the cHiPLC–nanoflex

system. The trap column was a Nano cHiPLC 200 µm × 0.5 mm ChromXP C18-CL 3 µm
120 Å followed by the analytical column, the Nano cHiPLC 75 µm × 15 cm ChromXP
C18-CL 3 µm 120 Å. The sample was injected into the Triple TOF 5600 plus through the
Nanospray III source. Data acquisition was performed at 50 precursors at 50 min/scan.
Analysis: WIFF files from mass spectrometric analysis were processed using the
MaxQuant computational proteomics platform version 1.5.2.8 220. The peak list generated
was screened against the Bos taurus (41521 entries unreviewed) and Staphylococcus
aureus (10972 entries reviewed) sequence from UNIPROT retrieved on 04/10/2015 and a
common contaminants database. The following settings were used for MaxQuant: initial
precursor and fragment mass tolerance set to 0.07 and 0.02 Da respectively, a minimum
peptides length of seven amino acids, data was analyzed with ‘Label-free quantification’
(LFQ) checked and the ‘Match between runs’ interval set to 1 min, the FASTA databases
were randomized and the protein FDR was set to 5%, enzyme trypsin permitted two missed
cleavage and three modifications per peptide, fixed modifications were carbamidomethyl
(C), variable modifications were set to Acetyl (Protein N-term) and Oxidation (M). The
MaxQuant results used in-house script, and the average LFQ intensity values for the
technical replicates were used for each sample. Both the Bos taurus and the common
contaminant proteins were removed. Values were transformed [log2(x)] and the missing
values were inputted using the average values of all samples. The heat maps and statistical
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analyses were performed in the R environment (www.cran.r-project.org) and Qlucore
OMICS explorer (version 3.0, Qlucore, Lund, Sweden). A one-way analysis of variance
(ANOVA) was performed on the LFQ intensities and only proteins with P < 0.05 were
selected for further analyses.

Growth curve of E. coli in the presence of auranofin
Wild-type and trxB/gor double mutant E. coli strains (wild-type: novablue (DE3)K12, trxB/gor double mutant: Origami-2) were incubated with indicated concentration of
auranofin in the presence and absence of PMBN (10 µg/ml) for 16 hours at 37°C. Bacterial
growth was monitored using a spectrophotometer (OD = 600 nm).

Analysis of S. aureus toxin production by ELISA
The effect of auranofin and two control antibiotics (vancomycin and linezolid)
on production of two key S. aureus toxins (α-hemolysin and Panton-Valentine leukocidin)
was measured by ELISA as has been previously described 211.

Intracellular infection assay
J774A.1 murine macrophage-like cells were infected with MRSA USA300 for
30 min at a multiplicity of infection (MOI) ratio of 1:100. Infected cells were subsequently
washed three times with DMEM medium containing 10 IU lysostaphin 221. Auranofin (0.5
µg/ml), vancomycin (4 µg/ml) and linezolid (8 µg/ml), in triplicates, in complete DMEM
medium containing 4 IU lysostaphin was then added. After 24 hours of incubation at 37°C
(with 5% CO2), the cells were washed three times with phosphate-buffered saline (PBS)
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and lysed with 0.1% Triton X-100 (Sigma-Aldrich). Cell lysates were plated onto TSA
plates and MRSA colony forming units (CFU) were counted after incubation of plates for
24 hours at 37°C.

Mice studies
Eight week old female BALB/c mice (Harlan Laboratories, Indianapolis, IN) were
used in all mice studies. The animal care and all experiments were approved and performed
in accordance with the guidelines approved by Purdue University Animal Care and Use
Committee (PACUC). Eight-week old female BALB/c mice (n = 10 per group) were used
and the study was carried out as described before 222
Systemic - lethal infection : An overnight culture of MRSA USA300 cells were washed
and re-suspended in PBS. Each mouse received an intraperitoneal (i.p.) injection (200 µl)
containing the bacterial suspension (9 × 109 CFU). One hour after infection, mice were
divided into four groups (ten mice per group). Mice were treated orally with auranofin
(either 0.125 or 0.25 mg/kg), linezolid (25 mg/kg), or the vehicle alone (10% ethanol).
Treatment was provided once daily for three days following infection. Mortality was
monitored daily for five days and the moribund mice were euthanized humanely using CO2
asphyxiation.
Systemic – non-lethal infection: The infection protocol was carried out as described above
(systemic-lethal infection) with the following exceptions. Each mouse received an i.p.
injection containing 2 × 107 CFU MRSA USA300. Mice were divided into three groups
(five mice per group) and treated orally with auranofin (0.25 mg/kg), linezolid (25 mg/kg),
or vehicle (10% ethanol) alone. Mice were treated once daily for two days. Twenty-four
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hours after the last dose, mice were euthanized and their spleen and liver were excised,
homogenized in TSB, plated onto MSA plates, and incubated at 37°C for 24 hours prior to
counting MRSA CFU post-treatment.

Combination testing of auranofin with commercial antibiotics
Additive activity of auranofin with conventional antibiotics (ciprofloxacin,
linezolid and gentamicin) was evaluated as described in a previous study223,224. Briefly,
MRSA USA300 was incubated with auranofin, control antibiotics, or a combination of
auranofin + a control antibiotic at different concentrations for 16 hours. Next, the optical
density (at 600 nm) was measured using a spectrophotometer. Percent bacterial growth for
each treatment regimen was calculated and presented.

Growth curve of S. aureus in the presence of auranofin
MRSA USA300 was incubated with indicated concentration of auranofin for 16
hours at 37°C and the percent bacterial growth was monitored using a spectrophotometer
(OD = 600 nm).

Time kill assay
An overnight culture of MRSA USA300 was diluted to 6 × 105 CFU/mL and
treated with 5 × MIC of auranofin, vancomycin or linezolid (in triplicate) in Mueller Hinton
broth and incubated at 37°C. Samples were collected at indicated time points, serially
diluted in PBS, and transferred to TSA plates. Plates were incubated at 37°C for 24 hours
prior to counting MRSA colony forming units (CFU).
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DNA intercalation assay
DNA intercalation assay was carried out using pUC 18 plasmid as described
elsewhere

225

. Briefly, 250 ng of plasmid DNA was incubated with the indicated

concentration of auranofin and doxorubicin in a total volume of 25 µl and the reaction
mixtures were incubated for 30 min at 37°C. An electrophoretic assay was run using 1%
agarose gel without ethidium bromide at 50 volts for 4 hours. The gel was stained with
ethidium bromide and visualized for DNA mobility.

Cytotoxicity assay
In vitro toxicity assay was carried out in mouse macrophage (J774A.1) cells by
MTS assay as described before 226. Briefly, auranofin at a concentration ranging from 0 to
256 µg/ml was added to the cells. After 24 hours of incubation, the cytotoxicity effect of
auranofin was measured by the addition of MTS assay reagent 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H

tetrazolium).

Results

are

expressed as percent cell viability of auranofin-treated cells in comparison to cells treated
with DMSO.

Statistical analyses
Statistical analyses were assessed using GraphPad Prism 6.0 (Graph Pad Software,
La Jolla, CA). P values were calculated via the Student t test or Kaplan-Meier
(log rank) survival test as indicated. P values of ≤ 0.05 were deemed significant.
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2.1.3

Results

Auranofin is a potent inhibitor of multidrug-resistant Gram-positive bacteria
The antimicrobial activity of auranofin was assessed against a panel of clinical
isolates of multidrug-resistant Gram-positive pathogens using the broth microdilution

Figure 2.1 Growth curve of MRSA USA300 in the presence of auranofin. Bacteria were
incubated with indicated concentrations of auranofin and the growth was measured using
a spectrophotometer

method (Table 2.1). Auranofin exhibited potent bactericidal activity against all tested
bacteria including strains that are resistant to conventional antimicrobials such as
methicillin and vancomycin. The minimum inhibitory concentration (MIC) of auranofin,
required to inhibit growth of different MRSA strains, were found to be in the range of
0.0625 to 0.125 µg/ml (Table 2.1 and Figure 2.1).
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Table 2.1 MICs of auranofin and control antibiotics against Gram-positive bacteria
Auranofin
MIC
(µg/ml)

Linezolid
MIC
(µg/ml)

0.125

2

Vancom
ycin
MIC
(µg/ml)
2

0.0625

2

1

0.125

2

1

0.0625
0.125
0.0625
0.125
0.125
0.125
0.125

2
4
4
2
2
2
2

1
1
1
1
1
1
1

0.125

2

8

0.25

2

>128

0.125
0.25

2
1

1
1

0.25

1

1

Beta-hemolytic, Serogroup: Group B

0.0625

0.25

0.25

Beta-hemolytic, Serogroup: Group B

0.0625

0.25

0.5

Beta-hemolytic, Serogroup: Group B

0.0015

0.25

0.25

Strain ID

Phenotypic Characteristics

MRSA (USA100)

Resistant to ciprofloxacin,
clindamycin,
erythromycin
Resistant to clindamycin, methicillin
erythromycin, gentamicin,
Resistant to erythromycin, methicillin,
tetracycline
Resistant to methicillin, tetracycline
Resistant to erythromycin, methicillin
Resistant to methicillin
Resistant to erythromycin, methicillin
Resistant to methicillin
Resistant to streptomycin
Resistant to Vancomycin. Sensitive to
Teicoplanin
Resistant to gentamicin and
vancomycin
Resistant to cephalosporins
Resistant to erythromycin, penicillin,
and tetracycline

MRSA (USA200)
MRSA (USA300)
MRSA (USA400)
MRSA (USA700)
MRSA (USA800)
MRSA (USA1000)
MRSA (USA1100)
E. faecalis ATCC49533
E. faecalis ATCC7080
E. faecalis ATCC 51229
(VRE)
E. faecium E0120 (VRE)
E. faecium ATCC6569
S. pneumoniae 51916
S. pneumoniae 70677
Streptococcus agalactiae
MNZ938
Streptococcus agalactiae
MNZ 933
Streptococcus agalactiae
MNZ 929

The antibacterial activity of auranofin against MRSA is superior (16-fold lower MIC for
auranofin) to several commercial antibiotics including vancomycin (MIC of 1 µg/ml) and
linezolid (MIC ranged from 2-4 µg/ml); the MIC values determined for auranofin against
MRSA correlate with MIC values reported in previous published studies 212,214. Auranofin
retained its antibacterial activity against an array of MRSA strains exhibiting resistance to
numerous antibiotic classes including glycopeptides, oxazolidones, tetracycline, β-lactams,
macrolides, and aminoglycosides; these results indicate that cross-resistance between these
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antibiotics and auranofin is unlikely to occur. The bactericidal activity of auranofin was
confirmed via a standard time-kill assay (Figure 2.2); auranofin, at 5 × MIC, exhibited slow
bactericidal activity (similar to vancomycin), completely eliminating MRSA USA300 cells
within 48 hours.

Figure 2.2 Time-kill assay for auranofin tested against S. aureus. Killing kinetics of
auranofin and antibiotics (vancomycin and linezolid) at 5 × MIC against MRSA USA300
in MHB are displayed. The results are presented as mean ± SD (n = 3). Data without error
bars indicate that the SD is too small to be seen.

Vancomycin required 24 hours to achieve the same effect, which is in agreement with
previously published reports 227. In addition to possessing anti-MRSA activity, auranofin
also exhibited potent antibacterial activity against vancomycin-sensitive enterococcus and
vancomycin-resistant enterococcus (VRE), Streptococcus pneumoniae and Streptococcus
agalactiae with MIC values ranging from 0.0015 to 0.25 µg/ml (Table 2.1).
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The outer membrane in Gram-negative bacteria negates auranofin’s antibacterial
activity
Confirmation of auranofin’s potent antibacterial activity against multiple Grampositive pathogens led us to analyze if auranofin exhibits broad-spectrum antibacterial
activity by also inhibiting growth of important Gram-negative pathogens. Interestingly,
auranofin alone did not show activity against Gram-negative bacteria which is in agreement
with previous reports212-214. We sought to investigate if the presence of the outer membrane
(OM) in Gram-negative bacteria contributed to the lack of antibacterial activity observed,
by preventing auranofin from gaining entry into the bacterial cell (as has been observed
with conventional antimicrobials such as erythromycin and fusidic acid)

217,218

. The

inclusion of the permeabilizing agent polymixin B nonapeptide (PMBN), at a sub
inhibitory concentration, in the culture broth resulted in auranofin exhibiting potent activity
against all tested strains of Gram-negative pathogens including Pseudomonas aeruginosa,
Escherichia coli, metallo-β-lactamase (NDM-1) and carbapenemase-resistant (KPC)
Klebsiella pneumoniae, Salmonella Typhimurium and extremely drug-resistant (XDR)
Acinetobacter baumannii with MICs ranging from 0.125 to 1 µg/ml (Table 2.2). In addition
to this, a four-fold decrease in auranofin’s MIC (from 32 to 8 µg/ml) was observed when
the efflux pump AcrAB was deleted in E. coli. AcrAB has been shown to contribute to the
antibiotic-resistant phenotype in multiple strains of E. coli and has been implicated in E.coli
resistance to numerous antibiotics including ampicillin, rifampicin, and chloramphenicol
228

. Thus, in addition to the physical barrier imposed by the Gram-negative OM, the ability

of auranofin to gain entry into Gram-negative bacteria to exhibit its antibacterial activity
may be impeded by the presence of efflux pumps (such as AcrAB).

41
Table 2.2 MICs of auranofin and control antibiotics against Gram-negative bacteria
Bacteria

Minimum Inhibitory Concentration (MIC) (µg/ml)
PMBN

Auranofin

Erythromycin

Fusidic acid

PMBN

PMBN

PMBN

(-)

(+)

(-)

(+)

(-)

(+)

Acinetobacter baumannii ATCC BAA19606

>256

16

0.25

64

0.5

64

0.5

Acinetobacter baumannii ATCC BAA1605

>256

16

0.5

64

0.5

128

1

Acinetobacter baumannii ATCC BAA747

>256

16

0.25

64

1

128

0.5

Escherichia coli O157:H7 ATCC 700728

256

64

0.5

128

1

>256

16

Escherichia coli O157:H7 ATCC 35150

256

32

0.5

128

1

>256

16

Salmonella Typhimurium ATCC 700720

>256

128

1

256

2

>256

16

Klebsiella pneumoniae ATCC BAA 2146

>256

256

0.5

>256

128

>256

32

Klebsiella pneumoniae ATCC BAA 1705

>256

256

1

>256

64

>256

64

Pseudomonas aeruginosa ATCC 9721

>256

>256

0.25

>256

1

>256

1

Pseudomonas aeruginosa ATCC 27853

>256

256

0.125

256

1

>256

1

Pseudomonas aeruginosa ATCC BAA-1744

>256

>256

0.25

>256

1

>256

1

Pseudomonas aeruginosa ATCC 25619

>256

256

0.25

256

1

>256

1

Pseudomonas aeruginosa ATCC 35032

>256

>256

0.5

>256

1

>256

1

Pseudomonas aeruginosa ATCC 10145

>256

256

0.25

256

1

>256

2

Pseudomonas aeruginosa ATCC 15442

>256

>256

0.25

>256

2

>256

1

Escherichia coli 1411

>256

32

0.5

32

4

>256

4

Escherichia coli SM1411∆ acrAB

>256

8

0.5

0.03

<0.03

8

<0.03

Escherichia coli (Novablue (DE3)-K12)

256

16

0.5

16

0.5

>256

0.5

Escherichia coli (Origami-2) (trxB/gor
mutant)

256

16

0.5

32

0.5

256

0.06

PMBN polymyxin B nonapeptide: (-) No PMBN was added to the media; (+) (10 µg/ml) of PMBN
was added to the media
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Auranofin inhibits multiple biosynthetic pathways in S. aureus
After confirming auranofin possesses potent antibacterial activity in vitro,
particularly against drug-resistant strains of S. aureus, we next moved to determine the
antibacterial mechanism of action of auranofin. A macromolecular synthesis assay was
employed to initially investigate auranofin’s antibacterial mechanism of action. The effect
of auranofin on the incorporation of radiolabeled precursors into five major biosynthetic
pathways of S. aureus was assessed. This assay revealed a clear dose-dependent inhibition
of three pathways, indicating that auranofin might possess multiple targets (Figure 2.3).
Auranofin, at a sub-inhibitory concentration, significantly inhibited cell wall and DNA
synthesis. When tested at its MIC, auranofin was found to also inhibit protein synthesis. At
higher concentrations (8 × MIC auranofin), partial inhibition of lipid synthesis was also
observed. However, auranofin did not significantly inhibit RNA synthesis at any of the
tested concentrations. The results from the macromolecular synthesis assay suggest that
auranofin possesses a complex mode of action that involves inhibition of multiple
biosynthetic pathways including cell wall, DNA, and protein synthesis.
Primary disruption of DNA synthesis in the macromolecular synthesis assay is often
associated with DNA intercalators. However, when auranofin was examined for evidence
of DNA intercalation, no effect on DNA migration was observed in relation to the untreated
control. Unlike doxorubicin, auranofin, even at a concentration (1mg/ml) that is 8000-fold
higher than the average MIC against MRSA, shows no evidence of a shift in plasmid DNA
(Figure 2.4). These data suggest that the disruption of DNA synthesis by auranofin is not
due to intercalation with DNA.
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Figure 2.3 Antibacterial mechanism of action of auranofin examined via the
macromolecular synthesis assay. Incorporation of radiolabeled precursors of DNA, RNA,
protein, cell wall and lipid synthesis ([3H] thymidine, [3H] uridine, [3H] leucine, [14C] Nacetylglucosamine and [3H] glycerol, respectively) were quantified in S. aureus ATCC
29213 after treatment with 1 × and 8 × MIC of auranofin, and 8 × MIC of control antibiotics.
Results are expressed as percent inhibition of each pathway based on the incorporation of
radiolabeled precursors. Statistical analyses were done using the two-tailed Student’s‘t’
test. P values of (* ≤ 0.05) are considered as significant.
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Figure 2.4 DNA mobility assay in the presence of auranofin and doxorubicin. pUC 18
plasmid was incubated with the indicated concentration of auranofin and doxorubicin for
30 min at 37°C. An electrophoretic assay was run using 1% agarose gel, stained with
ethidium bromide and visualized for DNA mobility.

Auranofin treatment in S. aureus leads to downregulation of proteins in five major
biosynthetic pathways
Proteomic profiling is a powerful tool that can be employed to investigate the
response of bacteria to antibacterial compounds and assess the impact of such compounds
on different cellular pathways

229-231

. Therefore, the alteration in the S. aureus proteome

caused by auranofin was investigated and compared with linezolid and vancomycin in
relation to an untreated control group. The proteomic analysis identified 530 proteins in all
samples and found 222 of these proteins showed significant differential expression (P ≤
0.05). The PCA analysis demonstrated that the variance inside each group is very low with
distinct classifications and the protein
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Figure 2.5 Auranofin treatment in S. aureus leads to downregulation of proteins in five
major biosynthetic pathways. (a) The PCA analysis shown for auranofin, vancomycin,
linezolid and control proteins quantified by proteomic analysis. The plot depicts the
variance inside each group and the protein expression pattern of drug treated and
control groups. (b) Heat map generated comparing auranofin-, vancomycin- and
linezolid-treated cells to untreated control S. aureus cells is shown. Triplicate samples
were used for each group. One-way analysis of variance (ANOVA) was used for
statistical analysis and the proteins that were significantly differentially (P ≤ 0.05)
expressed were mapped. Red color indicates significantly increased ratios and green
color represents significantly decreased ratios.
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expression pattern of the auranofin-treated group resembles that of the linezolid-treated
group more so than either the control or vancomycin-treated groups (Figure 2.5a). The
proteins were separated into five groups based on molecular function (DNA, RNA, protein
synthesis, cell wall and lipid synthesis) (Figure 2.5b). Similar to the protein synthesis
inhibitor linezolid, treatment with auranofin leads to the down regulation of most of the
proteins involved in all five major biosynthetic pathways. The average fold changes (log2)
of proteins between auranofin and the control group involved in each pathway was: -0.76
(DNA), -0.37 (RNA), -0.26 (protein), -0.76 (cell wall) and -0.18 (lipid). In the presence of
auranofin, approximately 55% of the proteins were significantly differentially expressed
as compared to the control group (P ≤ 0.05). Of the 222 proteins that showed significant
differential expression, only 20% of these proteins were upregulated in the auranofintreated group compared to 40% of proteins that were upregulated in the control group (P ≤
0.05). These results suggest that auranofin treatment leads to significant down regulation
of most of the proteins involved in all five major biosynthetic pathways, which contributes
to the bactericidal effect of auranofin against S. aureus.

Thioredoxin reductase is not the sole target for auranofin in S. aureus
A recent investigation of auranofin as an antibacterial agent

213

reported that

auranofin exerts its bactericidal activity by targeting thiol-redox homeostasis through direct
inhibition of the thioredoxin reductase enzyme. The authors postulate that the glutathione
system present in certain species of Gram-negative (and Gram-positive) bacteria limits
their susceptibility to auranofin (as this system is functionally similar to the thioredoxin
system and can maintain redox homeostasis inside the bacterial cell when the thioredoxin
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reductase enzyme is inhibited). This led the authors to conclude that auranofin’s primary
antibacterial mechanism is through inhibition of thioredoxin reductase. While auranofin
has been shown to inhibit thioredoxin reductase both in S. aureus and M. tuberculosis, we
suspect that this enzyme is not the sole antibacterial target of auranofin for the reasons
outlined below. First, we have confirmed that the lack of antibacterial activity of auranofin
against Gram-negative bacteria (as presented in Table 2.2) is due to the permeability barrier
conferred by the outer membrane (OM)

Figure 2.6 Growth curve of novablue (DE3)-K12 wild-type and trxB/gor Origami-2 double

mutant E. coli strains in the presence of auranofin. E. coli strains were incubated with
indicated concentrations of auranofin in the presence and absence of PMBN (10 µg/ml)
and the growth was measured using a spectrophotometer.

and is not glutathione-mediated. Second, an E. coli double mutant strain (Origami-2)
containing mutations to both the thioredoxin reductase (trxB), the purported target of
auranofin, and glutathione reductase (gor), responsible for maintaining redox homeostasis
in the absence of TrxB, genes exhibited identical antibacterial activity to the wild-type E.
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coli strain (Novablue (DE3)-K12) (MIC = 16 µg/ml) (Table 2.2). However, there is a
greater than 32-fold improvement in antibacterial activity of auranofin when combined
with a subinhibitory concentration of PBNP (MIC = 0.5 µg/ml) (Table 2.2). This
observation was further validated by assessing the growth of wild-type and the double
mutant E. coli (Origami-2) strains in the presence of increasing concentrations of auranofin
(with or without PBMN) (Figure 2.6). Once again, the viability of the Origami-2 double
mutant was severely impacted by auranofin in the presence of a subinhibitory concentration
of PBMN; however, in the absence of PBMN, the double mutant strain exhibited a similar
growth pattern to the wild-type E. coli strain. This analysis, when combined with the
macromolecular synthesis assay and proteomics results, supports the notion that
thioredoxin reductase is not the sole target of auranofin in bacteria. Additionally, the outer
membrane, and not the glutathione system alone, is responsible for limiting auranofin’s
antibacterial activity against Gram-negative bacteria.

Auranofin inhibits S. aureus toxin production
Confirmation

that

auranofin

inhibits

bacterial

protein

synthesis

by

macromolecular synthesis assay, led us to inquire whether this drug would be capable of
suppressing the production of key virulence factors, such as toxins, produced by pathogens
like MRSA. Antimicrobials capable of disrupting or suppressing bacterial protein synthesis,
including agents like linezolid, are valuable and preferred options for treating patients
impacted by toxin-mediated bacterial infections, such as toxic shock syndrome (TSS) and
pneumonia caused by S. aureus 232-235. For example, inhibition of protein synthesis and the
subsequent suppression of toxin production is one of the advantages of linezolid’s
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mechanism of action over vancomycin

232-235

. Therefore to assess the capability of

auranofin to dampen production of key S.-aureus toxins, ELISA was utilized to detect toxin
production for MRSA USA300 treated with auranofin and two control antibiotics
(vancomycin and linezolid). Auranofin significantly inhibited production of two major S.
aureus toxins including Panton-Valentine leukocidin (PVL) and α-hemolysin (Hla) (Figure
2.7a). These results indicate that auranofin, similar to linezolid, possesses an advantage in
the management of toxin-mediated staphylococcal infections due to its ability to suppress
production of key staphylococcal toxins.

Auranofin effectively clears intracellular bacteria
As auranofin exhibited potent anti-MRSA activity against extracellular bacteria,
we were curious to explore the ability of auranofin to eliminate MRSA harboring inside
eukaryotic cells. MRSA is capable of entering multiple cell types, including macrophages,
in mammalian tissues thus permitting it to evade host defenses and permitting an infection
to persist for an extended time period

236

. Such infections are particularly challenging to

treat given many antibiotics are unable to permeate cellular membranes to gain entry into
these intracellular niches to kill MRSA

226,237-242

. One such example is the antibiotic

vancomycin, which has a clinical failure rate of more than 40% in treating S. aureus
pneumonia; failure is attributed in part to the inability of vancomycin to penetrate infected
alveolar macrophages to kill MRSA 243.
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Figure 2.7 Auranofin inhibits MRSA toxin production and effectively clears intracellular
bacteria. (a) Toxin production (ng/ml) in S. aureus MRSA USA300 after treatment with
auranofin or control antibiotics (linezolid or vancomycin) for one hour (data corrected for
organism burden). The results are presented as mean ± SD (n = 3). Statistical analysis was
done by two-tailed Student’s ‘t’ test. Asterisks (**) indicate statistical significance in
relation to the control (DMSO or water). P values of (** P ≤ 0.01) are considered
significant. (b) MRSA USA300 infected J774A.1 cells were treated with auranofin and
control antibiotics (vancomycin or linezolid) for 24 hours and the percent bacterial
reduction was calculated compared to untreated control groups. The results are given as
mean ± SD (n = 3). Two-tailed Student’s ‘t’ test was employed and P values of (*, # ≤ 0.05)
are deemed significant. Auranofin was compared to controls (*) and to antibiotics (#).
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In order to investigate the efficacy of auranofin in clearing intracellular MRSA, this drug
was tested against macrophage cells (J774.A1) infected with MRSA. At a non-toxic
concentration of 0.5 µg/ml (Figure 2.9); auranofin effectively clears more than 60% of
intracellular MRSA (Figure 2.7b). In contrast, conventional antibiotics such as linezolid (8
µg/ml) and vancomycin (4 µg/ml) are not able to reduce the bacterial burden inside infected
macrophages by more than 30% (Figure 2.7b). Altogether the results suggest that auranofin
is capable of eradicating MRSA harboring inside mammalian cells. These findings suggest
that auranofin is a potential valuable treatment option for challenging infections/diseases
(such as pneumonia) where MRSA reside inside host cells.

Auranofin rescues mice from MRSA septicemic infection
The efficacy of auranofin was evaluated in both a lethal and non-lethal systemic
MRSA infection model. In the lethal septicemic study, mice were infected intraperitoneally
with MRSA USA300. One hour post-infection, four groups of mice (n = 10 mice per group)
were treated orally with auranofin at a clinical dose of 0.125 or 0.25 mg per kg, linezolid
at a dose of 25 mg per kg, or the vehicle alone as a control. Mice were treated once daily
for three days and monitored for a total of five days. Both auranofin and linezolid provided
a significant protection from mortality (Figure 2.8a). The survival rate of infected mice
improved dramatically when the dose of auranofin was increased. 80% of mice that
received a higher dose of auranofin, (0.25 mg per kg) survived for five days. All mice in
the group that received linezolid (25 mg per kg) survived for five days. These results
suggest that the potent in vitro activity of auranofin
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Figure 2.8 Auranofin is effective in a mouse model of MRSA septicemic infection. (a)
Ten mice per group were infected (i.p) with lethal dose of MRSA USA300 and treated
orally with auranofin (0.125 or 0.25 mg/kg), linezolid (25 mg/kg), or the vehicle alone for
three days (one dose per day). Mice were monitored for five days and the percent survival
was calculated. A log rank test was performed using 95% confidence intervals and the
statistical significance was calculated in order to compare treated to control groups. P
values of (* ≤ 0.05) (** P ≤ 0.01) are considered as significant. (b) Five mice per group
were infected (i.p) with non-lethal dose of MRSA USA300 and treated orally with
auranofin (0.25 mg/kg), linezolid (25 mg/kg), or the vehicle alone for two days (one dose
per day). 24 hours after the last treatment, mice were euthanized and their spleen and liver
were excised and homogenized in TSB to count viable MRSA colonies. The number of
CFU from each mouse is plotted as individual points. Statistical analysis was conducted
using the two-tailed Student’s ‘t’ test and P values of (* ≤ 0.05) are considered as
significant. (c) Auranofin in combination with systemic antimicrobials effectively inhibits
the growth of S. aureus. Growth of MRSA USA300 was measured after incubating with
auranofin, control antibiotics, or a combination of auranofin + a control antibiotic. The
checkerboard assay was performed by diluting one drug along the ordinate and the second
drug along the abscissa of a 96-well plate. Percent bacterial growth was measured using a
spectrophotometer.
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translates in vivo in protecting mice from septicemic MRSA infection. Next we moved to
study the efficacy of auranofin in reducing the burden of MRSA in a non-lethal septicemic
mouse model. Mice were infected with a non-lethal dose of MRSA USA300 and each
group of mice received two oral doses of auranofin (0.25 mg per kg), linezolid (25 mg per
kg) or the vehicle alone. As depicted in Figure 2.8b, auranofin and linezolid produced a
significant reduction in mean bacterial load in murine organs including the spleen and liver.
Both treatment with auranofin and treatment with linezolid reduced the mean bacterial load
by more than 95% in the spleen (Figure 2.8b). However, in the liver, auranofin produced a
90% reduction in MRSA load whereas linezolid was only able to reduce the burden of
MRSA by 70% (Figure 2.8b).

Combination therapy of auranofin with systemic antimicrobials
Utilizing a single agent to treat bacterial infections in the clinical setting appears to
have become less effective with the rise of additional strains of multidrug-resistant S.
aureus

244,245

. Combining two or more antibiotics together for the treatment of MRSA

infections has been explored as an alternative strategy in the healthcare setting in order to
improve the morbidity associated with these infections and to reduce the potential
emergence of additional resistant strains

244,246,247

. Therefore, we investigated auranofin’s

ability to be used in combination with antimicrobials frequently used to treat systemic
MRSA infections. When tested against a highly-prevalent strain of MRSA USA300,
auranofin exhibited an additive effect in inhibiting bacterial growth when combined with
the antibiotics ciprofloxacin, linezolid and gentamicin (average fractional inhibitory
concentration, FIC index = 0.5 to 1) (Figure 2.8c). Thus the above results indicate auranofin
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is a potential candidate for further investigation as a partner with conventional
antimicrobials for the treatment of systemic staphylococcal infections.
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Figure 2.9 Cytotoxicity assay in murine macrophage-like cells (J774A.1) cells. J774A.1
cells were treated with different concentration of auranofin ranging from 0 to 256µg/ml.
DMSO was used as a negative control. Cell viability was measured by MTS assay and IC50
of auranofin to cause cytotoxicity in J774A.1 cells was calculated.

2.1.4

Discussion

Methicillin-resistant Staphylococcus aureus infections continue to pose a
significant challenge to healthcare providers in part due to the diminishing arsenal of
effective antibiotics available to treat infected patients. The development of novel
antibacterial treatments utilizing the traditional approach in drug discovery has not kept
pace with the rapid emergence of bacterial resistance to conventional antibiotics. This has
led researchers to explore alternative methods to discover new treatment options for
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bacterial infections; one method that is less time-consuming and more financially viable is
repurposing drugs (initially approved for other clinical indications) that possess potent
antimicrobial activity. Auranofin is an example of a clinical drug that has been successfully
repurposed recently for another indication. Initially approved as a treatment option for
patients suffering from rheumatoid arthritis, auranofin was granted orphan-drug status
from the FDA as an anti-parasitic agent intended for treatment of human amebiasis in 2012
25

The successful repurposing of auranofin as an anti-parasitic agent paved the way
for researchers to explore other clinical applications for auranofin. Recent studies,
including the present work, demonstrate that auranofin possesses potent antibacterial
activity against important Gram-positive pathogens, including MRSA. One of the key
structural features of auranofin is that it is an organogold compound; however unlike other
gold compounds including sodium aurothiomalate and sodium aurothioglucose hydrate
(MIC >16 µg/ml), auranofin exhibits potent antibacterial activity against an array of
different Gram-positive bacteria (including S. aureus, E. faecium, E. feacalis, S.
pneumoniae and S. agalactiae) with an average minimum inhibitory concentration (0.125
µg/ml) eighteen times lower than the achievable drug concentration in human plasma (2.37
µg/ml which is equivalent to a mean steady-state blood gold concentration of 3.5 μM)25
This is in agreement with previous published studies

212,214

; however several of these

reports have indicated that auranofin lacks antibacterial activity against Gram-negative
bacteria. A recent study suggested that this lack of activity was due to the presence of the
glutathione system in Gram-negative bacteria which helps to mediate resistance to
auranofin in these pathogens

213

. However, when we assessed auranofin’s antibacterial
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activity against both wild-type and Origami-2 (trxb/gor double mutant) E. coli mutant
strains, neither strain was susceptible to auranofin even at a concentration of 16 µg/ml 248.
This suggests an alternative mechanism may be responsible for the lack of activity
observed with auranofin against Gram-negative bacteria.
Further investigation revealed that the presence of the outer membrane in Gramnegative bacteria is the main culprit responsible for the lack of antibacterial activity
observed. When wild-type and Origami-2 E. coli strains were incubated with auranofin
supplemented with a subinhibitory concentration of PMBN (to permeabilize the outer
membrane), both strains showed similar sensitivity to auranofin with a MIC value of 0.5
µg/ml (Table 2.2). This observation was further validated by assessing the growth of wildtype and double mutant E. coli strains in the presence of increasing concentrations of
auranofin (with or without PBMN). Once again, the viability of the Origami-2 double
mutant was severely impacted by the presence of auranofin (in the presence of a
subinhibitory concentration of PBMN); however, in the absence of PBMN, the double
mutant strain exhibited a similar growth pattern to the wild-type E. coli strain. Thus the
lack of direct antibacterial activity of auranofin observed against Gram-negative bacteria
appears to be a byproduct of the barrier imposed by the outer membrane in addition to the
presence of active efflux pumps more so than the presence of the glutathione system.
Confirmation of auranofin’s potent antibacterial activity led us to next explore the
potential mechanism of action (MOA) against S. aureus. Previous studies have found that
auranofin inhibits Clostridium difficile and Treponema denticola growth through the
disruption of selenium metabolism 249,250. We hypothesized that the MOA of auranofin in
S. aureus differs from the MOA in C. difficile and T. denticola due to the absence of
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selenoproteins in S. aureus 251. In order to examine this hypothesis, we tested the activity
of auranofin on S. aureus cultures supplemented with selenium in the form of selenite or
L-selenocysteine

249,250

. Unlike in C. difficile and T. denticola, our selenium

supplementation did not reverse the inhibitory action of auranofin observed with S. aureus
(data not shown). This clearly indicates that the MOA of auranofin differs between S.
aureus and C. difficile. Next, we attempted to generate a S. aureus mutant that is resistant
to auranofin. Determination of mutation frequencies for resistance to auranofin were
carried out as described before 252. No colonies resistant to auranofin at three-, five-, or tenfold the MIC were detected which is in agreement with a previous report 213.
The inability to generate a resistant mutant to auranofin suggests this drug may have
multiple targets or possess a nonspecific mode of action against S. aureus

253

. To assess

this, a macromolecular synthesis assay was employed testing auranofin at different
concentrations against S. aureus. Interestingly, at a subinhibitory concentration (0.5 ×
MIC), auranofin leads to significant reduction in both the cell wall and DNA biosynthetic
pathways. At its MIC, auranofin also suppresses bacterial protein synthesis, indicating
auranofin may in fact have a complex mode of action against S. aureus. Harbut et al’s
recently reported auranofin exerts its antibacterial activity primarily by targeting thiolredox homeostasis through direct inhibition of the thioredoxin reductase enzyme (TrxB in
Staphylococcus aureus and TrxB2 in Mycobacterium tuberculosis). While inhibition of
TrxB activity in S. aureus can lead to inhibition of DNA synthesis, it does not explain the
inhibition of cell wall synthesis observed with auranofin. Taken altogether, our analysis
indicates that the thioredoxin reductase enzyme most likely is not the sole target of
auranofin in S. aureus and in Gram-negative bacteria; this is in agreement with a recent
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report investigating auranofin’s antibacterial activity against Streptococcus pneumoniae
and S. aureus

215

. Further studies are needed to fully elucidate the exact antibacterial

molecular target(s) of auranofin.
In the course of investigating auranofin’s mode of action via macromolecular synthesis,
we discovered that auranofin inhibits protein synthesis in S. aureus. This discovery led us
to analyze whether auranofin’s inhibitory activity against bacterial protein synthesis would
lead to suppression in the production of key toxins in S. aureus. Our study revealed that
auranofin is capable of inhibiting production of both Panton-Valentine leukocidin and αhemolysin, two pore-forming cytotoxins that injure host immune cells and promote
infection 254. Thus, in addition to its direct –cidal effect on bacteria, auranofin may alleviate
the morbidity associated with MRSA infections by limiting bacteria from generating
harmful toxins.
We next moved to confirm auranofin’s antibacterial ability in vivo using two murine
MRSA systemic infection models (non-lethal and lethal). Both in vivo studies performed
in mice confirmed auranofin retains its antibacterial activity in vivo. In addition to this,
auranofin demonstrated the ability to eradicate intracellular MRSA present inside infected
macrophage cells; this expands the potential application if auranofin for use in treatment
of systemic MRSA infections. Furthermore, auranofin demonstrated additive activity when
combined with antibiotics traditionally used to treat systemic MRSA infections which is in
agreement with previous a study

213

. Thus, auranofin has potential use both as a single

agent and as a combinatorial partner with conventional antibiotics to treat MRSA infections.
This latter statement is important given the emergence of resistance to systemic
antimicrobials currently used in the clinic; pairing these antibiotics with auranofin may
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stymie the rate at which resistance to these antibiotics arises. Finally, because of increased
interest in repurposing auranofin, a Phase II clinical trial seeking to determine the
pharmacokinetic parameters and the safety of increased doses of auranofin are currently
underway (ClinicalTrials.gov identifier: NCT01419691 and NCT02089048). This strongly
supports the postulate that auranofin has considerable promise to be repurposed as an
antibacterial agent for the treatment of systemic bacterial infections.

2.2

Repurposing auranofin for the treatment of cutaneous staphylococcal
infections

(Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick VE,
Paul LN, Seleem MN. Repurposing auranofin for the treatment of cutaneous
staphylococcal

infections. International journal of antimicrobial agents and

chemotherapy. 2016 Jan 23; S0924-8579(16)00012-1)

2.2.1

Introduction

Staphylococcus aureus, is the most frequently isolated pathogen from human skin
infections and is the leading cause of nosocomial wound infections 107,211,255,256. Virulence
factors and toxins (such as α-hemolysin and Panton-Valentine leukocidin) secreted by
drug-resistant strains of S. aureus permit this pathogen to evade the host immune system,
leading to recurring/chronic infection, prolonged inflammation, and delayed healing of
infected wounds 107,256. Furthermore, cutaneous staphylococcal skin infections can develop
into invasive infections that ultimately result in septicemia 257,258. Recently, skin infections
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with biofilm-producing staphylococci have become an emerging clinical problem;
treatment failure is occurring more frequently with topical drugs of choice including
mupirocin and fusidic acid, indicating new treatment options are urgently needed 211,259,260.
The recent FDA approval of drugs such as tedizolid phosphate and dalbavancin to combat
skin infections caused by Gram-positive pathogens

261,262

further highlights the pressing

need for the identification of new antibacterials capable of treating cutaneous MRSA
infections.
Most current antibiotics were discovered by screening libraries of chemical
compounds in order to find new lead “hits” that could be subsequently modified to enhance
potency physicochemical properties and mitigate toxicity

210

. However, this process is a

risky venture given the significant financial and time investment required by researchers
and limited success rate of translating these compounds to the clinical setting. An
alternative approach to unearthing new antibacterials that has received more attention
recently is evaluating the repository of approved drugs (or drugs that made it to clinical
trials but failed to receive regulatory approval) in order to identify candidates that can be
repurposed as antimicrobials

210

. Recently, we assembled and screened half of all

commercially available drugs (~ 2,200 drugs) and small molecules used in human clinical
trials 7,211 and identified three drugs (auranofin, ebselen and 5-fluoro-2'-deoxyuridine) that
exhibited potent antibacterial activity against important clinical pathogens. One of these
drugs, auranofin, was found to inhibit growth of clinical isolates of MRSA at
submicrogram/mL concentrations in vitro.
Auranofin is an oral gold-containing drug initially approved for treatment of
rheumatoid arthritis

263

. Recent studies have demonstrated that auranofin also possesses

61
potent anti-parasitic

263

and antibacterial activity

249,264

, including against MRSA and

Streptococcus pneumoniae 58,212,213,265. Recent studies by Harbut et al. 213 and Aguinagalde
et al

265

demonstrated that auranofin is efficacious in the treatment of invasive

staphylococcal infections. However, the efficacy of auranofin for treatment of cutaneous
MRSA infections remains unexplored.
Building upon these recent reports, the present study investigated the in vitro
antibacterial and antibiofilm activities of auranofin against multidrug-resistant clinical
isolates of S. aureus and tested the efficacy of auranofin in a mouse model of MRSA skin
infection. In addition to this, our study aimed to examine the immune-modulatory activity
of auranofin in MRSA infected skin lesions. The findings presented in this study lay the
foundation for repurposing auranofin as a novel topical antibacterial agent for treatment of
cutaneous MRSA infections in humans.

2.2.2 Materials and Methods
Bacterial strains and reagents
Bacterial strains used in this study are presented in Table 1. Auranofin (Enzo Life
Sciences), mupirocin (AppliChem), clindamycin (Sigma-Aldrich), and fusidic acid
(Sigma-Aldrich) were all purchased from commercial vendors. Mueller-Hinton broth
(MHB) was purchased from Sigma-Aldrich while Trypticase soy broth (TSB), Trypticase
soy agar (TSA), and mannitol salt agar (MSA) were purchased from Becton, Dickinson
and Company (Cockeysville, MD).
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Antibacterial assays
In order to examine auranofin’s antibacterial activity against S. aureus, the broth
microdilution method was utilized to determine the minimum inhibitory concentration
(MIC) of each drug (tested in triplicate) following the guidelines outlined by the Clinical
and Laboratory Standards Institute (CLSI). Each drug was incubated with the appropriate
strain of S. aureus for 16 hours at 37°C before the MIC was confirmed. The MIC was
classified as the lowest concentration of each test agent where bacterial growth was not
visible.

Mice infection
Eight week old female BALB/c mice (Harlan Laboratories, Indianapolis, IN) were
used in this study. All animal procedures were approved by the Purdue University Animal
Care and Use Committee (PACUC) (protocol number: 1207000676). An in vivo murine
MRSA skin infection study was conducted, as described elsewhere

211,266

. Briefly, mice

(five mice per group) received an intradermal injection (40 µl) of MRSA USA300
containing 1.65×108 colony forming unit (CFU). Approximately two days later, an open
wound/abscess formed at the site of injection. Five groups of mice were then treated
topically with a suspension containing 2% fusidic acid, 2% mupirocin, or 0.5%, 1%, or 2%
auranofin in petroleum jelly. Another two groups were treated orally with 25 mg/kg of
either linezolid or clindamycin. The control group was treated with petroleum jelly
(vehicle). Mice were treated twice daily for five days. 24 hours after the last dose was
administered, mice were humanely euthanized via CO2 asphyxiation. The region around
the skin wound was slightly swabbed with 70% ethanol, and the wound (1 cm2) was

63
precisely excised, homogenized, serially diluted in PBS, and then transferred to MSA
plates. Plates were incubated at 37°C for 24 hours prior to counting MRSA CFU.

Detection of cytokines from MRSA murine skin infection experiment
Skin homogenates obtained from the murine skin infection experiment described above
were centrifuged. The supernatant was collected and used to quantify the levels of
inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6),
interleukin-1 beta (IL-1β), and monocyte chemo attractant protein-1 (MCP-1). Duo-set
ELISA Kits (R&D Systems, Inc.) were used for cytokine detection using the
manufacturer’s protocol.

Combination testing of auranofin with commercial antibiotics
The additive activity of auranofin with conventional topical antibiotics (mupirocin,
fusidic acid and retapamulin) was evaluated as described in a previous study 223,224. Briefly,
MRSA USA300 was incubated with auranofin, control antibiotics, or a combination of
auranofin + a control antibiotic at different concentrations for 16 hours. Next, the optical
density (at 600 nm) was measured using a spectrophotometer. The percent bacterial growth
for each treatment regimen was calculated and presented.

Biofilm assay
Auranofin’s ability to disrupt adherent staphylococcal biofilm was analyzed using the
microtiter dish biofilm formation assay 204,211. S. aureus (ATCC 6538) and S. epidermidis
(ATCC 35984) were inoculated in TSB supplemented with 1% glucose and transferred to
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all wells of a 96-well tissue-culture treated plate. Bacteria were incubated at 37°C for 24
hours to permit the formation of an adherent biofilm. The medium was removed and wells
were carefully washed with PBS four times to remove planktonic bacteria. TSB was
transferred to all wells of the 96-well plate prior to addition of auranofin and control
antibiotics (linezolid and vancomycin). Drugs were added at the indicated concentrations
and incubated again at 37°C for 24 hours. Afterward, plates were washed by submerging
in tap water. The biofilms were stained with 0.1% (wt/vol) crystal violet for 30 min at room
temperature before subsequently being washed four times with water. Plates were air dried
for one hour prior to the addition of 95% ethanol to solubilize dye bound to the biofilm.
The biofilm mass was quantified by measuring the optical density of wells (at 595 nm)
using a micro plate reader (Bio-Tek Instruments Inc.). Data are presented as the average
percent biofilm mass reduction of each test agent (tested in triplicate) in relation to
untreated wells.

Effect of auranofin and conventional antibiotics on persister cells
The effect of auranofin and conventional antibiotics (linezolid, retapamulin and
vancomycin) on S. aureus planktonic cells that demonstrated tolerance to ciprofloxacin
(persister cells) was investigated as described in a previous report 267. Briefly, an overnight
culture of MRSA USA300 (1 × 1010 CFU) was incubated with ciprofloxacin (10 µg/ml)
(80X MIC) at 37°C for six hours. Bacteria were then centrifuged and test agents (auranofin,
linezolid, retapamulin, vancomycin, ciprofloxacin) were added at a concentration of 100 ×
MIC. MIC of retapamulin and ciprofloxacin against MRSA USA300 were 0.5 and 0.125
µg/ml respectively. Bacteria were incubated with test agents at 37°C for 48 hours. Samples
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were collected after 0, 2, 4, 6, 24, and 48 hours, diluted in PBS, and transferred to TSA
plates. Plates were incubated at 37°C for 24 hours before viable CFU for each treatment
group was determined.
Toxicity assay
Human keratinocyte (HaCat) cells were seeded at a density of 40,000 cells per well in
a 96-well tissue culture plate and the MTS assay was carried out. Auranofin at a
concentration ranging from 0 to 16 µg/ml was added to appropriate wells and the cells were
incubated for 24 hours. Finally, the cells were washed with PBS and the MTS assay reagent
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H
tetrazolium) was added. After four hours incubation at 37°C, the absorbance was measured
at 490 nm using an ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Results are expressed as percent cell viability of auranofin-treated cells in comparison to
cells treated with DMSO.

Statistical analyses
Statistical analyses were assessed using GraphPad Prism 6.0 (GraphPad Software, La
Jolla, CA). P values were calculated using the Student’s t test or Kaplan-Meier (log rank)
survival test, as indicated. P values of ≤ 0.05 were deemed significant.

2.2.3

Results and Discussion

In vitro antibacterial activity of auranofin
The antimicrobial activity of auranofin was assessed against a panel of clinicallyrelevant strains of multidrug-resistant Staphylococcus aureus (Table 2.3). Auranofin
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inhibited growth of all tested strains including those resistant to conventional
antimicrobials such as methicillin and vancomycin. The minimum inhibitory concentration
(MIC) of auranofin required to inhibit 50% (MIC50) and 90% (MIC90) of MRSA, VRSA
and methicillin-sensitive S. aureus (MSSA) strains was found to be 0.0625 (MIC50) and
0.125 µg/ml (MIC90), respectively. With regards to vancomycin-intermediate S. aureus
(VISA), the MIC90 value were found to be 0.125 µg/ml. The MIC values determined for
auranofin correlate with results reported in other studies 212,214,265.

Table 2.3 Minimum Inhibitory Concentration (MIC) of auranofin and control antibiotics
against Staphylococcus aureus and S. epidermidis
Strain type

Strain ID

Methicillin-sensitive
S.
ATCC 6538
aureus (MSSA)
RN4220
NRS72
NRS77
NRS846
NRS860
Methicillin resistant
S.
USA300
aureus (MRSA)
NRS194
NRS108
NRS119
(Linr)
ATCC
43300
ATCC
BAA-44

Vancomycinintermediate S.
aureus (VISA)

Phenotypic properties
Quality control and biofilm-forming
strain
Resistant to penicillin

Resistant to erythromycin, methicillin,
and
tetracycline
Resistant to methicillin
Resistant to gentamicin

Auranofin Linezolid Vancomyc
(µg/ml) (µg/ml)
in
(µg/ml)
0.0625
2
1
0.0625
0.125
0.0625
0.0625
0.125
0.125

2
2
2
2
2
2

1
1
1
1
1
1

0.0625
0.125
0.0625

2
2
>16

1
1
1

0.0625

2

1

0.0625

2

1

0.0625

2

1

0.0625
0.0625
0.0625
0.0625
0.0625

2
2
2
2
2

1
1
2
1
8

0.125
0.125

1
1

2
4

Resistant to linezolid
Resistant to methicillin

NRS70
NRS71
NRS100
NRS123
NRS107

Multidrug-resistant strain
Resistant to erythromycin, clindamycin,
and
spectinomycin
Resistant to tetracycline and methicillin
Resistant to tetracycline and methicillin
Resistant to tetracycline and methicillin
Resistant to methicillin and mupirocin

NRS1
NRS19
NRS37

Resistant to aminoglycosides and
tetracycline; glycopeptideintermediate S. aureus
Glycopeptide-intermediate S. aureus
Glycopeptide-intermediate S. aureus
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Table 2.3 continued
Vancomycinresistant S.
aureus (VRSA)

VRS1
VRS2
VRS3a
VRS3b
VRS4
VRS5
VRS6
VRS7
VRS8
VRS9
VRS10
VRS11a
VRS11b
VRS12
VRS13

S. epidermidis

NRS101

Resistant to vancomycin
Resistant to vancomycin, erythromycin,
and spectinomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin, erythromycin,
and spectinomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin and β-lactams
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin
Prototype biofilm producer; resistant to
Methicillin and gentamicin

0.0625

1

>16

0.0625

1

8

0.0625
0.0625
0.0625

2
2
2

>16
>16
>16

0.0625
0.125
0.0625
0.0625
0.0625
0.125
0.0625
0.0625
0.125
0.0625
0.0625

2
2
2
2
2
2
2
2
2
2
2

>16
>16
>16
>16
>16
>16
>16
>16
>16
>16
1

Interestingly, auranofin (16-fold lower MIC) exhibited higher potent antibacterial
activity against MSSA and MRSA compared to the antibiotics vancomycin (MIC of 1
µg/ml) and linezolid (MIC ranged from 2-4 µg/ml). Auranofin managed to retain its
antibacterial activity against MRSA strains that are resistant to several antibiotic classes
including glycopeptides, oxazolidones, tetracycline, β-lactams, macrolides, and
aminoglycosides; this suggests that cross-resistance between these particular antibiotics
and auranofin is unlikely to occur.

Auranofin is superior to conventional antibiotics in reducing the bacterial load in a
mouse model of MRSA skin infection
Confirmation of auranofin’s potent in vitro anti-MRSA activity, led us to next
investigate the efficacy of this drug in treating MRSA skin infections. S. aureus, in
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particular MRSA, is a leading cause of skin infections in humans globally; of particular
concern is MRSA USA300 which has been linked to the majority of skin and soft tissue
infections present in the United States 255. To assess auranofin’s potential use as a topical
antimicrobial agent in vivo, mice were intradermally infected with MRSA USA300 and the
efficacy of auranofin and control antimicrobials on MRSA load were investigated. . A
significant reduction in the mean bacterial load was observed for each treatment condition
when compared with the control group receiving the vehicle (petroleum jelly) alone (P ≤
0.05) (Figure 2.10). Mice treated with 2% auranofin produced the largest reduction in
MRSA CFU (3.64±0.14 log10), followed by 2% fusidic acid (2.83±0.16 log10), 2%
mupirocin (2.63±0.14 log10), 1% auranofin(2.51±0.11 log10), clindamycin (25 mg/kg)
(1.90±0.24 log10), 0.5% auranofin (1.88±0.18 log10) and linezolid (25 mg/kg) (1.77±0.11
log10) (Figure 2.10).
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Figure 2.10 Efficacy of treatment of MRSA murine skin lesions with auranofin 0.5, 1, and
2%, linezolid and clindamycin (25 mg/kg), mupirocin (2%), fusidic acid (2%) and
petroleum jelly (negative control) twice daily for five days were evaluated. Statistical
analysis was calculated by the two-tailed Student’s t test. P values of (*, # P ≤ 0.05) are
considered as significant. Auranofin was compared both to controls (*) and to antibiotics
(#).
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Topical application of auranofin (2%) produced a more significant reduction (P ≤ 0.05) in
the mean bacterial load when compared to treatment with drugs of choice including
mupirocin (2%) and fusidic acid (2%). Thus auranofin shows promise for use as a topical
antimicrobial and, in our study, is superior to conventional antimicrobials commonly used
to treat MRSA skin infections.

Auranofin reduces inflammatory cytokines induced by MRSA skin infection
Exotoxins including α-hemolysin, leukocidins and toxic shock syndrome toxin (TSST1) secreted by S. aureus during an infection induce a strong inflammatory cascade reaction
107,256

.

This cascade is thought to play a greater role in the severity of S. aureus skin

infections more than the size of the bacterial burden and can lead to an infection persisting
for a longer time period 256. Therefore, we investigated the immunomodulatory activity of
auranofin in a topical application against MRSA skin infection. Supernatants collected
from the wounds of mice infected with MRSA USA300 were used to detect the levels of
inflammatory cytokines such as TNF-α, IL-6, IL-1β and MCP-1. Wounds treated with
either a 1 or 2% ointment of auranofin significantly reduced all inflammatory cytokines
tested (IL-6, IL-1β, TNF-α, and MCP-1) (Figure 2.11). Auranofin (at 0.5%) also
significantly reduced IL-6 and TNF-α. Mice administered an oral dose of clindamycin
reduced IL-1β and TNF-α, whereas oral treatment of mice with linezolid reduced only IL1β. Thus it appears that auranofin has more potent anti-inflammatory activity, due to the
reduction in the presence of several pro-inflammatory cytokines, compared to the
conventional antimicrobials tested (linezolid, clindamycin, mupirocin and fusidic acid).
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The results garnered from this study suggest auranofin’s anti-inflammatory properties
warrant further investigation in the treatment of chronic wounds caused by S. aureus
102,105,107
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Figure 2.11 Effect of auranofin on inflammatory cytokines in MRSA skin lesions.
Supernatants from skin homogenates were used for cytokine detection by ELISA.
Statistical analysis was calculated by the two-tailed Student’s t test. P values of (* P ≤
0.05) are classified as significant
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Combinational therapy of auranofin with topical antimicrobials
With the rapid emergence of MRSA strains resistant to topical antimicrobials of choice,
including to mupirocin and fusidic acid, combination therapy using multiple antibacterials
is being explored 260,268,269. Therefore, we assessed the activity of auranofin against MRSA
USA300 in the presence of topical antimicrobials such as mupirocin, retapamulin and
fusidic acid. Auranofin, in combination with all three tested topical antibiotics, exhibits
additive activity (average fractional inhibitory concentration (FIC) index ranges from 0.5
to 1) in inhibiting MRSA growth (Figure 2.12). This suggests that auranofin can be
potentially combined with traditional topical antimicrobials such as mupirocin,
retapamulin and fusidic acid for the treatment of staphylococcal skin infections though
further in vivo studies are needed to confirm this point.

Figure 2.12 Auranofin in combination with three topical antimicrobials effectively inhibits
the growth of S. aureus. Growth of MRSA USA300 was measured after incubating with
auranofin, control antibiotics, or a combination of auranofin + a control antibiotic. The
checkerboard assay was performed by diluting one drug along the ordinate and other drug
along the abscissa of the 96-well plate. Percent bacterial growth was measured using a
spectrophotometer.
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Auranofin kills bacterial persister cells and reduces pre-formed biofilms
Treatment of bacterial infections with current antimicrobials are often challenging due
to the inability of conventional antibiotics to target and disrupt adherent bacterial biofilms
270

. These problematic infections can become chronic when specialized dormant cells

Figure 2.13 Auranofin effectively kills persister cells and reduces established biofilms of
S. aureus and S. epidermidis. (A) Effect of auranofin and control antibiotics on
ciprofloxacin tolerant MRSA USA300 were determined by time kill assay. (B) Effect of
auranofin, vancomycin and linezolid on pre-formed Staphylococcus biofilms. The results
are presented as means ± SD (n = 3). Statistical analysis was calculated using the twotailed Student’s t test. P values of (*, # P ≤ 0.05) are deemed significant. Auranofin was
compared both to controls (*) and to antibiotics (#).
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called persisters (that are normally resistant to antibiotics), become encased within these
biofilms thus protecting them from exposure to and eradication by antibiotics 267. To assess
the ability of auranofin to mitigate the impact of staphylococcal biofilms, we first
investigated the effect of auranofin on persister cells. When treated with ciprofloxacin,
MRSA USA300 (in exponential growth phase) produces a biphasic killing pattern that
results in surviving persister cells (Figure 2.13a). The subsequent addition of conventional
antimicrobials such as linezolid and retapamulin had minimal impact in reducing the
number of persisters. However, treatment with auranofin resulted in complete eradication
of persister cells after 48 hours, a result that is comparable to vancomycin (Figure 3.4a).
Auranofin’s ability to kill S. aureus persisters led us to next assess auranofin’s impact on
disrupting pre-formed staphylococcal biofilms. Auranofin, at 1 µg/ml, significantly
reduced S. aureus biofilm mass by more than 60%; in contrast, even at high concentrations
neither linezolid (256 µg/ml) nor vancomycin (128 µg/ml) were able to reduce biofilm
mass by more than 30% (Figure 2.13b). Similarly, auranofin, at 4 µg/ml, was more
effective at reducing S. epidermidis biofilm mass (60% reduction observed), compared to
both linezolid (512 µg/ml) and vancomycin (256 µg/ml), which reduced biofilm mass by
only 20% (Figure 2.13b). These results demonstrate that auranofin is capable of killing S.
aureus persister cells and reducing adherent staphylococcal biofilms. This lays the
foundation for further analysis using auranofin as a novel treatment option for both chronic
and biofilm-related staphylococcal infections.
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In vitro cytotoxicity study
Toxicity of auranofin to HaCaT cells was investigated using the MTS assay. Results
indicate that the concentration of auranofin required to inhibit 50% (IC50) of HaCaT cell
growth is 6.38+0.29 µg/ml (Fig. 2.14). This value is nearly one hundred times larger than
the MIC50 value for auranofin against MRSA. Additionally, auranofin is currently
approved for long-term treatment of rheumatoid arthritis and patients have been taking the
drug daily (6 mg/day) for more than five years, a much longer course of treatment than is
traditionally prescribed for antibiotics (one to two weeks) 271. Thus toxicity with auranofin
should not be a significant impediment to repurposing this drug as a novel antibacterial

Cell Viability (%)

agent for the treatment of cutaneous MRSA infections.

IC50 = 6.38+0.29

Auranofin (µg/ml)

Figure 2.14 Cytotoxicity assay in human keratinocyte (HaCaT) cells. HaCaT cells treated
with different concentration (0 to 16 µg/ml) of auranofin for 24 hours were assessed for
cell viability by MTS assay. IC50 of auranofin (reducing viability of HaCaT cells by 50%)
was calculated.
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2.2.4

Conclusion

In summary, the present study demonstrates that auranofin, an antirheumatic drug,
also possesses potent in vitro antistapylococcal activity against multidrug-resistant S.
aureus. The in vitro results for auranofin were confirmed in a murine MRSA skin infection
model that demonstrated that auranofin is superior to conventional antimicrobials
(mupirocin and fusidic acid) in reducing the bacterial burden in infected wounds. In
addition to decreasing the bacterial load, auranofin exhibits potent anti-inflammatory
activity, reducing the presence of four key cytokines (IL-6, IL-1β, TNF-α, and MCP-1)
known to increase the morbidity associated with skin infections. Furthermore, auranofin’s
ability to disrupt adherent staphylococcal biofilms and kill persister cells combined with
its excellent safety profile, collectively support the notion that auranofin is a good
candidate for repurposing as a topical antimicrobial for the treatment of staphylococcal
skin infections.

2.3

Repurposing ebselen for the treatment of staphylococcal infections

(Thangamani S, Younis W, Seleem MN. Repurposing ebselen for treatment of multidrugresistant staphylococcal infections. Scientific Reports. 2015, Jun 26;5:11596)

2.3.1

Introduction

In 2013, the Centers for Disease Control and Prevention (CDC) reported that more
than 11,000 people died from a methicillin-resistant Staphylococcus aureus (MRSA)related infection in the United States; this figure represents nearly half of all fatalities
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caused by antibiotic-resistant bacteria. Apart from the high mortality rate, S. aureus is the
most common pathogen associated with skin and soft tissue infections in humans272-274 .
Furthermore, S. aureus and its secreted toxins, and ability to form biofilm, are responsible
for interfering with the wound-healing process and causing systemic complications in
affected patients. In addition, the rising prevalence of multidrug-resistant S. aureus strains
and the extensive use of drugs of choice increase the likelihood that more challenging–totreat isolates will become a new scourge. Without a doubt, novel antimicrobials and novel
approaches to developing them are urgently needed; however, new antimicrobials are
becoming increasingly difficult to develop and are currently unable to keep pace with the
emergence of resistant bacteria109. The concept of repurposing drugs to find new
applications outside the scope of their original medical indication is recently gaining much
attention and has resulted in successes in a number of disease areas275,276. Unlike de novo
drug discovery, repurposing old drugs with known pharmacology and toxicology greatly
reduces the time, cost, and risk associated with antibiotic innovation277,278. In an attempt to
repurpose non-antibiotic drugs as antimicrobial agents, we screened National Institute of
Health (NIH) Clinical Collection library against MRSA275. Ebselen (2-phenyl-1, 2benzisoselenazol-3(2H)-one, PZ51), a selenium-containing compound, showed potent
activity, in an applicable clinical range, against S. aureus, which is in agreement with the
previous finding67.
Previous studies reported that ebselen possesses anti- atherosclerotic, antiinflammatory and antioxidative properties59-62. In addition, antimicrobial properties of
ebselen has also been explored. It has been shown to inhibit yeast and Escherichia coli in
vitro67,68. It interferes with proton-translocation function and ATPase activity in yeast,
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while in E. coli, it inhibits the thioredoxin reducatse (TrxR) enzyme69,68. However, clinical
applications and the underlying mechanism of action for its antibacterial activity against S.
aureus still remain unclear68.
Thus, the aim of our study is to assess the antibacterial action of ebselen and its
spectrum of activity against clinical isolates of MRSA; to investigate its antimicrobial
mechanism of action, anti-biofilm activity, and effect on toxin production in MRSA; and
finally to validate its antimicrobial efficacy, anti-inflammatory properties, and potential
clinical applications in MRSA infected animal model.

2.3.2 Materials and Methods
Bacterial strains and reagents
Staphylococcus strains used in this study are presented in Table 1. Mueller-Hinton broth
(MHB) was purchased from Sigma-Aldrich. Trypticase soy broth (TSB), Trypticase soy
agar (TSA), and Mannitol salt agar (MSA) were purchased from Becton, Dickinson
(Cockeysville, MD). Ebselen was purchased from (Adipogen corp, San Diego),
vancomycin hydrochloride (Gold Biotechnology), linezolid (Selleck Chemicals),
mupirocin (applichem, NE), and chloramphenicol (Sigma-Aldrich).

Antibacterial assays
MICs of drugs and antibiotics were evaluated by broth micro dilution method in
MHB according to the Clinical and Laboratory Standards Institute (CLSI)216. The MIC was
interpreted as the lowest concentration of the drug that completely inhibited the visible
growth of bacteria after incubating plates for at least 16hrs at 37°C. Each drug was tested
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in triplicate in at least two independent experiments and the highest MIC value was
reported.

Macromolecular synthesis assay
Macromolecular synthesis assay was carried out in S. aureus strain ATCC 29213.
Briefly, 100 μl of S. aureus grown in TSB at exponential phase (OD600 = 0.2 to 0.3), was
added to triplicate wells and different concentrations of ebselen and control antibiotics
(ciprofloxacin, rifampicin, linezolid, vancomycin and cerulenin) was added. DMSO treated
cells served as a negative control. Cells treated with drugs and DMSO were incubated at
37°C to allow the drug to act on bacterial cells. After 30 min incubation, radio labeled
precursors for DNA, RNA, protein, cell wall and lipid synthesis such as [3H] thymidine
(0.5μCi), [3H] uridine (0.5μCi), [3H] leucine (1.0 μCi), [14C] N-acetylglucosamine (0.4
μCi), [3H] glycerol (0.5 μCi), respectively, were added for each reaction. After 15 min,
reactions of DNA and RNA synthesis were stopped using 12 μl of 5% trichloroacetic acid
(TCA). Similarly, protein synthesis was stopped after 40 min using 12 μl of 5% TCA.
Reaction wells containing cell wall and lipid synthesis were stopped after 40 min using 100
μl of 8% SDS and 375 μl of chloroform/methanol (1:2) respectively. Reactions (DNA,
RNA and protein) were incubated on ice for 30 min and the TCA precipitated materials
were collected on a 25 mm GF/1.2 μM PES 96 well filter plate. After washing five times
with cold 5% TCA, the filters were dried and counted using a Packard Top Count
microplate scintillation counter. For cell wall synthesis, reaction tubes were then heated at
95°C for 30 min, cooled, centrifuged, and spotted onto nitrocellulose membrane filters (0.8
μM). After washing three times with 0.1% SDS, the filters were rinsed two times with
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deionized water, allowed to dry, and then counted using a Beckman LS3801liquid
scintillation counter. For lipid synthesis, reactions tubes were centrifuged at 13,000 rpm in
a microfuge for 10 min, and then 150 μl of the organic phase was transferred to a
scintillation vial and allowed to dry for at least 1 hour. Samples were then counted using
liquid scintillation counting. Based on the incorporation of radiolabeled precursors of DNA,
RNA, protein, cell wall and lipid synthesis, results were expressed as percent inhibition of
macromolecular synthesis pathways.

Measuring toxin production by ELISA
We tested the effect of ebselen on production of two important toxins Hla and PVL
by ELISA as described before279,280. Briefly, Overnight grown MRSA USA300 bacterial
culture was diluted approximately to 5×108 CFU/ml in TSB. 10X MICs of drugs and
antibiotics were added and incubated in the shaking incubator at 37°C. After 1hr the
bacterial culture was centrifuged and the supernatants were used for toxin detection.
ELISA plates (Nunc) were coated with 2 μg/ml of sheep anti-Hla IgG (Toxin
technology) in 100 μl of coating buffer and left overnight at 4 °C. Plates were then washed
3 times with Tris-buffered saline (TBS) containing 0.05% tween 20 (wash buffer) and then
blocking solution containing TBS with 2% bovine serum albumin was added. After 1hour
incubation at 37°C, plates were washed 3 times with wash buffer. A total of 100 μL of
bacterial supernatants were added and incubated the plates at 37°C for 2 hours. Purified
Hla (Toxin technology) was used to generate a standard curve. Plates were again washed
3 times with wash buffer and 100 μL of sheep anti-Hla HRP conjugate at a dilution of
1:300 was added. After 1 hour of incubation at 37°C and final washing, 100 μL of 3, 3′, 5,
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5′-tetramethylbenzidine substrate (Sigma-Aldrich) was added, and the reaction was
stopped after 10 minutes with 100 μL of 0.2N H2S04. Plates were read on a
spectrophotometer at optical density (OD) 450, and data were analyzed with SoftMax Pro
(Molecular Devices). The nominal range of this assay was 0.1–6 μg /mL
For PVL Luk-S toxin, ELISA plates (Nunc) were coated as before with 2 μg /ml of
mouse anti- PVL Luk-S monoclonal antibody (IBT Bioservices). Purified S. aureus LukSPV (His-tag) (IBT Bioservices) was used to generate a standard curve. The experiment was
carried as before except detection antibodies rabbit anti-PVL Luk-S (2 μg/ml) and rabbit
IgG HRP conjugate (R&D Systems) at a dilution of 1:6000 was used. The concentrations
of each toxin was compared as unadjusted concentrations (ng/ml) and corrected for
organism inoculum for each treatment (ng/ml to log10 CFU/ml).

Biofilm assay
Biofilm assay was performed as described before216. Briefly, biofilm-forming clinical
isolates of S. aureus (ATCC 6538) and S. epidermidis (ATCC 35984) were inoculated in
96-well flat-bottom cell culture plates (polystyrene) in TSB supplemented with 1% glucose
at 37°C for 24 h. Then culture medium was removed, and wells were carefully washed with
PBS four times to remove planktonic bacteria. Ebselen and antibiotics (linezolid,
mupirocin and vancomycin) were added at different concentrations in TSB, and plates were
incubated at 37°C for 24 h. The wells were rinsed by submerging the entire plate in a tub
containing tap water. Biofilms were stained with 0.1% (wt/vol) crystal violet for 30 min.
After staining, the dye was removed and the wells were washed four times with water. The
plates were dried for 1 h and ethanol (95%) was added to solubilize the dye bound to the
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biofilm. The OD of biofilm mass was measured at 595-nm absorbance by using a micro
plate reader (Bio-Tek Instruments Inc.)

Cytotoxicity assay
Human keratinocyte (HaCat) cells were seeded at a density of 10,000 cells per well
in a 96-well tissue culture plate (CytoOne, CC7682-7596) in DMEM media containing
10% fetal bovine serum (FBS) and incubated overnight at 37˚C. Then cells were treated
with ebselen at different concentrations from 0 to 128 µg/ml for 24 hours. Treated cells
were washed four times with PBS and the DMEM media containing MTS assay reagent,
3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium) (Promega, Madison, WI, USA) was added. After 4hrs of incubation at 37˚C,
absorbance was measured using ELISA microplate reader (Molecular Devices, Sunnyvale,
CA, USA). Percent cell viability of ebselen treated cells were calculated in relative to the
untreated cells.

Mice infection
Eight weeks old female BALB/c mice were used for this study (Harlan Laboratories,
Indianapolis, IN). All animal procedures were approved by Purdue University Animal Care
and Use Committee (PACUC). The murine model of MRSA skin infection has been
described before
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. Mice were injected intradermally with 40 µl of MRSA USA300

(6.7×108) CFU per mouse. Forty-eight hours after infection and formation of open wound,
the mice were divided into eight groups (n=5). Four groups were treated topically with
either 0.5%, 1%, or 2% ebselen in petroleum jelly (ointment- skin protectant) or 1% ebselen
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in lipoderm (dermal and transdermal delivery cream base). Two groups received the
vehicles alone (petroleum jelly or lipoderm). One group was treated topically with 2%
mupirocin in petroleum jelly and the last group was treated orally with linezolid (25 mg/kg).
All groups were treated twice a day for 5 days. Twenty-four hours after the last treatment,
the area around the wound was lightly swabbed with 70% ethanol and the wound was
excised for bacterial counting on MSA after homogenization.

Cytokines detection
Skin homogenates were centrifuged and the supernatants were used to detect the
cytokine level by ELISA. Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6),
interleukin-1 beta (IL-1β), and monocyte chemo attractant protein-1(MCP-1) Duo-set
ELISA Kits (R&D Systems, Inc.) were used for the quantification of cytokines The
experiment was carried out as per the manufacture instructions 281.

Bliss model of synergism
Synergism was calculated using the Bliss Independence Model, which calculates a
degree of synergy using the formula: S = (fA0/f00)(f0B/f00)-(fAB/f00), where fAB refers to
bacterial growth rate in the presence of the combined drugs at a concentration A, for one
of the antibiotics, and B for the ebselen; fA0 and f0B refer to the bacterial growth rates in the
presence of antibiotics (or) ebselen at a concentration of A and B, respectively; f00 refers to
the bacterial growth rate in the absence of drugs; and S corresponds to the degree of synergy,
a parameter that determines a synergistic interaction for positive values and an antagonistic
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interaction for negative ones. Growth rates at 12hr are determined and the degree of
synergism was calculated as described before282.

Statistical analyses
Statistical analyses were assessed by Graph Pad Prism 6.0 (Graph Pad Software, La
Jolla, CA). P values were calculated by the two-tailed Student t test. P values of ˂ 0.05
were considered as significant.

2.3.3

Results

Antibacterial activity of ebselen
The antimicrobial activity of ebselen was tested against a panel of clinical isolates
of multi-drug resistant S. aureus (Table 2.4). Ebselen showed potent bactericidal activity
against MRSA, vancomycin-resistant S. aureus (VRSA), linezolid-resistant S. aureus,
mupirocin-resistant S. aureus, methicillin-resistant S. epidermidis, and multidrug-resistant
strains with a minimum inhibitory concentration (MIC) ranging from 0.125 µg/ml to 0. 5
µg/ml (Table 2.4).
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Table 2.4 MICs of ebselen and antibiotics against clinical isolates of Staphylococcus
strains
Strain type

Strain ID

Methicillin resistant
S.
USA100
aureus (MRSA) USA200
USA300
USA400
USA500
USA700
USA800
USA1000
USA1100
ATCC
43300
ATCC
BAA-44
Linezolid-resistant
S. aureus
NRS119
Mupirocin-resistant
S. aureus
NRS 107
Vancomycinresistant S.
VRS1
aureus (VRSA) VRS2
VRS3a
VRS3b
VRS4
VRS5
VRS6
VRS7
VRS8
VRS9
VRS10
S. epidermidis
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Mechanism of action
Given the potent anti-staphylococcal activity of ebselen in vitro, we investigated its
anti-staphylococcal mechanism of action by macromolecular synthesis assay. As shown in
Figure 2.15, ebselen primarily inhibited protein synthesis at 1X the MIC. However,
additional secondary effects were observed at a higher concentration (8X MIC). At higher
concentration, ebselen inhibited DNA, RNA and lipid synthesis similar to control
antibiotics such as ciprofloxacin, rifampicin and cerulenin respectively.

Ebselen inhibits MRSA toxin production
The effect of ebselen on production of important toxins such as Panton-Valentine
leucocidin (PVL) and α-hemolysin (Hla) was tested by ELISA. The concentrations of each
toxin were compared as unadjusted concentrations (ng/ml) and corrected for organism
inoculum for each treatment (ng/ml to log10 colony-forming units, CFU/ml). Ebselen
significantly suppressed toxin production in MRSA USA300 (Figure 2.16).
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Figure 2.15 Macromolecular synthesis in the presence of ebselen. Incorporation of
radiolabeled precursors of DNA, RNA, protein, cell wall and lipid synthesis ([3H]
thymidine, [3H] uridine, [3H] leucine, [14C] N-acetylglucosamine and [3H] glycerol,
respectively) were quantified in S. aureus ATCC 29213. Results were expressed as percent
of inhibition calculated based on the incorporation of radiolabeled precursors.
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Figure 2.16 Effect of ebselen on toxin production. Toxin production (ng/ml) in S. aureus
MRSA USA300 after antibiotic/drug exposure for 1 hour corrected for organism burden.
The results are given as means ± SD (n = 3). ** indicate statistical significant different
from control (DMSO or water). P values of (* P≤ 0.05) (** P≤ 0.01) are considered as
significant.
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Figure 2.17 The effects of ebselen and antibiotics (linezolid, mupirocin, vancomycin and
rifampicin) on established biofilms of S. aureus (a) or S. epidermidis (b). The established
biofilms were treated with control antibiotics or ebselen and stained with crystal violet.
Optical density of dissolved crystal violet was measured using a spectrophotometer. Values
are the mean of triplicate samples with the standard deviation bars. P values of (*,#P≤
0.05) are considered as significant. Ebselen was compared to controls (*) and to antibiotics
(#).
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Activity against biofilms
Considering the excellent broad-spectrum activity of ebselen against the MRSA and
VRSA strains, we also considered the possibility that ebselen would be active against
established biofilm. Biofilm-forming strains of S. aureus and S. epidermidis were used and
the biofilm mass was estimated after treatment with ebselen and control antibiotics. Ebselen
was significantly superior in reducing adherent biofilms of both S. aureus and S.
epidermidis when compared to conventional antibiotics (linezolid, mupirocin, vancomycin
and rifampicin). Ebselen (2µg/ml) at 16X MIC significantly reduced the biofilm mass,
approximately by 60%. Control antibiotics, such as linezolid (256µg/ml), mupirocin
(16µg/ml) and vancomycin (128µg/ml) at 128X MIC were able to reduce the biofilm mass
only by 20%. Rifampicin (0.5µg/ml) at 16X MIC reduced the biofilm mass by only 40%
(Figure 2.17a).
Ebselen (8µg/ml) at (16X MIC), significantly reduced the strong biofilms of S.
epidermidis, by more than 50%. However, linezolid (512µg/ml), mupirocin (32µg/ml) and
vancomycin (256µg/ml) at 256X MIC reduced biofilm mass by only 20% and rifampicin
(2µg/ml) at 64X MIC reduced biofilm mass by 40% (Figure 2.17b).

Cytotoxicity study
Safety of ebselen in mammalian cells was evaluated against human keratinocyte
cells (HaCat) by MTS assay. Ebselen did not show toxicity up to 32 µg/ml. The results
demonstrated that half maximal inhibitory concentration (IC50) required by ebselen to
inhibit 50% of HaCat cells was found to be 58.78+0.64µg/ml (Figure 2.18).
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Figure 2.18 Cytotoxicity assay in human keratinocyte (HaCat) cells. HaCat cells were
treated with different concentration of ebselen ranging from 0 to 128µg/ml. DMSO was
used as a negative control. Cell viability was measured by MTS assay and IC 50 of ebselen
to cause cytotoxicity in HaCat cells was calculated.

The therapeutic efficacy of ebselen in a mouse model of MRSA skin infection
(i) Bacterial load
Five groups of mice were treated topically either with vehicle alone (petroleum
jelly) or control antibiotic (2% mupirocin) or ebselen (0.5%, 1%, or 2%) twice a day for
five days. One group of mice was treated with linezolid orally. As shown in Figure 2.19a,
ebselen (1% and 2%) significantly reduced the mean bacterial counts compared with the
control group (P≤ 0.01). The group treated with 2% mupirocin had the highest reduction
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in CFU (2.28±0.25 log10), followed by 2% ebselen (1.71±0.11 log10), linezolid (25 mg/kg)
(1.55±0.01 log10), and 1% ebselen (1.02±0.17 log10).

Figure 2.19 Efficacy of treatment of MRSA skin lesions with ebselen 0.5, 1, and 2%,
linezolid (25 mg/kg), mupirocin (2%) and petroleum jelly (negative control) twice daily
for 5 days (a). Treatment with ebselen 1% and lipoderm (negative control) twice daily for
5 days (b). Statistical analysis was calculated by the two-tailed Student t test. P values of
(* P≤ 0.05) (** P≤ 0.01) are considered as significant. (#).
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(ii) Effect of vehicle
In order to investigate the effect of the vehicle on the efficacy of ebselen in the
treatment of MRSA skin infections, two groups of mice were treated topically either with
vehicle alone (lipoderm base)283 or ebselen 1% formulated in lipoderm base twice a day
for five days. Ebselen 1% significantly reduced the mean bacterial counts by 1.37±0.20
log10 compared with the control group (P≤ 0.01) (Figure 2.19b). No significant difference
was observed in reducing the mean bacterial count between the ebselen 1% formulated in
petroleum jelly and lipoderm base (Figure 2.19a and 2.19b).

Effect of ebselen on inflammatory cytokines induced by MRSA skin infection
To study the immune-modulatory activities of ebselen in a topical application
against MRSA skin infection, we used ELISA to measure the pro-inflammatory cytokines
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β) and
monocyte chemo attractant protein-1(MCP-1) in the infected wounds. As shown in Figure
2.20, ebselen 2% and 1% significantly reduced all tested pro-inflammatory cytokines,
including IL-6, IL-1β, TNF-α, and MCP-1. However, ebselen at 0.5% significantly reduced
IL-6 and MCP-1 only. Ebselen had considerably higher anti-inflammatory activity
compared to antibiotics (linezolid and mupirocin).
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Figure 2.20 Effect of ebselen on cytokines production in MRSA skin lesions. Supernatants
from skin homogenates were used for cytokine detection by ELISA. Each points represents
single mice and each group has 5 mice. Statistical analysis was calculated by the two-tailed
Student t test. P values of (* P≤ 0.05) (** P≤ 0.01) are considered as significant.
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Figure 2.21 Synergistic activity of ebselen with topical antimicrobials. The Bliss Model
for Synergy confirms a synergistic effect, between ebselen and topical antimicrobials
(mupirocin, fusidic acid, retapamulin and daptomycin) against various resistant strains of
S. aureus. Degree of synergy was quantified after 12h of treatment with ebselen (0.0312
µg/ml) in combination with sub-inhibitory concentrations of topical antimicrobials. (Circle)
daptomycin + ebselen, (Square) retapamulin + ebselen, (Triangle) fusidic acid + ebselen
and (Inverted triangle) mupirocin + ebselen.
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Synergistic activity of ebselen with topical antimicrobials in vitro
The antimicrobial activity of ebselen in combination with topical antimicrobials
(mupirocin, fusidic acid, retapamulin and daptomycin) was investigated in vitro by the
Bliss model of synergism against four clinical isolates. With the exception of the VRSA5
strain and the antibiotic daptomycin, ebselen acted synergistically with all tested antibiotics
against S. aureus clinical isolates (Figure 2.21).

2.3.4

Discussion

For the past few decades the rise of multi-drug resistant S. aureus has been an
emerging issue in hospital and community settings109,206. More importantly, the
management of S. aureus strains associated with skin infections is becoming a serious issue
in community settings284,285. With the increasing incidence of multidrug-resistant S. aureus
strains, there is a pressing need for new antimicrobials to circumvent this burgeoning
problem. However, the discovery and development of new antimicrobials has been
slowing since 1960. Even today, the global antibiotic market is still dominated by a few
classes of antibiotics that were discovered half a century ago109. Moreover, pharmaceutical
companies are not interested in investing in antibiotic research and development because
of low return compared to other drugs being developed for chronic ailments109,286,287. As
an alternative to the traditional de novo antibiotic development, repurposing nonantimicrobial drugs is a novel and less expensive way to speed up the drug-development
process.
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In an intensive search for antimicrobial activity among non-antibiotic drugs, we and
others67,68 identified ebselen as a potent antimicrobial agent against Gram-positive
pathogens including MRSA. Ebselen, an organoselenium compound, is known to be
clinically safe with a well-known pharmacology profile and it is currently undergoing
clinical trials for the prevention and treatment of various disorders such as cardiovascular
disease, arthritis, stroke, atherosclerosis, and cancer60,63-66. Ebselen showed potent
bactericidal activity against multiple clinical isolates of MRSA, including MRSA USA100,
USA200, USA500, USA1000, and USA1100, which are resistant to various antimicrobials,
including penicillin, fluoroquinolone, macrolides, and aminoglycosides. It also showed
potent activity against multidrug-resistant clinical isolates of S. aureus strains, including a
linezolid-resistant strain (NRS119), vancomycin-resistant strains (VRSA1-VRSA10), and
a mupirocin-resistant strain (NRS107). Moreover, ebselen demonstrated excellent activity
against MRSA USA300, a community-associated strain responsible for outbreaks of
staphylococcal skin and soft-tissue infections (SSTI) in the United States288.
Although the antimicrobial activity of ebselen has been reported before67,68, its
mechanism of action in S. aureus and its in vivo efficacy have never been explored. Ebselen,
in our study, inhibited protein synthesis in S. aureus. Inhibition of protein synthesis at a
concentration equivalent to the MIC demonstrates that, protein synthesis is likely primary
antibacterial mechanism of action of ebselen. In addition, secondary effects on DNA,
RNA ,lipid synthesis and to a lesser extent on cell wall synthesis were also noticed at higher
concentrations (8X MIC). It is possible that disruption of protein synthesis could lead to
downstream inhibition of other pathways. This provides valuable insight into ebselen’s
potential target in S. aureus. However, further work is needed to identify the cellular target
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of ebselen in S. aureus. For treatment of infections caused by toxin-producing pathogens
such as S. aureus, inhibition of protein synthesis is an important consideration in the
selection of antimicrobial agents280. Because antimicrobials that suppress translation in S.
aureus markedly suppress the formation of toxins such as PVL and Hla , which will lead
to better treatment outcomes280,289-291. In the light of our results, showing potent inhibition
of bacterial protein synthesis, we tested the effect of ebselen on production of two
important toxins in MRSA USA300 (Hla and PVL) by ELISA. Ebselen significantly
suppressed toxin production after 1hour incubation with MRSA. Inhibition of protein
synthesis and the subsequent inhibition of toxin production are great advantages of ebselen
as an antimicrobial agent.
Bacterial biofilms, which serve to protect the bacteria and hinder penetration of
antibacterial drugs, contribute significantly to the treatment failure of Staphylococcus
infections216. Given the potent antibacterial activity of ebselen against planktonic
multidrug-resistant strains, we also considered the possibility that ebselen would be active
against established bacterial biofilms of S. aureus and S. epidermidis (a leading cause of
hospital-acquired implant-based infections)292. Ebselen was superior in reducing adherent
biofilms of both S. aureus and S. epidermidis when compared to conventional antibiotics
(linezolid, mupirocin and vancomycin).
In view of our results demonstrating the potent antimicrobial and antibiofilm
activities of ebselen in vitro against MRSA, we moved forward with an in vivo experiment
in a mouse model of MRSA skin infection. Ebselen 1% and 2% in petroleum jelly
significantly reduced the mean bacterial counts compared with the control group (P ≤ 0.01).
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The lipoderm base enhanced the antimicrobial activity of ebselen but the reduction in
bacterial load was not significant from petroleum jelly vehicle.
Since the clinical severity of S. aureus skin infections is driven by the excess host
pro-inflammatory cytokines rather than by bacterial burden256,293, ebselen with its
recognized immune-modulatory, anti-inflammatory, and antioxidant activities59,294 should
be superior to traditional antibiotics for treatment of skin infections107,293. In this study,
topical treatment with ebselen 1 and 2% significantly reduced IL-1β, IL-6, TNF-α and
MCP-1 which might benefit the healing of infected wounds102-106. Linezolid also inhibits
IL-1β which is in line with previous findings293,295. Prolonged inflammation especially due
to inflammatory cytokines such as IL-6, TNF-α, and MCP-1, greatly delays healing in
chronic wounds107. Ebselen significantly (P≤ 0.01) inhibits all three cytokines (IL-6, TNFα, and MCP-1), which should provide a favorable outcome in wound healing107.
With the increasing incidence of MRSA strains resistant to topical drugs of choice,
such as mupirocin and fusidic acid, combination therapies are being explored259,260,268,269.
To investigate whether ebselen has the potential to act synergistically with topical
antimicrobials against multidrug-resistant strains, the Bliss independence model was
utilized282. Ebselen acted synergistically with topical antimicrobials against resistant
strains of S. aureus, thus providing a strong platform to combine ebselen with topical
antimicrobials in treating staphylococcal skin infections and reducing the likelihood of
strains developing resistance to monotherapy.
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2.4

Repurposing clinical molecule ebselen to combat drug resistant pathogens

(Thangamani S, Younis W, Seleem MN. Repurposing Clinical Molecule Ebselen to
Combat Drug Resistant Pathogens. PLoS One. 2015 Jul 29;10(7):e0133877)

2.4.1

Introduction

Infections caused by Gram-positive drug-resistant pathogens are a leading cause of
mortality.

Three

Streptococcus

species—methicillin-resistant

pneumoniae

and

Staphylococcus

vancomycin-resistant

aureus

enterococcus

(MRSA),

(VRE)—are

responsible annually for at least 84% of the antibiotic-resistant bacteria mortality in the
United States alone 1. Further exacerbating the issue of bacterial resistance is the slow rate
of the development and approval of new antimicrobials. For almost 80 years,
antimicrobials have been crucial allies in the treatment of bacterial infections caused by
these pathogens. However, multidrug resistant strains have recently emerged that are
resistant to almost all antimicrobials once deemed effective, including fluoroquinolones,
macrolides, and β-lactams 296. Collectively, this points to an urgent need for the discovery
of new antimicrobials and novel strategies to develop them. One novel strategy that
warrants more attention as a unique method for development of new antimicrobials is drug
repurposing

276

. Our recent attempt to identify non-antibiotic drugs with potent

antimicrobial activity, within an applicable clinical range, identified organoselenium
compound ebselen (EB) as having potent antibacterial activities against Gram-positive
pathogens 297. EB is considered a clinically safe molecule but without proven use yet 275.
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It has anti-oxidative, anti-inflammatory, and anti-atherosclerotic properties 59. Additionally,
EB has been shown to exhibit antimicrobial activity in vitro and in vivo

67,68,298,299

. EB

exhibited antimicrobial activity by inhibition of thioredoxin reducatse (TrxR) enzyme of
Escherichia coli and H+-ATPase function and proton-translocation function in yeast

67-69

.

However, the antibacterial mechanism of action of EB against Gram-positive bacteria
remains unidentified 68.
The potent antimicrobial activity of EB against Gram-positive pathogens motivated
us to further investigate the therapeutic applications of EB. The aims of the present study
are to investigate the antibacterial activity of EB against Gram-positive clinical pathogens,
including MRSA and VRE in vitro, to identify antibacterial mechanism of action, to
analyze the ability of EB to clear MRSA intracellular infection, to evaluate antibacterial
efficacy in MRSA-infected Caenorhabditis elegans whole animal models, to evaluate the
effect on mitochondrial biogenesis and toxicity in C. elegans, and to assess whether EB is
capable of working synergistically with conventional antibiotics against MRSA in in vitro
and in infected cell cultures. This study provided valuable insights into potential
therapeutic applications of EB for use as antimicrobial agents for the treatment of
multidrug-resistant Gram-positive infections.

2.4.2 Materials and Methods
Bacterial strains and reagents
Bacterial strains employed in this study are presented in Table 1. Mannitol salt agar
(MSA) was purchased from Hardy Diagnostics (Santa Maria, CA). Muller-Hinton broth
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(MHB) was purchased from Sigma-Aldrich (St. Louis, MO). Trypticase soy broth (TSB)
and Trypticase soy agar (TSA) were purchased from Becton, Dickinson (Cockeysville,
MD). EB was purchased from (Adipogen corp, San Diego), vancomycin hydrochloride
(Gold Biotechnology, St. Louis, MO), linezolid (Selleck Chemicals, Houston, TX),
clindamycin (TCI chemicals, Portland, OR), erythromycin, rifampicin, ampicillin,
gentamicin, chloramphenicol and fetal bovine serum (FBS) were purchased from SigmaAldrich. DMEM media were purchased from Life technologies and MTS reagent (Promega,
Madison, WI, USA).

In vitro antibacterial assays
Minimum inhibitory concentrations (MICs) were evaluated using micro dilution
broth as per the standards of Clinical and Laboratory Standards Institute (CLSI)
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. MICs

of drugs were interpreted as the lowest concentration of the drug which inhibits the growth
of bacteria after incubating for at least 16-24 h at 37 °C. The minimum bactericidal
concentration (MBC) was determined by sub-culturing 10 μl from the wells were no
growth was observed onto TSA plates. The plates were incubated for 24 h before the
MBCs were determined. The MBC was categorized as the concentration where ⩾99.9 %
reduction in bacterial cell count was observed 296 .

Intracellular infection assay
J774A.1 murine macrophage-like cells were seeded at a density of 20,000 cells per
well in 96-well tissue culture plates. Cells were infected with MRSA USA300 (NRS 3840114; ST-8) for 30 min at a 1:100 multiplicity of infection (MOI). Then the cells were
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washed three times with DMEM medium containing 10 IU lysostaphin to kill the
extracellular bacteria

221

. Drugs (vancomycin, linezolid and EB) were added at a

concentration of 1 µg/ml to the DMEM medium supplemented with 10% FBS and 4 IU
lysostaphin. After 24 h incubation, the cells were washed three times with phosphate
buffered saline (PBS) and lysed with 0.1% Triton X-100. Lysates were diluted and plated
on TSA plates and MRSA colony forming units (CFU) were counted.

Toxicity assay
The toxicity assays were performed in cell culture and C. elegans. (a) Cell
culture:J774A.1 murine macrophage-like cells at a density of 20,000 cells per well were
seeded and allowed to adhere in a 96-well tissue culture plate in DMEM media containing
10% FBS overnight. EB at various concentrations ranging from 0 to 256 µg/ml were added
to the cells in DMEM media with FBS. After 24 h incubation with the drug, cells were
washed with PBS and the MTS assay reagent,3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) in DMEM medium was added
and incubated for 4 h at 37 °C. Absorbance was measured at 490 nm using ELISA
microplate reader (Molecular Devices, Sunnyvale, CA, USA). Cell viability after treatment
with EB was expressed as a percentage of the control, DMSO. (b) C. elegans: Temperaturesensitive C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) was used for toxicity studies
and the worms were synchronized as described before 301. Synchronized L4-stage worms
were re-suspended in buffer containing 50% M9 buffer and 50% TSB. Then 100 µl of the
buffer containing approximately 15-20 worms were deposited in each well in 96-well
plates and EB (4 and 8 µg/ml) and vancomycin (8 µg/ml) were added. Worms were counted

103
daily for three days and the percent of live worms was calculated in each group. At least
triplicate wells were used for each treatment

Cell-free bacterial and mammalian transcription/translation assay
The cell-free bacterial translation and mammalian translation assays were performed
by the commercially available Escherichia coli S30 System and Rabbit Reticulocyte Lysate
System (Promega), respectively. The assays were performed as described by the
manufacturer, in conjunction with appropriate positive control (chloramphenicol) and
negative control (ampicillin) antibiotics. In bacterial translation assay, the reaction
mixtures were incubated at 37 °C for 1 h. Mammalian translation assay reaction mixtures
were incubated at 30 °C for 1 h. Luciferase assay reagent was added to the reaction and the
intensity of the luminescence was measured by luminescence microplate reader (FLx800
BioTek Instruments, Inc. Winooski, Vermont) according to the manufacturer’s instructions.
Average luciferase readout of protein production from two replicates from two independent
experiments was calculated.

Mitochondrial biogenesis assay
The mitobiogenesis assay was done using In-Cell ELISA Kit (MitoSciences Inc.,
Eugene, OR) as per the manufactures instruction
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. Briefly, J774A.1 cells were seeded

(40,000 cells per well) in 96-well plates for overnight. EB and control antimicrobials
(chloramphenicol and ampicillin) were added to the cells and the cells were allowed to
grow for approximately 3 days with the drugs. Media were removed and cells were washed
with PBS, then fixed with 4% paraformaldehyde. After fixing, cells were washed with PBS
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and permeabilization and blocking processes were done according to the manufacturer’s
instructions. Primary antibodies to detect the levels of two proteins (subunit I of Complex
IV (COX-I), which is mitochondrial DNA (mtDNA)-encoded, and the 70 kDa subunit of
Complex II (SDH-A), which is nuclear DNA (nDNA)-encoded were added and incubated
for overnight at 4 °C. After incubation, cells were washed with PBS and secondary
antibodies were added and incubated at room temperature for 1 h. The expression of SDHA and COX-1 were measured after washing and development at 405 nm and 600 nm
wavelength, respectively. The ratio between COX-I and SDH-A was calculated and the
percent of inhibition of mitochondrial biogenesis was measured.

Efficacy of EB in infected animal model (C. elegans)
L4-stage worms of C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) were used to test
the antimicrobial efficacy of EB as described before 301. Briefly, worms were infected with
MRSA USA300 (NRS 384-0114; ST-8) in nematode growth media plate for 8 h at room
temperature. After 8 h of infection, worms were collected and washed with M9 buffer four
times before incubation with the drugs. Worms were transferred to 96-well plates (20
worms per well) and the drugs (EB and vancomycin) were added to the wells in triplicates
to achieve a final concentration of either 4 or 8 μg/ml. After 24 h incubation with the drugs,
worms were transferred to 2-ml centrifuge tubes, washed four times with PBS and 100 mg
1.0-mm silicon carbide particles (Biospec Products, Bartlesville, OK) were added to each
tube. The tubes were vortexed for one minute at maximum speed to disrupt the worms
without affecting bacterial survival
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. The resulting suspension was diluted and plated

onto MSA plates to count the MRSA CFU. The total CFU obtained from each well was
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divided by the number of worms in respective wells and the results were expressed as
percent of bacterial reduction per worm.

Synergistic activities of EB with conventional antibiotics in vitro and in cell culture
(a) In vitro synergistic assay: The synergistic activities of EB with conventional antibiotics
were evaluated using the Bliss Independence Model as described before
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. Briefly, the

optical density of the bacteria grown in the presence of antibiotics and EB (fAB), antibiotics
alone (fA0), EB alone (f0B) and in the absence of drugs (f00) were measured and a degree of
synergy (S) was calculated using the formula: S = (fA0/f00)(f0B/f00)-(fAB/f00). Positive and
negative values represent the degree of synergism and antagonism, respectively. (b)
Intracellular synergistic assay in J774A.1 cells: J774A.1 cells were seeded and infected as
described before under intracellular infection assay. EB at concentration of 0.5 µg/ml was
added to infected cells alone or in in combination with control antibiotics such as linezolid
(4 µg/ml), clindamycin (1 µg/ml), vancomycin (4 µg/ml), chloramphenicol (4 µg/ml),
erythromycin (8 µg/ml), rifampicin (0.5 µg/ml) and gentamicin (1 µg/ml). Untreated cells,
and cells treated with antibiotics alone were used as a control. After 24 h incubation, the
cells were lysed and intracellular MRSA CFU were determined as described above..
Percent bacterial reduction was calculated in relative to the untreated groups. Combination
therapy was compared with single antibiotic therapy treatment groups.
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Statistical analyses
Statistical analyses were done using Graph Pad Prism 6.0 (GraphPad Software, La Jolla,
CA). P values were calculated by the one-tailed Student t test. P values of ˂ 0.05 were
considered as significant.

2.4.3

Results and Discussion

In vitro antibacterial assays
In an attempt to repurpose approved drugs as antimicrobial agents, we investigated the
antimicrobial activity of EB against various multidrug-resistant clinical isolates of Grampositive and Gram-negative pathogens (Table 2.5). EB exhibited potent bactericidal
activity, in a nanogram range, against all tested Gram-positive strains regardless of their
resistance phenotype. EB showed potent activity against clinical isolates of Enterococcus
faecalis and Enterococcus faecium with MIC90 of 0.5 µg/ml (see Table 2.5). EB also
showed potent activity against vancomycin-resistant strains of Enterococcus (VRE). Next,
we tested the activity of EB against the clinical isolates of multidrug-resistant S. aureus.
EB showed more potent activity against methicillin-sensitive S. aureus, MRSA,
vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA)
strains than VRE with MIC90 of 0.25 µg/ml (see Table 2.5). Finally, EB also showed potent
activity against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae
with MIC of 0.5 µg/ml (see Table 2.5). On the other hand, EB did not show potent
antimicrobial activity (MIC ≥16 µg/ml) against Gram-negative pathogens, including
Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Salmonella
Typhimurium, and Acinetobacter baumannii. The lack of activity of EB against Gram-
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negative pathogens might be due to its reduced ability to enter the cells due to outer
membrane barrier or the efflux pump rather than lack of target of EB inside Gram-negative
bacteria 303-306.

Intracellular infection and cell toxicity
Some extracellular pathogens such as S. aureus are also capable of invading and
surviving within the mammalian host cells, leading to persistent chronic infections.
Moreover, during the S. aureus intracellular invasion phase, treatment with antimicrobials
is very challenging because most antibiotics do not actively pass through cellular
membranes

237-242

. Therefore, clinical failures of drug of choice, such as vancomycin, to

cure S. aureus pneumonia have exceeded 40% and have been attributed mainly to poor
intracellular penetration of the drug and consequently to the failure to kill intracellular
MRSA in alveolar macrophages 307. Hence, finding antimicrobials that possess both extraand intracellular activity would be an optimum strategy to treat such invasive intracellular
S. aureus infections. Therefore, we investigated if EB possesses intracellular antistaphylococcal activity. As shown in Figure 2.22, EB at a concentration of 1 µg/ml
significantly reduced the intracellular MRSA by 32%. In contrast, the conventional
antimicrobials such as vancomycin and linezolid (drugs of last resort for treatment of
Staphylococcal infections) at the same concentration reduced intracellular MRSA by only
16% and 21%, respectively. EB toxicity was assayed against J774A.1 cells at a
concentration ranging from 0 to 256 µg/ml for 24 h. The results shown in Figure 2.23
indicate that EB does not show toxicity up to 64 µg/ml. The concentration of the EB that
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Table 2.5 The MIC and MBC of EB against Gram-positive and Gram-negative bacteria

Strain ID
E. faecalis ATCC49533
E. faecalis ATCC7080
E. faecalis ATCC49532
E. faecalis ATCC14506
E. faecalis ATCC 51229 (VRE)
E. faecalis SF24397
E. faecalis SF24413 (VRE)
E. faecalis SF28073 (VRE)
E. faecalis HH22

E. faecalis MMH594
E. faecalis SV587 (VRE)
E. faecium E1162
E. faecium E0120 (VRE)
E. faecium ERV102 (VRE)

E. faecium ATCC6569
E. faecium ATCC 700221 (VRE)
MSSA (NRS 72)
MRSA (NRS 384)
MRSA (NRS119)
MRSA (NRS 123)
MRSA (NRS194)
MRSA (NRS108)
MRSA (NRS70)
VISA (NRS 1)
VISA (NRS 19)
VRSA11a

Phenotypic Characteristics
Resistant to streptomycin
Resistant to gentamicin
Resistant to Vancomycin. Sensitive
to Teichoplanin
Resistance to erythromycin (ermB+)
and gentamicin
Resistant to erythromycin,
gentamicin and vancomycin.
Resistant to erythromycin,
gentamicin and vancomycin
Resistance to penicillin,
erythromycin, tetracycline and high
levels of aminoglycosides
Resistance to erythromycin and
gentamicin
Resistance to vancomycin
Resistance to ampicillin.
Resistant to gentamicin and
vancomycin
Resistant to ampicillin and
vancomycin, and displays high
levels of resistance to streptomycin.
Resistant to Vancomycin and
Teicoplanin
Resistant to penicillin
Resistant to erythromycin,
methicillin, and tetracycline
Resistant to linezolid
Resistant to methicillin; susceptible
to nonbeta-lactam antibiotics
Resistant to methicillin
Resistant to gentamicin
Resistant
to
clindamycin,
erythromycin and spectinomycin
Resistant to aminoglycosides and
tetracycline (minocycline)
Glycopeptide-intermediate S. aureus
Resistant to erythromycin and
spectinomycin

MIC/MBC
(µg/ml)
0.25/8
0.25/8
0.25/8
0.5/8
0.5/0.5

0.125/4
0.125/4
0.0625/8
0.125/4
0.125/4
0.125/8
0.25/16
0.5/32
0.5/16
1/32
0.5/1
0.25/0.5
0.125/0.125
0.125/0.25
0.25/0.5
0.25/1
0.25/0.25
0.25/0.25
0.125/0.125
0.25/0.025
0.125/0.25
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Table 2.5 continued
VRSA11b
VRSA12
VRSA13
Streptococcus pyogenes ATCC 12344
Streptococcus agalactiae MNZ938
Streptococcus agalactiae MNZ 933
Streptococcus agalactiae MNZ 929
Acinetobacter baumannii ATCC
BAA1605

E. coli O157:H7 ATCC 700728
Salmonella enterica serovar
Typhimurium ATCC 700720
Klebsiella pneumonia ATCC BAA
2146
Pseudomonas aeruginosa ATCC 9721

Resistant to erythromycin and
spectinomycin
Resistant to vancomycin
Resistant to vancomycin
Quality control strain
Beta-hemolytic, Serogroup: Group B
Beta-hemolytic, Serogroup: Group B
Beta-hemolytic, Serogroup: Group B
Resistant to ceftazidime, gentamicin,
ticarcillin, piperacillin, aztreonam,
Cefepime, ciprofloxacin, imipenem,
and meropemem
Clinical isolate New Delhi Metalloβ-Lactamase (NDM-1) positive
-

0.25/0.25
0.25/0. 5
0.25/0.25
0.5/1
0.5/0.5
0.5/0.5
0.5/0.5
16/ND

32/ND
32/ND
64/ND
>256/ND

VRE: vancomycin-resistant Enterococcus; MSSA: methicillin-sensitive S. aureus;
MRSA: methicillin-resistant S. aureus; VISA: vancomycin-intermediate S. aureus;
VRSA: vancomycin-resistant S. aureus; ND: not determined

causes 50% toxicity (half inhibitory concentration: IC50) in J774A.1 cells is 95.68 + 4.12
µg/ml. This value is more than 380-fold higher than the concentration required to inhibit
inhibit MRSA. Collectively, these results suggest that EB has great potential for treatment
of S. aureus infections where not only is eradication of extracellular bacteria important, but
the killing of intracellular bacteria is also critical 308.
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Figure 2.22 Activity of EB, vancomycin and linezolid against intracellular MRSA USA300
in J774A.1 cells. MRSA infected J774A.1 cells were treated with EB and control
antibiotics (vancomycin and linezolid) for 24 h and the percent bacterial reduction was
calculated compared to untreated control groups. The results are given as means ± SD (n=3).
P values of (**, # ≤ 0.05) are considered as significant. EB was compared to controls (**)
and to antibiotics (#).

Figure 2.23 Cytotoxicity assay in murine macrophage-like cells (J774A.1) cells. J774A.1
cells were treated with different concentration of EB ranging from 0 to 256µg/ml. DMSO
was used as a negative control. Cell viability was measured by MTS assay and IC50 of EB
to cause cytotoxicity in J774A.1 cells was calculated.
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Cell-free bacterial transcription/translation assay
Antimicrobials that target microbial protein synthesis such as oxazolidinones and
lincomycins are considered excellent choices for the treatment of toxin-mediated bacterial
infections caused by S. aureus, such as toxic shock syndrome (TSS) and pneumonia 232-235.
In addition to the suppression of S. aureus toxins such as Panton-Valentine leucocidin
(PVL), α-hemolysin (hla), and toxic shock syndrome toxin–1 (TSST-1), these
antimicrobials also reduce excessive host-inflammatory responses associated with these
toxins 309,310. Hence, protein synthesis inhibitors are often preferred in clinical practice for
the treatment of toxin-associated staphylococcal infections 232-235. We tested the effects of
EB in our study on bacterial, mammalian and mitochondrial protein-synthesis. For bacterial
protein-synthesis inhibition, we used E. coli cellular extracts in a transcription and
translation assay that monitors protein production via luciferase readout. Unlike the
antibiotic ampicillin that inhibits cell wall synthesis, EB strongly inhibited bacterial
transcription/translation process similar to chloramphenicol antibiotic that inhibits protein
synthesis (Figure 2.24a). EB inhibited bacterial protein synthesis in the cell-free
transcription-translation, exhibiting IC50 of 0.25±0.10 µg/ml which is comparable to IC50
of chloramphenicol antibiotic 0.48 ± 0.10 µg/ml (Figure 2.24b). These results indicate that
EB acts by a favorable mechanism of action and inhibits bacterial protein synthesis and,
most likely, toxin production. However, inhibition of bacterial protein synthesis does not
exclude other possible mechanism of action of EB.
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Figure 2.24 Effects of EB on coupled transcription-translation (TT) in S30 extracts from
E. coli. (a) Average luciferin protein production in the presence of EB, ampicillin and
chloramphenicol at the concentration of 2µg/ml were shown. The results are given as
means ± SD (n = 3). (b) Concentration dependent TT-inhibition of EB and chloramphenicol
were shown. IC50 of the drugs required to inhibit 50% TT-activity were determined. P
values of (** ≤ 0.05) are considered as significant.
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Cell-free mammalian transcription/translation assay and mitochondrial biogenesis
Due to concern about the possible mitochondrial toxicities associated with many
antibacterial protein synthesis inhibitors such as linezolid and chloramphenicol 311-317, we
tested the effect of EB on the inhibition of eukaryotic transcription/translation process
using the rabbit reticulocyte lysate system with the cellular components necessary for
mammalian protein synthesis

318,319

. As shown in Figure 2.25a, EB showed high safety

profile with IC50 of mammalian protein synthesis of 166.09 + 12.08 µg/ml. This value is
more than 660-fold higher than the concentration required to inhibit protein synthesis in
bacteria. However, in order to test the effect of EB more specifically on mitochondrial
biogenesis and to confirm the above in vitro results obtained from rabbit reticulocyte lysate
system, we measured the effect of EB on mitochondrial protein synthesis directly within
the mammalian cells. In-cell ELISA was performed in J774A.1 cells treated with EB and
chloramphenicol for three days to detect the levels of mtDNA-encoded COX-I and nDNAencoded SDH-A proteins. Results shown in Figure 2.25b indicate that EB had no
significant inhibition (less than 10%) of mitobiogenesis, similar to the effect of ampicillin,
which does not interfere with mitochondrial protein synthesis process. At the same time,
chloramphenicol had more than 60% inhibition of mitochondrial protein synthesis. These
results provide valuable information about EB’s safety profile and the lack of interference
with mammalian protein synthesis and mitobiogenesis.

114

Figure 2.25 Effects of EB on mammalian protein synthesis. (a) Concentration dependent
inhibition of protein synthesis were determined using rabbit reticulocyte lysate extract
system. IC50 of the EB required to inhibit 50% translational activity were determined. (b)
Effect of EB, chloramphenicol and ampicillin on mitobiogenesis. J774A.1 cell In cellELISA was carried out in the presence and absence of these drugs, and the levels of
mitochondrial (mt)-DNA encoded protein (COX-I) and nuclear-DNA encoded protein
(SDH-A) were quantified. Ratio of COX-I and SDH-A were calculated and the results were
shown as percent inhibition of mitochondrial biogenesis.
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Efficacy of EB in infected animal model (C. elegans)
To investigate if the potent in vitro antimicrobial activity of EB translates to
antimicrobial efficacy in vivo, we tested antimicrobial efficacy of EB in an infected C.
elegans whole animal model. A whole animal model, such as C. elegans, represents a great
platform for drug discovery and enables simultaneous assessment of efficacy and toxicity
of the tested drugs. Additionally, using a C. elegans model reduces the associated cost of
drug discovery and lowers the burden for extensive animal testing

301,320

. Prior to testing

the efficacy of treatment with EB in infected C. elegans, we tested toxicity of EB in noninfected C. elegans. As shown in Figure 2.26a, treatment of C. elegans with EB at 4 and 8
µg/ml for three days did not show any significant toxicity, similar to control groups. With
no observable toxicity noticed in EB treated groups at a concentration of 4 and 8 µg/ml,
we moved forward with an in vivo infection model using C. elegans infected with MRSA.
As seen in Figure 2.26b, treatment with EB had a significant reduction in bacterial load
when compared to untreated groups. EB at a concentration of 4 and 8 µg/ml significantly
reduced the mean bacterial count by 56% and 85%, respectively. Moreover, treatment with
EB at a concentration of 8 µg/ml showed comparable effect to treatment with the drug of
last resort vancomycin in reducing MRSA burden in infected C. elegans. Taken together,
these results show that EB exhibits potent in vivo antistapylococcal efficacy in MRSAinfected C. elegans.
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Figure 2.26 Evaluation of toxicity and antimicrobial efficacy of EB in C. elegans model.
(a) C. elegans strain glp-4; sek-1 (L4-stage) were grown for three days in the presence of
EB (4µg and 8 µg/ml) and vancomycin (8 µg/ml). Live worms were counted and the results
were expressed as percent live worms in relative to the untreated control groups. (b) MRSA
USA300 infected L4-stage worms were treated with EB (4µg and 8 µg/ml) and
vancomycin (8 µg/ml) for 24 h. Worms were lysed and the CFU were counted and the
percent bacterial reduction per worm in treated groups were calculated in relative to the
untreated control groups. P values of (** ≤ 0.05) are considered as significant.
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Synergistic activities of EB with conventional antibiotics in vitro and in cell culture
After confirming that EB has a potential use as an antibacterial agent for the
treatment of infections caused by multidrug resistant pathogens, it was important to explore
the synergistic relationship of EB with conventional antibiotics in vitro and in cell culture.
With the rapid emergence of multidrug-resistant strains of S. aureus, monotherapy with
single antibiotic has become less effective 244,245. Therefore, alternative strategies such as
combinational therapy have been used in the healthcare setting to improve the morbidity
associated with MRSA infections and to reduce the likelihood of emergence of resistant
strains 244,246,247,296. To ascertain whether EB has the potential to be combined in vitro and
in cell culture with conventional antimicrobials such as linezolid, clindamycin,
vancomycin, chloramphenicol, erythromycin, rifampicin, and gentamicin against MRSA
USA300, we used the in vitro Bliss independence model of synergism and infected cell
culture assay

282

. In vitro results from the Bliss independence model of synergism are

presented in Figure 2.27a. EB was found to exhibit a synergistic relationship with all tested
conventional antimicrobials in vitro against MRSA USA300. Results of synergistic
relationship of EB with conventional antimicrobials in infected cell culture against
intracellular MRSA USA300 are presented in Figure 2.27b. Conventional antimicrobials
(clindamycin, erythromycin, and rifampicin) showed synergistic activity when combined
with EB and significantly reduced intracellular MRSA when compared to monotherapy.
However, EB did not show synergistic activity with linezolid, vancomycin,
chloramphenicol, or gentamicin in clearing intracellular MRSA. Identifying antibiotics that
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Figure 2.27 Synergistic activities of EB with conventional antibiotics in vitro and in cell
culture. (a) The Bliss Model for Synergy confirms the in vitro synergism with conventional
antimicrobials (gentamicin, rifampicin, erythromycin, chloramphenicol, vancomycin,
clindamycin and linezolid) against MRSA USA300. Degree of synergy was calculated in
the presence of EB (0.0312 µg/ml) in combination with sub-inhibitory concentrations of
conventional antimicrobials. (b) Synergistic activity of EB with conventional
antimicrobials in infected cell culture. Efficacy of EB (0.5µg/ml) in combination with
linezolid (4µg/ml), clindamycin (1µg/ml), vancomycin (4µg/ml), chloramphenicol
(4µg/ml), erythromycin (8µg/ml), rifampicin (0.5µg/ml) and gentamicin (1µg/ml) in
clearing intracellular MRSA USA300 was determined in J774A.1 cells. Percent bacterial
reduction was calculated in relative to the untreated groups. The results are given as means
± SD (n=3). Combination therapy was compared to monotherapy and the P values of (**,
≤ 0.05) are considered as significant.
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can be synergistically paired with EB can potentially prolong the clinical utility of these
antibiotics and reduce the likelihood of emergence of resistant strains.

In conclusion, we have successfully explored the potential applications of EB in vitro, in
cell culture, and in vivo to combat multidrug-resistant Gram-positive pathogens, especially
MRSA. We demonstrated that EB inhibits the bacterial translation process without
affecting mitochondrial biogenesis. Additionally, we demonstrated the efficacy of EB in
vivo in a C. elegans MRSA-infected model. Finally, we identified potential antibiotics that
can be synergistically combined with EB to prolong the clinical utility of these antibiotics
and reduce the likelihood of the emergence of resistant strains. Taken together, our study
results demonstrate that EB, with its potent antimicrobial activity and safety profiles, might
be a potential candidate drug for systemic and (or) topical applications to treat multidrug
resistant Gram-positive bacterial infections alone or in combination with other antibiotics
and should therefore be further clinically evaluated.
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2.5

Exploring simvastatin, an antihyperlipidemic drug, as a potential topical
antibacterial agent

(Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick VE, Paul
LN, Seleem MN. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical
antibacterial agent. Scientific Reports. 2015 Nov 10;5:16407)

2.5.1

Introduction

The blockbuster statin drugs have revolutionized the treatment of cardiovascular
disease, primarily by reducing low-density lipoprotein cholesterol (LDL-C) levels,
leading to a decline in the morbidity and mortality associated with coronary artery
diseases 1. All statins drugs exert their effect by inhibiting the enzyme class I 3-hydroxy3-methyl-glutaryl- Coenzyme A reductase (HMG-CoA) leading to decreased synthesis of
cholesterol and increased removal of low-density lipoprotein (LDL) circulating in the
body 2,3. These drugs possess a good safety profile with limited side effects thus
permitting their frequent use in reducing lipid levels in patients with high cholesterol levels
4,5. In addition to their lipid-lowering effect, statins have been found to have potential
use for other applications including influencing the host immune response via the drugs’
anti-inflammatory and immune-modulatory properties 6. Furthermore, multiple reports
have investigated the potential role of statins in preventing and treating various
infectious diseases and have demonstrated that statins can prevent the establishment of
infections (by decreasing host cholesterol synthesis 7-9 limiting certain bacterial species’
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ability to invade host cells) and potentially decrease the mortality rate attributed to
bacterial infection 10-12. Interestingly, several studies have shown that certain statins
possess antimicrobial activity directly inhibiting growth of

Staphylococcus,

Streptococcus, Enterococcus and Moraxella spp. 13-17. In addition, simvastatin and
atorvastatin are capable of increasing the mycobactericidal effect of rifampicin18.
However, limited information is available regarding the mechanism by which statins
exert their antibacterial effect, statins’ antimicrobial effect on Gram-negative pathogens,
and potential applications for statins as novel antibacterial agents.
Given the tremendous pressure bacterial resistance to currently available antibiotics
has placed on the healthcare system (with certain bacterial strains of Staphylococcus
aureus and Pseudomonas aeruginosa exhibiting resistance to nearly every class of
antibiotics), new antimicrobials are urgently needed to counter this significant public
health challenge 19. Repurposing existing drugs (initially approved for treatment of
one clinical indication such as lowering cholesterol levels) that also possess antibacterial
activity has the potential to expedite the process to discovering new antibacterial agents
(given much of the rigorous safety, pharmacokinetic, and pharmacodynamic studies have
already been conducted) 20. Based upon preliminary studies performed to date, statins,
in particular simvastatin, have potential to be repurposed as novel antibacterial agents.
However additional research is required to understand statins’ antibacterial spectrum of
activity, their antibacterial mechanism of action, and to elucidate potential clinical
applications in the management of bacterial infections. In this study, we aim to lay the
foundation for utilizing statins as topical antibacterial agents by investigating the
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antibacterial activity of statins and their spectrum of activity on clinically-relevant Grampositive and Gram-negative pathogens, elucidating the antibacterial mode of action of the
most active statin (simvastatin), examining the effect of simvastatin on specific virulence
factors (such as bacterial toxins and disruption of staphylococcal biofilms) and
finally to validate the therapeutic efficacy of simvastatin in an appropriate animal model
of S. aureus infection. Our study reveals that simvastatin has considerable promise for
use as a therapeutic agent to treat MRSA skin infections and does warrant further
investigation as a novel topical antibacterial agent.

2.5.2

Materials and Methods

Bacterial strains and reagents
Bacterial strains used in this study are presented in Table 1 and Table 2. MuellerHinton broth (MHB), gentamicin and tetracycline were purchased from Sigma-Aldrich
while mupirocin (Applichem), linezolid (Selleck Chemicals), and vancomycin
hydrochloride (Gold Biotechnology) were acquired from other commercial vendors.
Mannitol salt agar (MSA), Trypticase soy agar (TSA) and Trypticase soy broth (TSB)
were purchased from Becton, Dickinson and Company (Cockeysville, MD). All statin
drugs used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA),
with the exception of pitavastatin and rosuvastatin which were obtained from
Selleckchem (Houston, TX, USA).
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Antibacterial assays
The antibacterial activity (MIC) of all test agents was examined using the broth
microdilution method as per the guidelines outlined by the Clinical and Laboratory
Standards Institute (CLSI)55.

Gram-negative bacteria outer membrane permeabilization assay
The MIC of simvastatin and control antibiotics, in the presence of a subinhibitory concentration of colistin, against Gram-negative bacteria was evaluated as
described in the antibacterial assay section above.

Macromolecular synthesis assay
The macromolecular synthesis assay was conducted as described elsewhere 56.
Briefly, S. aureus strain ATCC 29213 was grown in TSB, until it reached exponential
phase (OD600 = 0.2 to 0.3), and then treated with different concentrations of
simvastatin and control antibiotics (ciprofloxacin, rifampicin, linezolid, vancomycin
and cerulenin). Bacterial cells treated with drugs were incubated at 37 °C for 30 min
and the radio labeled precursors for DNA ([3H] thymidine (0.5μCi)), RNA ([3H] uridine
(0.5μCi)), protein ([3H] leucine (1.0 μCi)), cell wall ([14C] N-acetylglucosamine (0.4
μCi)) and lipid synthesis ([3H] glycerol (0.5 μCi)) were added for each reaction. The
incorporation of radiolabeled precursors was quantified and the results expressed as
percent inhibition of each specific pathway examined.
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Proteomics assay
An overnight culture of MRSA USA300 was treated with 10 × MIC of simvastatin
for one hour at 37 °C. Bacterial cells were centrifuged and sequence grade LysC/Trypsin (Promega) was used to enzymatically digest samples. Samples were
reduced and alkylated prior to digestion. All trypsin digestions were carried out in a
Barocycler NEP2320 (PBI) at 50 °C under 20 kpsi for two hours. After digestion,
samples were cleaned using MicroSpin C18 columns (Nest Group, Inc.) and the
resulting pellets were re-suspended in 97% H2O/3% ACN/0.1% FA. A small aliquot (5
µL) of sample was analyzed via nanoLC-MS/MS.
The WIFF files from MS analysis were processed using the MaxQuant
computational proteomics platform version 1.5.2.8 (Cox and Mann, 2008). The peak list
generated was screened against the Staphylococcus aureus (10972 entries reviewed) and
Bos taurus (41521 entries unreviewed) sequence from UNIPROT retrieved on 04/10/2015,
in addition to a common contaminants database. The following settings were used for
MaxQuant: initial precursor and fragment mass tolerance set to 0.07 and 0.02 Da
respectively, Minimum peptides length of seven amino-acid, data were analyzed with
‘Label-free quantification’ (LFQ) checked and the ‘Match between runs’ interval set to
one min, the fasta databases were randomized and the protein FDR was set to 1%, enzyme
trypsin allowing for two missed cleavages and three modifications per peptide, fixed
modifications were carbamidomethyl (C), variable modifications were set to Acetyl
(Protein N-term) and Oxidation (M).
The MaxQuant results were used in in-house script, and the average LFQ intensity
values for the technical replicates were used for each sample. All the Bos taurus and
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the common contaminant proteins were removed. All the values were transformed
[log2(x)] and the missing values were inputted using the average values of all samples.
The volcano plot and statistical analyses were performed in the R environment
(www.cran.r-project.org). A t-test was performed on the LFQ intensity and only proteins
with P ≤ 0.05 were used for further analyses. A function-enrichment analysis of proteins
was annotated using the Database for Annotation, Visualization and Integrated
Discovery – DAVID 57

Cell-free bacterial transcription/translation assay
The cell-free bacterial transcription/ translation assay was performed using
Escherichia coli S30 System (Promega). The assay was carried out as per the
manufacturer’s instructions. Gentamicin was used as a positive control. Briefly,
simvastatin and gentamicin were added at the indicated concentrations to the reaction
mixtures and incubated at 37 °C for one hour. The intensity of luminescence was
quantified using a standard FLx800 microplate reader (BioTek Instruments, Inc.
Winooski, Vermont) after addition of the luciferase assay reagent.

Mitochondrial biogenesis assay
An In-Cell ELISA Kit (MitoSciences Inc., Eugene, OR) was employed to evaluate
the effect of simvastatin and control antibiotics (tetracycline and vancomycin) on
mitochondrial protein synthesis and the experiment was conducted as described
previously 58. The ratio between COX-I and SDH-A was calculated and the percent
inhibition of mitochondrial protein synthesis was determined.
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Measuring toxin production by ELISA
The effect of simvastatin and control antibiotics (linezolid and vancomycin) on
production of two important S. aureus toxins (Hla and PVL) was measured utilizing
ELISA as described elsewhere 56,59,60.

Mice infection
The animal care and all experiments were performed in accordance with the
guidelines approved by Purdue University Animal Care and Use Committee (PACUC).
The murine model of MRSA skin infection utilized in this study has been described
previously 56. Briefly, mice (eight week old female BALB/c mice, five mice per group)
were injected intradermally with MRSA USA300 (1.65×108 CFU per mouse) and left
for 48 h before an open wound formed at the injection site. Each group was
subsequently treated with either 1% or 3% simvastatin or 2% mupirocin (using
petroleum jelly as the vehicle) once a day for four days. Control group was treated with
the vehicle alone. 24 h after the last treatment, the area around the wound was lightly
swabbed with 70% ethanol and the wound (1 cm2) was excised, homogenized, serially
diluted, and plated on MSA. Plates were incubated at 37 °C for 18 hours before counting
viable bacterial CFU.

Quantifying inflammatory cytokines by ELISA
Skin homogenates obtained from the mice skin infection procedure described above
were centrifuged and the supernatants were assayed in order to measure the levels of
three cytokines TNF-α, IL-6 and IL-1β by Duo-set ELISA Kits (R&D Systems, Inc.) The
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quantification of cytokines and the experiment were carried out as per the
manufacturer’s instructions 56.

Biofilm assay
The effect of simvastatin and control antibiotics (vancomycin and linezolid) on
disrupting established staphylococcal biofilm was evaluated using the microtiter dish
biofilm formation assay 56. Briefly, S. aureus (ATCC 6538) and S. epidermidis (ATCC
35984) were grown in TSB supplemented with 1% glucose in a 96-well tissue-culture
treated plate. Bacteria were incubated at 37 °C for 24 h to permit the formation of an
adherent biofilm. The medium was removed and washed with PBS. Drugs at indicated
concentration were added and incubated again at 37 °C for 24 h. Plates were washed
again and biofilms were stained with 0.1% (wt/vol) crystal violet. Plates were washed,
air dried and biofilm mass was dissolved using 95% ethanol. The intensity of crystal
violet was measured using a micro plate reader (Bio-Tek Instruments Inc.). Data are
presented as the percent biofilm mass reduction in treated groups in relation to untreated
wells.

Synergistic assay
Synergism was calculated using the Bliss independence model as described in
previous reports 54,56. Briefly, bacterial strains were incubated with a sub-inhibitory
concentration of simvastatin and control antimicrobials for 12 h and the degree of synergy
was calculated using the formula: S = (fA0/f00)(f0B/f00)-(fAB/f00), where fAB refers to
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bacterial growth rate in the presence of the combined drugs at concentration A, for one of
the antibiotics, and B for the simvastatin; fA0 and f0B refer to the bacterial growth rates
in the presence of antibiotics (or) simvastatin at a concentration of A and B, respectively;
f00 refers to the bacterial growth rate in the absence of drugs. Positive values correlate
with synergistic behavior while negative values are indicative of an antagonistic interaction
between the drugs.

ATP release assay
In order to determine if simvastatin and control antibiotics were capable of disrupting
the MRSA cell membrane, MRSA USA300 cells were treated with 5 × MIC of simvastatin,
tetracycline, or lysostaphin for one hour at 37°C. DMSO was used as a negative control.
Bacteria were centrifuged and supernatants were analyzed using the Enliten ATP Assay
System (Promega) per the manufacturer’s instructions. Aliquots (10 µl) of supernatant
were mixed with 75 µl of luciferase assay reagent and the intensity of luminescence was
recorded using a microplate reader (FLx800 BioTek Instruments, Inc. Winooski, Vermont).

Electron Microscopy
An overnight culture of MRSA USA300 was diluted (OD600 = 0.3) and incubated with
5 × MIC of simvastatin before samples were subsequently collected at two time points (0
and 12 hours). Samples were centrifuged and the bacterial pellets were fixed with 2.5%
buffered glutaraldehyde for one hour. Cells were next treated with 1% osmium tetroxide
and 1% uranyl acetate. Further dehydration was done using ethanol and embedded in white
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resin. The samples were stained with 1% uranyl acetate and lead citrate prior to viewing
samples under a Philips CM-100 microscope

Statistical analyses
Statistical analyses were assessed using GraphPad Prism 6.0 (Graph Pad Software,
La Jolla, CA). P values were calculated using the two-tailed Student t test. P ˂ 0.05
was deemed significant.

2.5.3

Results

In vitro antibacterial assays
The antibacterial activity of eight statin drugs including simvastatin, atorvastatin,
fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin and rosuvastatin were
evaluated against two representative Gram-positive and Gram-negative bacterial
pathogens (methicillin-resistant Staphylococcus aureus (MRSA) ATCC 4330 and
Pseudomonas aeruginosa ATCC 15442 respectively) (see Table 2.6). Simvastatin was
the only drug capable of inhibiting MRSA ATCC 4330 growth with a minimum
inhibitory concentration (MIC) value of 32 µg/ml. Interestingly, none of the statin drugs
examined possessed antibacterial activity against P. aeruginosa ATCC 15442
(MIC>1024 µg/ml), indicating simvastatin’s effectiveness as an antibacterial activity
may be restricted to Gram-positive pathogens.
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Table 2.6 Screening statins for antibacterial activity
Statins/
Molecular formula
Simvastatin
C25H38O5
Atorvastatin
C33H35FN2O5
Fluvastatin
C24H26FNO4
Lovastatin
C24H36O5
Mevastatin
C23H34O5
Pitavastatin
C25H24FNO4
Pravastatin
C23H36O7
Rosuvastatin
C44H54CaF2N6O12S2

Pub
Chem ID

M.wt

54454

418.56

60823

558.63

446155

411.46

53232

404.53

64715

390.51

5282452

421.46

54687

424.52

5282455

1001.1

InChIKey
RYMZZMVNJRMUD
DHGQWONQESA-N
XUKUURHRXDUEB
CKAYWLYCHSA-N
FJLGEFLZQAZZCD
MCBHFWOFSA-N
PCZOHLXUXFIOCF
BXMDZJJMSA-N
AJLFOPYRIVGYMJI
NTXDZFKSA-N
VGYFMXBACGZSIL
MCBHFWOFSA-N
TUZYXOIXSAXUG
OPZAWKZKUSA-N
LALFOYNTGMUKG
GBGRFNVSISA-L

MRSA
ATCC 4330
(µg/ml)

P. aeruginosa
ATCC 15442
(µg/ml)

32

>1024

>1024

>1024

>1024

>1024

>1024

>1024

>1024

>1024

>1024

>1024

>1024

>1024

>1024

>1024

Confirmation of simvastatin’s antibacterial activity against MRSA ATCC 43300
led us to examine simvastatin’s ability to inhibit growth of important multidrug-resistant
strains of Gram-positive pathogens (Table 2.7). Simvastatin exhibited bacteriostatic
activity against all methicillin-sensitive S. aureus (MSSA), MRSA, vancomycinintermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA), vancomycinsensitive Enterococcus, vancomycin-resistant Enterococcus (VRE) and Listeria
monocytogenes strains, inhibiting 90% of the strains (MIC90) tested at a concentration
of 32µg/ml. Simvastatin also inhibited growth of strains of Streptococcus pneumoniae
and Bacillus anthracis with a MIC90 of 64 and 16 µg/ml respectively.
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Table 2.7 MIC of simvastatin against a panel of Gram-positive bacteria
Bacteria (no. of strains screened)
Methicillin-resistant S. aureus (18)
Vancomycin-resistant S. aureus (15)
Methicillin-sensitive S. aureus (6)
Vancomycin-intermediate S. aureus (3)
Vancomycin-sensitive Enterococcus (9)
Vancomycin-resistant Enterococcus (7)
Listeria monocytogenes (6)
Streptococcus pneumoniae (2)
Bacillus anthracis (3)

Simvastatin
(µg/ml)
MIC50
MIC90
32
32
32
32
32
32
32
32
32
32
32
32
32
32
64
64
16
16

The antimicrobial activity of simvastatin was next assessed against various Gramnegative pathogens (Table 2.8). Initial investigation indicated that simvastatin did not
possess antibacterial activity against Gram-negative bacteria. However, when the outer
membrane (OM) permeability in these bacteria was compromised using a sub-inhibitory
concentration of colistin, simvastatin displayed antimicrobial activity against all tested
strains of Gram-negative pathogens including Acinetobacter baumannii, Escherichia
coli, Salmonella Typhimurium, Klebsiella pneumoniae, and P. aeruginosa with the MIC
ranging from 8-32 µg/ml. The antibacterial activity of simvastatin was further
investigated against E. coli SM1411∆ acrAB, a strain that is deficient in the multidrugresistant AcrAB efflux pump. Simvastatin alone was not active against E. coli SM1411∆
acrAB (MIC>256 µg/ml). However simvastatin was able to inhibit growth of this strain
when combined with colistin (the MIC was 16 µg/ml).
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Table 2.8 MIC of simvastatin against a panel of Gram-negative bacteria

Bacterial strains

Acinetobacter baumannii ATCC
BAA19606
Acinetobacter baumannii ATCC
BAA1605
Acinetobacter baumannii ATCC
BAA747
Escherichia coli O157:H7
ATCC 700728
Escherichia coli O157:H7
ATCC 35150
Salmonella Typhimurium ATCC
700720
Klebsiella pneumoniae ATCC
BAA 2146
Klebsiella pneumoniae ATCC
BAA 1705
Pseudomonas aeruginosa
ATCC 9721
Pseudomonas aeruginosa
ATCC 9027
Pseudomonas aeruginosa
ATCC 27853
Pseudomonas aeruginosa
ATCC BAA-1744
Pseudomonas aeruginosa
ATCC 25619
Pseudomonas aeruginosa
ATCC 35032
Pseudomonas aeruginosa
ATCC 10145
Pseudomonas aeruginosa
ATCC 15442
Escherichia coli 1411
Escherichia coli SM1411∆
acrAB

MIC of
colistin

Sub-inhibitory
concentration
of colistin used

Simvastatin
(µg/ml)

Erythromycin
(µg/ml)

Fusidic acid
(µg/ml)

colistin
(-)
(+)
64
2

o
colistin
f
(-) c
(+)
64 o
0.5
l
i
128 s
1
t
i
128 n
1
u
s
>256e
4
d
>256
4

0.25

0.0625

colistin
(-)
(+)
>256
16

0.25

0.0625

>256

16

64

2

0.25

0.0625

>256

16

64

2

0.25

0.0625

>256

16

128

1

0.125

0.0625

>256

8

128

4

1

0.25

>256

16

256

0.5

>256

0.5

0.25

0.125

>256

16

>256

0.125

>256

0.125

0.25

0.125

>256

16

>256

8

>256

8

0.5

0.25

>256

16

>256

2

>256

1

0.5

0.25

>256

32

>256

0.5

>256

2

0.5

0.25

>256

16

256

0.5

>256

0.5

0.25

0.125

>256

16

>256

1

>256

2

0.125

0.0625

>256

16

256

2

>256

0.5

0.5

0.25

>256

16

>256

1

>256

1

0.25

0.125

>256

16

256

1

>256

2

0.5

0.25

>256

16

>256

0.5

>256

1

0.25
0.25

0.0625
0.0625

>256
>256

16
16

32
0.03

0.03
<0.03

>256
8

0.03
<0.03
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Figure 2.28 Macromolecular synthesis in the presence of simvastatin. Effect of simvastatin
and control antimicrobials at indicated concentration (in fold MICs) on incorporation
of radiolabeled precursors of DNA, RNA, protein, cell wall and lipid synthesis ([3H]
thymidine, [3H] uridine, [3H] leucine, [14C] N-acetylglucosamine and [3H] glycerol,
respectively) were quantified in S. aureus ATCC 29213. Results are expressed as percent
of inhibition calculated based on the incorporation of each radiolabeled precursor.
Statistical analyses were done using the two-tailed Student’s‘t’ test. P values of (* ≤ 0.05)
are considered as significant.
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Figure 2.29 Quantitative proteome analysis of S. aureus cells treated with simvastatin
reveals extensive protein degradation. (a) S. aureus treated with simvastatin in biological
triplicates was analyzed for changes in the global proteome in relation to untreated controls,
as shown in the volcano plot. The volcano plot depicts the P-values (-log10) versus gene
ratio in the simvastatin- treated group (log2). Genes marked in blue indicate an absolute
fold change higher than 1. The genes marked in red represent an adjusted P-value lower
than 0.05 and an absolute fold change higher than 1.5. (b) Function–enrichment analysis
of proteins degraded by simvastatin were annotated using Database for Annotation,
Visualization and Integrated Discovery (DAVID). The overrepresented pathways are
shown in columns and their P-values are represented by the red dots.

Simvastatin inhibits multiple macromolecular synthesis pathways
Simvastatin’s antibacterial mechanism of action was investigated using a standard
macromolecular synthesis inhibition assay in S. aureus ATCC 29213. As shown in Figure
2.28, DNA, protein and lipid synthesis were significantly inhibited at concentrations
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below the drug’s MIC (0.25×). In addition, simvastatin also significantly inhibited RNA
synthesis at 0.5× MIC. Inhibition of cell wall synthesis was observed only at the MIC.

Simvastatin causes extensive protein degradation and disrupts cellular homeostasis
In order to gain additional insight into the different cellular pathways regulated by
simvastatin, proteomic profiling was employed to investigate the response of bacteria to
simvastatin 21-23. The alterations in the proteome caused by treatment with
simvastatin were compared to an untreated control group. The proteomic analysis
identified 521 proteins with 85 proteins that were significantly differentially expressed (P
≤ 0.05) in the simvastatin treatment group as compared to the control group (Figure 2.29a).
The seven proteins marked in red have an adjusted P-value lower than 0.05 and absolute
fold change higher than 1.5. An important protein that is regulated is adenylate kinase
(adk) which is involved in the interconversion of ADP to AMP and ATP and helps to
maintain the adenine nucleotide balance within cells 24. From the six upregulated
proteins, three are ATP-dependent enzymes; clpC (ATP- dependent Clp protease), clpB
(chaperone protein ClpB) and thrS (threonine-tRNA ligase). The Clp proteases and
chaperon proteins are central components in bacteria necessary to help mount an
appropriate stress response to cope with adverse conditions experienced inside the host
25,26.

The function-enrichment analysis found eight pathways showed a significant (P ≤
0.05) fold enrichment ranging from 8.6 to 47 (Figure 2.29b). From these pathways, the
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proteins involved in pyrimidine metabolism, valine, leucine and isoleucine biosynthesis
and aminoacyl- tRNA biosynthesis were significantly downregulated (average log2 fold
change: -1.42, -0.29 and -0.11 respectively). On the other hand, the proteome involved
in 3-chloroacrylic acid degradation, butanoate metabolism, glycolysis/gluconeogenesis,
pyruvate metabolism and the proteins that bind to one or more ribosomal subunits were
significantly upregulated (average log2 fold change:1.98, 1.26, 1.26, 0.82 and 0.61
respectively). Thus the proteomic analysis suggests that simvastatin treatment leads
to an extensive degradation of different proteins involved in various essential cellular
pathways resulting in dysregulation of cellular homeostasis and ultimately leading to
arrest of bacterial growth.

Simvastatin inhibits bacterial but not mammalian protein synthesis
In order to confirm simvastatin is a potent, selective inhibitor of bacterial protein
synthesis, its activity against both bacterial and mammalian mitochondrial protein
synthesis was assessed. An E. coli S30 coupled transcription and translation assay
was performed to determine the concentration of simvastatin required to inhibit 50% of
the bacterial translational process (IC50). As presented in Figure 2.30a, the IC50 of
simvastatin was found to be 18.85 ± 0.95 µg/ml. The effect of simvastatin on
mammalian mitochondrial protein synthesis was subsequently evaluated in J774A.1
cells.
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Figure 2.30 Simvastatin inhibits bacterial protein synthesis and toxin production. (a)
Transcription- translation (TT) assay was carried out using S30 extracts from E. coli.
IC50 of simvastatin and gentamicin required to inhibit 50% TT-activity in bacteria
were determined. (b) Effect of simvastatin, vancomycin and tetracycline on mammalian
mitobiogenesis was assessed via In cell- ELISA. J774A.1 cells were treated with
indicated concentration of drugs and the levels of mitochondrial (mt)-DNA encoded
protein (COX-I) and nuclear-DNA encoded protein (SDH-A) were quantified. The ratio
of COX-I and SDH-A was calculated and the results shown are percent inhibition of
mitochondrial biogenesis. (c) Effect of simvastatin on S. aureus toxin production. MRSA
USA300 was treated with drugs for one hour and toxin production (ng/ml) (corrected for
organism burden) was measured by ELISA. The results are given as means ± SD (n = 3).
P values of (* P ≤ 0.05) (** P ≤ 0.01) are considered as significant in comparison to
control groups.
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The change in expression level of subunit I of Complex IV (COX-I), which is
mitochondrial DNA (mtDNA)-encoded, and the 70 kDa subunit of Complex II (SDHA), which is nuclear DNA (nDNA)-encoded proteins, after treatment with simvastatin
and control antibiotics (tetracycline and vancomycin) was measured by In-cell ELISA. As
presented in Figure 2.30B, simvastatin (40 µg/ml), similar to vancomycin (40 µg/ml), has
a very minimal effect (less than 15% inhibition observed) on inhibition of
mitochondrial protein synthesis (Figure 6.3b). In contrast, the positive control antibiotic,
tetracycline, inhibited more than 50% of mitochondrial protein synthesis, at a
concentration of 40 µg/ml (Figure 2.30b).

Simvastatin inhibits S. aureus toxin production
In view of results demonstrating the specific effect of simvastatin on bacterial
protein synthesis inhibition, its effect on production of S. aureus toxins such as PantonValentine leucocidin (PVL) and α-hemolysin (Hla) was investigated using ELISA.
Simvastatin significantly suppressed two key toxins (PVL and Hla) produced by
MRSA USA300 when compared to the control group. This mimics the results obtained
with linezolid (an antibiotic that inhibits protein synthesis) which also significantly
suppressed production of both PVL and Hla by MRSA USA300 (Figure 2.30c).

Simvastatin effectively reduces pre-formed staphylococcal biofilms
Given the challenge associated with bacterial biofilms and their role in promoting
recurring infection in hosts, we next moved to investigate the effect of simvastatin on
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disrupting established biofilms caused by S. aureus and S. epidermidis. Utilizing the
microtiter dish biofilm formation assay, simvastatin was found to be capable of
significantly reducing the adherent biofilms of both S. aureus and S. epidermidis
when compared to conventional antibiotics (linezolid and vancomycin) (Figure 6.4).
Simvastatin, at 2 × MIC and 4 × MIC, significantly reduced S. aureus and S. epidermidis
biofilm mass by approximately 40%. Contrary to simvastatin, the control antibiotics
(linezolid and vancomycin) even at 64 × MIC and 128 × MIC were only able to reduce
the biofilm mass of both S. aureus and S. epidermidis by 10% (Figure 2.31).

Figure 2.31 The effects of simvastatin and antibiotics (linezolid and vancomycin) on
established biofilms of S. aureus (a) or S. epidermidis (b) were evaluated. The pre-formed
biofilms were treated with control antibiotics or simvastatin and then stained with crystal
violet. The optical density of the dissolved crystal violet was measured using a
spectrophotometer. Values are the mean of triplicate samples with standard deviation bars.
P values of (*, # P ≤ 0.05) are considered as significant. (*) indicates simvastatin was
compared to control and (#) to control antibiotics.
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Figure 2.32 Antibacterial and anti-inflammatory activities of simvastatin in a mouse
model of MRSA skin infection. (a) Efficacy of treatment of MRSA skin lesions with
simvastatin (1 and 3%), mupirocin (2%) and petroleum jelly (negative control) once daily
for four days. Percent bacterial reduction was calculated and shown in the figure. Statistical
analysis was performed via the two- tailed Student t test. P values of (** P ≤ 0.01) are
considered as significant. (b) Effect of simvastatin on cytokines production in supernatants
from skin homogenates of MRSA skin lesions. Percent reduction in inflammatory
cytokines was calculated. Statistical analysis was performed via the two-tailed Student t
test. P values of (** P≤ 0.01) are considered as significant.
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Simvastatin is effective in reducing bacterial load in a mouse model of MRSA
skin infection
Four groups of MRSA-infected mice were treated topically either with simvastatin (1%
or 3%), a control antibiotic (2% mupirocin), or the vehicle alone (petroleum jelly) once
a day for four days. As shown in Figure 2.32a, all treatment groups significantly reduced
the mean bacterial counts compared with the control group (P ≤ 0.01). Topical treatment
with 1 and 3% simvastatin significantly reduced the MRSA load in infected skin wounds
by 75 and 90% respectively. Mupirocin (2%) produced a 99% reduction in mean bacterial
count as compared to the untreated group.

Simvastatin reduces inflammatory cytokines induced by MRSA skin infection
The immune-modulatory activity of simvastatin against MRSA skin infection was
evaluated by measuring levels of pro-inflammatory cytokines produced during infection
including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 beta
(IL-1β) in the MRSA infected wounds of mice from the skin infection experiment
described above. As shown in Figure 2.32b, topical application of simvastatin (1 and 3%)
significantly reduced all tested inflammatory cytokines. Simvastatin-treated (3%) group
reduced production of all three cytokines examined (IL-6, TNF-α and IL-1β).
Topical application of 1% simvastatin also decreased production of inflammatory
cytokines in the MRSA infected wound lesions by 20%. However, mice treated with
mupirocin (2%) did not show a significant reduction in the levels of all the tested
inflammatory cytokines when compared to the control group.
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Figure 2.33 Synergistic activity of simvastatin with topical antimicrobials. The Bliss
independence model confirms a synergistic relationship between simvastatin and four
topical antimicrobials (mupirocin, fusidic acid, retapamulin and daptomycin) against
various clinical isolates of multidrug-resistant strains of S. aureus. The positive and
negative values along the x-axis represent the degree of synergism and antagonism
respectively.

Figure 2.34 Simvastatin does not disrupt the cell membrane of S. aureus. (A) MRSA
USA300 cells were treated with 5 × MIC of simvastatin, tetracycline or lysostaphin and
the level of ATP was measured in the supernatant for each treatment condition . (B)
Transmission electron microscopy (TEM) images of untreated and simvastatin (5 × MIC)
treated MRSA USA300 cells at the indicated time points, in hours (h), are shown.
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Simvastatin exhibits synergistic activity with conventional topical antimicrobials
Combination therapy employing two or more antibiotics together has been utilized
for treating skin wounds and infections in the healthcare setting. Given simvastatin
exhibited good antibacterial activity against MRSA both in vitro and in vivo, we
examined the possibility of using simvastatin with antimicrobials commonly used to treat
skin infections. The antimicrobial activity of simvastatin in combination with four topical
antimicrobials (fusidic acid, mupirocin, daptomycin, and retapamulin) was investigated
in vitro using the Bliss independence model of synergism against three S. aureus clinical
isolates. As shown in Figure 2.33, simvastatin demonstrated a synergistic relationship
with all tested topical antibiotics against S. aureus clinical isolates.

2.5.4

Discussion

Antibiotics have long been key allies in the treatment of bacterial infections.
However, the emergence of pathogens (in particular MRSA) exhibiting resistance to
many antimicrobial classes including to therapeutic agents of last resort, such as
vancomycin and linezolid, presents an ominous premonition that our current arsenal of
antibiotics will no longer be effective in the near future 27-29. Thus there is an urgent
need to drive research efforts to discover new antimicrobials in order to circumvent
this burgeoning health challenge. The conventional strategies used to develop new
drugs are highly unlikely to keep pace with acquired resistance by bacterial pathogens
and often comes at a significant financial risk to pharmaceutical companies (the
success rate of receiving regulatory approval for a new antibiotic varies between 1.5 –
3.5% even after investing nearly one billion dollars in research and development costs)
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30 . Though government regulatory agencies have attempted to provide incentives to
encourage pharmaceutical companies to re-enter the arena of antibacterial drug
discovery, such as the U.S. Food and Drug Administration’s "reboot" pledge, it will
take many years for these incentives to translate into the discovery of new antibiotics
(using conventional methods of screening compound libraries for lead hits) 31. An
alternative strategy that has promise to expedite the discovery and approval process is
repurposing old drugs, such as statins that have already passed rigorous safety
assessments, as novel antibacterial agents to combat multidrug-resistant pathogens 32.
Statins, widely used to control hyperlipidemia, are known to exhibit antimicrobial
properties 13-17. We investigated the antibacterial activity of eight statin drugs
including simvastatin, atorvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin,
pravastatin and rosuvastatin against a representative Gram-positive and Gram-negative
bacterial species (methicillin-resistant S. aureus ATCC 4330 and P. aeruginosa ATCC
15442). Our results correlate with previous reports that have found that only simvastatin
exhibits antibacterial activity against Gram-positive bacteria 17. However its activity
against Gram-negative bacteria was previously unknown. Our initial investigation
indicated that simvastatin lacks antibacterial activity against the Gram-negative
pathogen P. aeruginosa. However, further analysis revealed that the outer membrane in
Gram-negative bacteria acts as an intrinsic barrier for simvastatin to gain entry into
Gram-negative bacteria. When the OM is compromised using a sub-inhibitory
concentration of colistin, simvastatin exhibits antibacterial activity against many
clinically-pertinent Gram- negative pathogens including A. baumannii, E. coli, S.
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Typhimurium, K. pneumoniae, and P. aeruginosa.. The enhanced antimicrobial activity
of simvastatin in comparison to other statin drugs may be related to differences in their
chemical characteristics, as described previously 14,17. However, further structureactivity relationship studies need to be performed to confirm the structural elements in
simvastatin that contribute to its antimicrobial properties. This will permit rational
modifications to be made to the drug’s structure in order to potentially enhance its
potency against bacterial pathogens and mitigate potential toxicity issues to host tissues.
In view of the broad-spectrum activity of simvastatin, its antibacterial mode
of action was investigated. Simvastatin exerts its antihyperlipidemic effect in humans
by inhibiting the enzyme class I HMG-CoA reductase present in the mevalonate
pathway 2,3. We hypothesized that the mechanism of action (MOA) of simvastatin in
S. aureus differs from the MOA in humans due to the absence of the class I HMG-CoA
reductase enzyme in S. aureus 33. In order to confirm this hypothesis, we tested the
activity of simvastatin on S. aureus cultures supplemented with mevalonate. As
expected, mevalonate supplementation (0.1 and 1 mM) did not diminish simvastatin’s
antibacterial activity against S. aureus (data not shown). This clearly indicates that the
MOA of simvastatin differs between S. aureus and humans. In order to further explore
the MOA of simvastatin on S. aureus, a macromolecular synthesis assay was performed.
Treatment of S. aureus cells with a subinhibitory concentration of simvastatin resulted
in the suppression of multiple biosynthetic pathways including DNA, protein, lipid and
RNA synthesis indicating that simvastatin might have a complex mechanism of action
involving multiple targets. Additionally, the impact of simvastatin on multiple
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biosynthetic pathways might be due to dysregulation in pathways involved in general
cellular homeostasis and energy metabolism such as glycolysis, pyruvate metabolism
and butanoate metabolism as observed in the proteomic profiling. In order to ascertain
whether cell membrane damage is the cause for inhibition of multiple macromolecular
synthesis pathways, as noticed in antimicrobial peptides such as lactoferricin B and
pleurocidin-derived peptides 34,35, we performed an ATP release assay. Our results
strongly suggest that simvastatin does not physically damage the bacterial cell
membrane as was validated using transmission electron microscopy (Figure 2.34).
Finally, in an attempt to determine the exact molecular target of simvastatin, S. aureus
was serially passaged for two weeks in the presence of simvastatin. Though S. aureus
mutants that were resistant to simvastatin were generated, whole genome sequencing
indicated that these mutants were not stable. This result provides indirect evidence that
multiple targets might be a reason for the inability to form stable mutants resistant to
simvastatin (data not shown). Future studies are needed to elucidate the exact molecular
target(s) of simvastatin by which it exerts its antibacterial activity.
The macromolecular synthesis assay revealed that simvastatin inhibits
bacterial protein synthesis which raises an important question; is this action specific or
can simvastatin also inhibit protein synthesis in mammalian cells? Multiple
antibacterials that inhibit bacterial protein synthesis (including tetracycline, linezolid
and chloramphenicol) are non- selective and result in toxicity to the mitochondria in
mammalian cells (given the similarity between the ribosomal subunits involved in
protein synthesis in bacterial and human cells) 36,37. When simvastatin’s ability to
inhibit protein synthesis was further examined it was found that, unlike tetracycline
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which had a profound impact on inhibiting mitochondrial protein synthesis, simvastatin
was a selective inhibitor of bacterial protein synthesis. The discovery led us to examine
if this effect on protein synthesis inhibition would lead to suppression in the production
of key toxins by S. aureus. Utilizing ELISA, we found that simvastatin is capable of
inhibiting production of both PVL and αHla, two pore-forming cytotoxins that injure
host immune cells and promote infection of host tissues 38.
Confirmation of simvastatin’s broad spectrum antimicrobial activity in vitro led
us to proceed forward with an in vivo experiment in a mouse model of MRSA infection.
However, given simvastatin’s high MIC value cannot be achieved systemically, this
limits the application of this drug to being used as a topical agent 39. Due to the fact that
S. aureus causes the vast majority of skin infections in humans and there is a demand
for topical antimicrobial agents to treat these infections (given increasing resistance to
first-line agents such as mupirocin), there is great potential for using simvastatin to
treat/prevent bacterial infections in wounds 40,41. Therefore we assessed the
effectiveness of simvastatin as a topical antibacterial in a MRSA skin infection mouse
model. Simvastatin, both at 1% and 3%, significantly reduced the mean MRSA counts
compared with the control group (P ≤ 0.01), producing a 90% reduction in bacterial
burden at the higher concentration. Thus, this skin infection study appears to strongly
suggest that simvastatin has potential use as a topical antimicrobial for treatment of
MRSA skin infections.
The clinical severity of S. aureus-based skin infections is driven in large part
by production of excess host pro-inflammatory cytokines more so than by bacterial
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burden42,43. As simvastatin has known anti-inflammatory properties, it should be
superior to traditional antibiotics for treatment of skin infection (as it should
hypothetically suppress production of inflammatory cytokines) 44. To confirm this,
we measured the levels of three inflammatory cytokines in the supernatant of
homogenized skin tissues obtained from the MRSA murine skin infection experiment
described above. As predicted, topical treatment with simvastatin, both at 1 and 3%,
significantly reduced production of three inflammatory cytokines (IL-1β, IL-6 and TNFα); the suppression of these cytokines may contribute to enhanced healing of infected
wounds45,46. Prolonged inflammation, especially due to the presence of inflammatory
cytokines such as TNF-α and IL-6, delays healing in chronic infected wounds 47.
Simvastatin significantly (P ≤ 0.01) inhibits both cytokines (TNF-α and IL-6), which
should provide a favorable outcome in wound healing 47. Additionally, simvastatin
has been shown to play a beneficial role in the healing process of diabetic and
infected wounds by enhancing the formation of new blood and lymphatic vessels and
increasing the formation of new tissue; these three effects undoubtedly confer an added
advantage for using simvastatin to treat bacterial skin infections 48,49 Recurring
infection in skin wounds can persist and impair wound healing due to the presence
of complex microbial communities called biofilms. Bacterial biofilms, contribute
significantly to the treatment failure of staph infections, due to hindering penetration of
antibacterial drugs 50. Simvastatin has been previously reported to exhibit anti-biofilm
activity as it inhibited both growing and mature biofilms of Candida spp. and
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Cryptococcus spp 51,52. Thus we decided to examine simvastatin’s capability to disrupt
staphylococcal biofilms given their prevalence in the healthcare setting (in particular on
medical implant devices). In addition to its broad-spectrum antibacterial activity, we
confirmed that simvastatin is capable of disrupting established bacterial biofilms of two
leading cause of hospital-acquired implant-based infections caused (S. aureus and S.
epidermidis)17. The ability to disrupt staphylococcal biofilms by simvastatin lends
further support to its potential use as a topical agent in the treatment of skin wounds.
The final component of the present study involved examining simvastatin’s ability
to be used in combination with other topical antimicrobials. Due to the increasing
incidence of MRSA strains demonstrating resistance to topical drugs of choice, such
as fusidic acid and mupirocin, combination therapies are being explored as a potential
mechanism to ward off the emergence of further resistance to these important agents
53. The Bliss independence model was utilized to investigate if simvastatin has the
potential to act synergistically with topical drug of choice against multidrug-resistant S.
aureus 54. Simvastatin behaved synergistically with fusidic acid, mupirocin,
daptomycin, and retapamulin against S. aureus strains resistant to vancomycin, linezolid,
and methicillin. This result provides a strong platform to further examine combining
simvastatin with topical antimicrobials to treat staphylococcal skin infections (and
potentially contribute to reducing the likelihood of strains developing resistance to each
agent if used alone).
In conclusion, the present study builds upon previous reports that demonstrate
simvastatin possesses antimicrobial activity against important Gram-positive pathogens,
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in particular methicillin-resistant S. aureus. We confirmed that simvastatin does possess
antibacterial activity against Gram-negative pathogens as well, once the barrier imposed
by the outer membrane is permeabilized, a finding not previously known. The
antibacterial mechanism of action of simvastatin appears to be complex and involve
inhibition of multiple biosynthetic pathways and cellular processes, including selective
interference with bacterial protein synthesis. This property appears to play an important
role in simvastatin’s ability to suppress production of key toxins (α-hemolysin and PVL)
critical to permit skin wounds infected by S. aureus to fully heal. A murine MRSA skin
infection experiment revealed simvastatin is capable of significantly reducing the
bacterial burden present in infected wounds. Additionally, simvastatin demonstrates the
ability to disrupt adherent staphylococcal biofilms and to be used in combination with
other topical antimicrobials currently employed to treat MRSA skin infections.
Collectively the present study lays the foundation for further investigation of
repurposing simvastatin as a topical antibacterial agent to treat skin infections caused
by pathogens including MRSA.
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2.6

Repurposing celecoxib as a topical antimicrobial agent for staphylococcal skin
infections

(Thangamani S, Younis W, Seleem MN. Repurposing celecoxib as a topical antimicrobial
agent. Frontiers in Microbiology. 2015 Jul 28;6:750)

2.6.1

Introduction

Bacterial infections caused by multi-resistant pathogens have emerged as a major
global crisis during the past few decades 109. In 2013, the U.S. Centers for Disease Control
and Prevention indicated that at least two million individuals per year in the United States
become infected with multidrug-resistant pathogens, including methicillin-resistant
Staphylococcus

aureus

(MRSA),

multidrug-resistant

Pseudomonas

aeruginosa,

carbapenem-resistant Klebsiella pneumoniae, and vancomycin-resistant Enterococcus
faecium 1. More importantly, the emergence and spread of multidrug-resistant S. aureus
clones such as MRSA USA300 are highly virulent and cause skin and soft tissue infections
that lead to morbidity and mortality in infected patients 288. Furthermore, the exo-proteins
and toxins secreted by these MRSA strains trigger excess host inflammatory responses and
further complicate the situation, especially in the management of wound infections
107,310,321,322

. In addition, virulence factors secreted by MRSA strains hinders wound healing

and often contagious staphylococcal skin infections lead to invasive infections resulting in
septicemia 257,258,323. These observations speak to the specific need for topical antibacterial
agents with novel mechanism of action combined with anti-inflammatory and wound
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healing property that can address the issue of skin infections cause by multidrug-resistant
staphylococcal strains.
The number of conventional antimicrobials available to treat MRSA skin infections
is highly limited and those that are available are becoming less effective

324,325

. Though

topical antimicrobials such as tedizolid and dalbavancin to treat Gram-positive pathogens
including MRSA has been recently approved by FDA, still there is an unmet need exist for
novel topical drugs to combat these pathogens

261,262

. The development of new

antimicrobials capable of being used to treat multidrug-resistant pathogens is very slow
and has not been able to keep pace with the emergence of bacterial resistance

109

. Hence,

novel drugs and treatment strategies are urgently needed to combat these bacterial
pathogens. Repurposing of approved drugs is a promising alternative strategy that can
accelerate the process of antimicrobial research and development

276,326

. Unlike

conventional drug discovery, finding new uses for existing drugs is a proven shortcut from
bench to bedside, that reduces the cost and time associated with antibiotic development 276278,326

.
Celecoxib (Celebrex) is a nonsteroidal anti-inflammatory drug widely used for the

treatment of pain, fever, and inflammation

327,328

. It specifically inhibits the enzyme

cyclooxygenase-2 (COX2), thereby reducing the synthesis of proinflammatory
prostaglandins

329

. Beyond its anti-inflammatory activity, celecoxib has been shown to

possess antimicrobial activity against several microbial pathogens. In a study by Pereira et
al, celecoxib was found to reduce the total fungal load in Histoplasma capsulatum infected
mice 330. Further, celecoxib treatment also increased the survival rate of the mice infected
with lethal dose of H. capsulatum 330. Another study by Chiu et al, found that celecoxib
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inhibited the growth of Francisella tularensis and F. novicida

331

. In addition, celecoxib

also exhibited antibacterial activity against S. aureus and S. epidermidis

80

. Apart from

antimicrobial activity, celecoxib inhibits multidrug efflux pumps in Mycobacterium
smegmatis and S. aureus, and increases the sensitivity of bacteria to various antibiotics,
including ampicillin, kanamycin, ciprofloxacin and chloramphenicol 332,333. However, the
antibacterial mechanism of action of celecoxib and its potential clinical application remain
underexplored.
In this study, we investigated the antibacterial activity of celecoxib, as well as the
spectrum of its activity against various clinical isolates of multidrug-resistant Grampositive and Gram-negative pathogens. We also investigated its mechanism of action and
validated its in vivo antimicrobial efficacy in two different animal models, including C.
elegans and mouse models of MRSA infection. Finally, we tested the activity of celecoxib
in combination with various antimicrobial agents to investigate the potential for synergistic
activities.

2.6.2 Materials and Methods
Bacterial strains and reagents
The bacterial strains used in this study are presented in Tables 1-3. Mueller-Hinton
broth was purchased from Sigma-Aldrich. Trypticase soy broth (TSB), Trypticase soy agar
(TSA), and Mannitol salt agar (MSA) were purchased from Becton, Dickinson
(Cockeysville, MD). Celecoxib was purchased from TSZ chemicals. Vancomycin
hydrochloride was obtained from Gold Biotechnology; linezolid from Selleck Chemicals,
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mupirocin from Aapplichem, NE, clindamycin from TCI Chemicals, and fusidic acid and
rifampicin from Sigma-Aldrich.

Antibacterial assays
Minimum inhibitory concentrations (MICs) were determined in triplicate, in MuellerHinton broth, using the broth micro dilution method described by the Clinical and
Laboratory Standards Institute (CLSI)

216

. The MIC was interpreted as the lowest

concentration of the drug able to completely inhibit the visible growth of bacteria after
incubating plates for at least 16 h at 37°C. The highest MIC value taken from two
independent experiments was reported.

Determining antibacterial activity in Gram-negative bacteria: (i) Outer membrane
permeability assay
The MIC of celecoxib in the presence of colistin was measured as described in the
antibacterial assays section, above. Sub-inhibitory concentration of colistin was added to
the media to increase outer membrane permeability and facilitate the entrance of celecoxib.
The following sub-inhibitory concentration of colistin was used for the strains used in this
study. Pseudomonas aeruginosa ATCC15442 and Salmonella Typhimurium (0.25 µg/ml),
P. aeruginosa ATCC BAA-1744 and Klebsiella pneumoniae (0.125 µg/ml), Escherichia
coli O157:H7ATCC 700728 and Acinetobacter baumannii (0.0625 µg/ml). (ii) Inactivation
of efflux pumps: Role of efflux pumps in contributing resistance to celecoxib in Gramnegative bacteria was investigated by using an efflux pump inhibitor (reserpine) and an
efflux pump deletion mutant strain of E.coli. The MIC of celecoxib was examined in the
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presence of sub-inhibitory concentration of reserpine (32 µg/ml) against all the strains of
Gram-negative bacteria used in this study. Efflux pump deletion mutant strain of E. coli
SM1411 ∆ acrAB was employed to determine if acrAB efflux pump plays a role in
contributing intrinsic resistance to celecoxib in E. coli as described 217.

Time kill assay
The time kill assay was performed as described before

216

. Briefly, MRSA USA300

was diluted to 1 × 106 CFU/mL and treated with 4X MIC of control antimicrobials
(vancomycin or linezolid), 4X and 8X MIC of celecoxib (in triplicates) in MHB. Samples
were incubated at 37°C and collected at indicated time points to count MRSA colony
forming units (CFU).

Macromolecular synthesis assay
S. aureus strain ATCC 29213 was grown overnight on TSA plates and the isolated
colonies cultured in 15ml of MHB to an early exponential phase (OD600 = 0.2 to 0.3) was
used for the macromolecular synthesis assay. Aliquots (100 μl) of the culture were added
to triplicate wells of a 96-well microtiter plate. Antibiotics with known mechanisms of
action (ciprofloxacin, rifampicin, linezolid, vancomycin, and cerulenin) and auranofin
were added to the plate as controls. DMSO was added to the control groups. After 30 min
of incubation at 37°C, radiolabeled precursors such as [3H] thymidine (0.5μCi), [3H]
uridine (0.5μCi), [3H] leucine (1.0 μCi), [14C] N-acetylglucosamine (0.4 μCi), and [3H]
glycerol (0.5 μCi) were added to quantify the amount of for DNA, RNA, protein, cell wall
and lipid synthesis respectively. Reactions measuring the inhibition of DNA and RNA
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synthesis were stopped after 15 min by the addition of 5% trichloroacetic acid (TCA). Then,
the tubes were chilled on ice for 30 min. The TCA-precipitated materials were collected
on a 25 mm GF/1.2 μM PES 96-well filter plate. Filters were washed five times with 5%
TCA, dried, and then counted using a Packard Top Count microplate scintillation counter.
Reaction wells measuring the inhibition of protein synthesis were stopped after 40 min,
precipitated, and counted in a manner similar to that used for the DNA and RNA synthesis
inhibition assays. Reaction wells measuring the inhibition of cell wall synthesis were
stopped after 40 min by the addition of 8% SDS and then heated for 30 min at 95°C. After
cooling, the material were spotted onto nitrocellulose membrane filters (0.8 μM) and
washed three times with 0.1% SDS. Filters were dried and counted using a Beckman
LS3801 liquid scintillation counter. Reactions measuring the inhibition of lipid synthesis
were stopped after 40 min by the addition of chloroform/methanol (1:2) and centrifuged at
13,000 rpm for 10 min. Then, the organic phase was carefully transferred to a scintillation
vial, dried, and counted using liquid scintillation counting. Incorporation of radiolabeled
DNA, RNA, protein, cell wall, and lipid precursors was quantified using the scintillation
data and inhibition was calculated. Results were presented as the percent inhibition of each
macromolecular synthesis pathway.

Toxicity assay in C. elegans
C. elegans AU37 (sek-1; glp-4) strain glp-4(bn2) were used for the toxicity studies. L4stage worms were synchronized as described previously

301

. Synchronized worms

(approximately 20 worms) in 50% M9 buffer and 50% TSB were added to each well of a
96-well plate. Drugs (celecoxib and linezolid) at indicated concentrations (16 or 32 µg/ml)
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were added to the wells and the plates were incubated for 4 days at room temperature.
Worms were assessed every day; the percentage of worms remaining alive in each group
was calculated.

Efficacy of celecoxib in MRSA-infected C. elegans
C. elegans AU37 (sek-1; glp-4) strain glp-4(bn2) was used to test the in vivo
antimicrobial efficacy of celecoxib as described previously

301

. S. aureus strain MRSA

USA300 was used for infection and the MIC of control antibiotic (linezolid) and celecoxib
against MRSA USA300 were 2 and 32 µg/ml. Briefly, L4-stage worms were infected with
MRSA USA300 for 8 h at room temperature. The worms were washed with M9 buffer,
and then drugs (celecoxib and linezolid) at indicated concentrations were added to the 96well plates containing approximately 20 worms per well. After 24 h, the worms were
washed four times with PBS and 100 mg of sterile, 1.0-mm silicon carbide particles
(Biospec Products, Bartlesville, OK) were added to each tube. Worms were disrupted by
vortexing the tubes at maximum speed for one minute. The final suspension containing
MRSA was plated onto MSA plates to count the bacteria. The total CFU count in each well
was divided by the number of worms present in the respective well. The results shown are
the percent reduction in CFU per worm, compared with an untreated control.

Efficacy of celecoxib in MRSA-infected Mice
Eight-week-old female BALB/c mice (Harlan Laboratories, Indianapolis, IN) were
used in this study. All animal procedures were approved by the Purdue University Animal
Care and Use Committee (PACUC). The mouse model of MRSA skin infection was
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performed as described previously

334-336

. Briefly, mice were infected intradermally with

1.65×108 CFU MRSA300. After 48 h of infection, open wounds formed and the mice were
divided into five groups of 5 mice each. Two groups were treated topically with 20 mg of
either 1%, or 2% celecoxib in petroleum jelly. One group received the vehicles alone (20
mg petroleum jelly). Another group was treated topically with 20 mg of 2% fusidic acid in
petroleum jelly and the last group was treated orally with clindamycin (25 mg/kg). All
groups were treated twice a day for 5 days. 24 h after the last treatment, the skin area around
the wound was swabbed with 70% ethanol and the wound (around 1 cm2) was precisely
excised and homogenized. Bacteria in the homogenate were counted using MSA plates.

Determination of Cytokine levels
Skin homogenates obtained from infected mice were centrifuged at 4000 rpm for 10
min and the supernatants were used for the detection of cytokine levels. Tumor necrosis
factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and monocyte chemo
attractant protein-1 (MCP-1) ELISA kits (R&D Systems, Inc.) were used to determine the
levels of these cytokines according to the manufacture’s instruction 281.

Synergy assay
Synergy between celecoxib and conventional antimicrobials (gentamicin, clindamycin,
vancomycin, linezolid, daptomycin, retapamulin, fusidic acid and mupirocin) in the
treatment of four clinical isolates of S. aureus (MRSA300, NRS107, NRS119 and VRSA5)
was evaluated using the Bliss Independence Model, as described previously

282

. Synergy

(S) was calculated using the formula: S = (fA0/f00)(f0B/f00)-(fAB/f00). The parameter fAB refers
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to the optical density of the bacteria grown in the presence of celecoxib and antibiotics;
parameters fA0 and f0B refer to the bacterial growth rate in the presence of antibiotics alone
and celecoxib alone, respectively; the parameter f00 refers to the bacterial growth in the
absence of drugs. Degree of synergy (S) values corresponds to the following cut-offs.: Zero
indicates neutral, values above zero (positive value) represents synergism and values
below zero (negative values) correspond to antagonism. Drug combinations with higher
positive value represents high degree of synergism.

Statistical analyses
Statistical analyses were performed using Graph Pad Prism 6.0 software (Graph Pad
Software, La Jolla, CA). P values were calculated by using two-tailed unpaired Student t
tests. P values ˂ 0.05 were considered significant.

2.6.3

Results

Antibacterial activity
The antibacterial activity of celecoxib was tested using various important multidrugresistant strains of Gram-positive (Table 2.9) and Gram-negative (Table 7.2) pathogens.
Celecoxib showed activity against most of the Gram-positive bacteria tested, including
methicillin- and vancomycin-resistant S. aureus, Streptococcus pneumonia, Listeria
monocytogenes, Bacillus anthracis, Bacillus subtilis, and Mycobacterium smegmatis, with
MICs ranging from 16 to 64 µg/ml (Table 2.9).
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Table 2.9 MIC of celecoxib against Gram-positive bacteria
Bacteria

Description

Celecoxib
(µg/ml)

Methicillin-resistant S. aureus
ATCC 4330

Clinical isolate resistant to methicillin and
oxacillin

32

Vancomycin-resistant S.
aureus (VRSA10)
Streptococcus pneumoniae
ATCC 49619
Bacillus anthracis

Resistant to ciprofloxacin, clindamycin,
erythromycin and gentamicin
Isolated from sputum of 75-year-old male,
Phoenix, AZ, USA
Stern vaccine strain
Weybridge strain which contains the
toxigenic pXO1 plasmid and lacks the pXO2
capsule plasmid
Isolated from 14-month-old heifer that died in
Texas in 1981. It is a derivative of B.
anthracis, strain Ames that was treated with
novobiocin to cure it of the pXO2 plasmid.
F4244 CDC. Clinical isolate from patient
cerebrospinal fluid (CSF)
Reference strain

32

B. anthracis UM23

B. anthracis AMES35
Bacillus subtilis CU 1065
Listeria monocytogenes
Mycobacterium smegmatis
ATCC 14468

64
16
16

16

16
32
16

In contrast, celecoxib alone did not show antibacterial activity against Gram-negative
bacteria. However, when the outer membranes of Gram-negative bacteria were
compromised with a sub-inhibitory concentration of colistin, celecoxib showed
antimicrobial activity against all Gram-negative pathogens tested, including P. aeruginosa,
Escherichia coli, K. pneumonia, Salmonella Typhimurium, Acinetobacter baumannii, with
MICs ranging from 8 to 32 µg/ml (Table 2.10).
Next, the activity of celecoxib was investigated in the presence of sub-inhibitory
concentration of an efflux pump inhibitor reserpine. Celecoxib did not exhibited
antibacterial activity against all tested strains of Gram-negative bacteria in the presence of
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reserpine (Table 2.10). However, celecoxib showed activity against E. coli SM1411∆
acrAB which is deficient for acrAB efflux pump at a concentration of 64 µg/ml (Table
2.10).
Table 2.10 MIC of celecoxib against Gram-negative bacteria
MIC of celecoxib (µg/ml)
Bacteria
Pseudomonas aeruginosa
ATCC15442
Pseudomonas aeruginosa ATCC
BAA-1744
Escherichia coli O157:H7ATCC
700728
Acinetobacter baumannii ATCC
BAA1605
Acinetobacter baumannii ATCC
BAA747
Salmonella Typhimurium ATCC
700720
Klebsiella pneumoniae ATCC
BAA 2146
Klebsiella pneumoniae ATCC
BAA 1705
Escherichia coli 1411
Escherichia coli SM1411 ∆ acrAB

Description
(-)

(+)colistin

(+)reserpine

Isolated from animal room
water bottle
Clinical isolate and VITEK 2
GN identification card quality
control organism
Nontoxigenic and quality
control strain
MDR strain isolated from the
sputum of a Canadian soldier

>256

16

>256

>256

16

>256

>256

16

>256

>256

8

>256

Human clinical specimen - ear
pus
Wild type strain isolated from
a natural source
Clinical isolate New Delhi
Metallo-β-Lactamase (NDM1)
Clinical isolate with
Carbapenemase (KPC)
resistant to carbapenem
Wild type strain
Mutant for acrAB efflux
pump

>256

16

>256

>256

32

>256

>256

8

>256

>256

16

>256

>256
64

ND
ND

ND
ND

The antibacterial activity of celecoxib was also assessed using a series of multidrugresistant S. aureus clinical isolates (Table 2.11). The MIC of celecoxib required to inhibit
90% (MIC90) of the MRSA and vancomycin-intermediate S. aureus (VISA) clinical
isolates was found to be 32 µg/ml. However, the MIC90 of celecoxib against vancomycinresistant S. aureus (VRSA) clinical isolates tested was 128 µg/ml.
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Table 2.11 MIC of celecoxib against clinical isolates of Staphylococcus aureus strains

Strain type

Strain ID

Methicillin resistant
S.
USA100
aureus (MRSA)
USA200
USA300
USA400
USA500

USA700
USA800
USA1000
USA1100
NRS194
NRS108
NRS119 (Linr)
ATCC 43300
ATCC BAA-44
NRS70
NRS71
NRS100
NRS107
Vancomycinintermediate
NRS1
S. aureus (VISA)

Vancomycinresistant S.
aureus (VRSA)

Phenotypic properties
Resistant to ciprofloxacin, clindamycin,
erythromycin
Resistant to clindamycin, methicillin
erythromycin, gentamicin,
Resistant to erythromycin, methicillin, tetracycline
Resistant to methicillin, tetracycline
Resistant to ciprofloxacin, clindamycin,
erythromycin, gentamicin,
methicillin, tetracycline, trimethoprim
Resistant to erythromycin, methicillin
Resistant to methicillin
Resistant to erythromycin, methicillin
Resistant to methicillin
Resistant to methicillin
Resistant to gentamicin
Resistant to linezolid
Resistant to methicillin
Multidrug-resistant strain
Resistant to erythromycin, clindamycin, spectinomycin
Resistant to tetracycline, methicillin
Resistant to tetracycline, methicillin
Resistant to methicillin, mupirocin

Celecoxib
(µg/ml)
32
32
32
16
32

32
32
32
32
32
32
16
32
32
32
32
32
32
32

Resistant to aminoglycosides and
tetracycline; glycopeptide- intermediate S. aureus

NRS19
NRS37

Glycopeptide-intermediate S. aureus
Glycopeptide-intermediate S. aureus

VRS1
VRS2
VRS3a
VRS3b
VRS4
VRS5
VRS6
VRS7
VRS8
VRS9
VRS11a
VRS11b
VRS12
VRS13

Resistant to vancomycin
Resistant to vancomycin, erythromycin, spectinomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin, erythromycin, spectinomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin, β-lactams
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin
Resistant to vancomycin

32
32
128
128
32
32
128
16
16
128
32
64
32
32
32
32
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Killing kinetics of S. aureus by celecoxib
Celecoxib with broad-spectrum activity, we determined to investigate the rate of bacterial
killing. As seen in Figure 2.35, MRSA USA300 treated with 4X and 8X MIC of celecoxib
exhibits a typical biphasic killing pattern. Treatment with celecoxib consist of an initial
rapid bactericidal phase (2.49±0.23 log10 and 3.01±0.26 log10 CFU reduction at 4 h with
4X and 8X MIC) followed by a predominant regrowth. In comparison, vancomycin had a
bactericidal activity after 24 h, while linezolid treatment results in single log reduction after
24 h incubation exhibiting a bacteriostatic activity.

Figure 2.35 Time-kill assay for celecoxib tested against S. aureus. Killing kinetics of
celecoxib (4X and 8X MIC), vancomycin (4X MIC), and linezolid (4X MIC), against
MRSA USA300 in MHB are shown. The results are presented as means ± SD (n = 3). Data
without error bars indicate that the SD is too small to be seen.
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Mechanism of action
In view of the results demonstrating broad-spectrum antibacterial activity, we used
macromolecular synthesis assays in S. aureus ATCC 29213 to investigate the antibacterial
mode of action of celecoxib. As shown in Figure 2.36, RNA, DNA and protein synthesis
inhibition were detected at concentrations significantly below the MIC (0.25X).

Figure 2.36 Macromolecular synthesis assay in the presence of celecoxib and control
antibiotics. Incorporation of radiolabeled precursors such as [3H] thymidine, [3H] uridine,
[3H] leucine, [14C] N-acetylglucosamine and [3H] glycerol for DNA, RNA, protein, cell
wall and lipid synthesis respectively were quantified in S. aureus ATCC 29213. Based on
the incorporation of radiolabeled precursors, percent of inhibition by celecoxib at
concentration dependent manner was examined. Control antibiotics including
ciprofloxacin (DNA), rifampicin (RNA), linezolid (protein), cerulenin (lipid synthesis) and
vancomycin (cell wall synthesis) at 8X MIC were used. Triplicate samples were used for
each group and the statistical analysis was calculated by the two-tailed Student t test. All
treatment groups were compared to untreated control group. P value of (*P ≤ 0.05) is
considered as significant.
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However, a secondary effect was also observed at higher concentration, with a clear dosedependent disruption of [3H] glycerol incorporation indicating decreased lipid synthesis.
Cell wall synthesis inhibition was evident only at a concentration above the MIC (2X).

Toxicity in C. elegans
The safety of celecoxib was evaluated in a C. elegans whole-animal model. As shown
in Figure 2.37, C. elegans treated with 16 or 32 µg/ml of celecoxib for four days did not
show any significant toxicity. These results are similar to those seen in the linezolid
(16µg/ml) and untreated control groups

Figure 2.37 Evaluation of toxicity in C. elegans model. C. elegans strain glp-4; sek-1 (L4stage) were grown for four days in the presence of celecoxib (16 and 32 µg/ml) and
linezolid (16µg/ml). Worms were monitored daily and the live worms were counted.
Results were expressed as percent live worms in relative to the untreated control groups.
Triplicate wells were used for each group and the results were means ± SD (n = 3).
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Efficacy in animal models
Having demonstrated a comfortable safety profile, the antibacterial efficacy of
celecoxib was tested in a C. elegans, whole-animal MRSA infection model. As seen in
Figure 2.38A, celecoxib treatment significantly reduced the mean bacterial count,
compared with the untreated control. Treatment with celecoxib at 16 and 32 µg/ml
significantly decreased the bacterial CFU of

0.56±0.33 log10 and 0.94±0.43 log10

respectively. For comparison, linezolid at 16 µg/ml also had significant reduction in
bacterial CFU (0.99±0.17 log10 ), compared with the untreated control.

Figure 2.38 Efficacy of celecoxib in MRSA-infected animal models (a) L4-stage worms
infected with MRSA USA300 were treated with celecoxib (16 and 32 µg/ml) and linezolid
(16µg/ml) for 24 h. At this point, the worms were disrupted and the amount of MRSA in
the lysate (CFU) was determined. CFU per worm in treated groups relative to the untreated
control groups were shown. Triplicate wells were used for each group and the results were
means ± SD (n = 3). (b) Efficacy of treatment of MRSA-infected mouse skin lesions with
celecoxib 1 and 2%, clindamycin (25 mg/kg), fusidic acid 2% and petroleum jelly (negative
control) twice daily for five days were evaluated. Five mice per group was used and the
results were means ± SD of five mice. CFU per wound was calculated and presented. . *P
≤ 0.05 and *P ≤ 0.01 were considered as significant.
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Figure 2.39 Effect of celecoxib on IL-6, TNF-α, IL-1β and MCP-1 production in MRSA
infected skin lesions. Supernatants from skin homogenates were used for cytokine
detection by ELISA. Each point represents single mice and each group has five mice.
Statistical analysis was calculated by the two-tailed Student t test. P values of (*P ≤ 0.05)
(**P ≤ 0.01) are considered as significant.
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Next we tested the in vivo antibacterial efficacy of celecoxib in a mouse model of
MRSA skin infection. As shown in Figure 2.38B, all treatment groups (1 or 2% celecoxib,
2% fusidic acid, or clindamycin oral treatment) significantly reduced the mean bacterial
counts, compared with the control group (P ≤ 0.05). Groups treated topically with 1% and
2% celecoxib had a reduction in MRSA CFU of 0.66±0.19 log10and 1.02±0.27 log10
respectively. Topical treatment with 2% fusidic acid and oral clindamycin (25 mg/kg)
treatment reduced the bacterial load of 2.90±0.23 log10 and 2.40±0.32 log10 CFU
respectively.

Effect of celecoxib on inflammatory cytokine levels induced by MRSA skin infection
We investigated the immune-modulatory activity of celecoxib in MRSA skin infection
by measuring the levels of the inflammatory cytokines IL-6, TNF-α, IL-1β and MCP-1
using ELISA. As shown in Figure 2.39, treatment with 2% celecoxib significantly reduced
the levels of all tested inflammatory cytokines, compared with an untreated control.
Treatment with 1% celecoxib significantly reduced the levels of IL-6 and IL-1β.
Clindamycin treatment also reduced levels of TNF-α and IL-1β.

Synergism with topical and systemic antimicrobials
The antimicrobial activities of combinations of celecoxib with topical and systemic
antimicrobials were investigated in vitro, using the Bliss independence model, with clinical
isolates of multidrug-resistant S. aureus. Celecoxib acted synergistically with all tested
antimicrobials (with the exception of linezolid) against all strains of multi-drug resistant S.
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aureus tested, including MRSA300, VRSA5, linezolid-resistant S. aureus (NRS119) and
mupirocin-resistant S. aureus (NRS107). However, celecoxib showed slight antagonism
when combined with linezolid against VRSA5 (Figure 2.40).

2.6.4

Discussion

The emergence of bacterial resistance is not a new phenomenon. However, because
only a few antibiotics have been developed over the past few decades, the continuous
evolution and spread of multidrug-resistant bacterial strains is a serious threat to the public
health 1. The pharmaceutical companies’ lack of interest in antimicrobial research and
development has also become a major concern
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. The World Health Organization has

already warned that we are heading toward a “post-antibiotic era” and suggested that urgent
measures need to be taken 337. Therefore, recent research had been directed toward finding
new antimicrobials and novel strategies to combat multidrug-resistant bacterial pathogens.
One promising approach gaining increased attention is the repurposing of existing
approved drugs as antimicrobials.
In an attempt to repurpose approved drugs, we and others

80,330,331

have found that

celecoxib exhibits broad-spectrum antimicrobial activity against Gram-positive and Gramnegative bacterial pathogens. Celecoxib, a classical NSAID drug and inhibitor of the
enzyme cyclooxygenase-2 (COX2), has been widely used as an anti-inflammatory drug for
tularensis and S. aureus 80,331.
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Figure 2.40 Synergistic activity of celecoxib with topical and systemic antimicrobials.
The Bliss Independence Model confirms a synergistic effect between celecoxib and
conventional antimicrobials against various drug-resistant strains of S. aureus (MRSA300,
NRS119, NRS107 and VRSA5). The degree of synergy was quantified after 12 h of
treatment with celecoxib (8µg/ml) in combination with sub-inhibitory concentrations of
topical (mupirocin, fusidic acid, daptomycin and retapamulin) and systemic antimicrobials
(gentamicin, clindamycin, vancomycin and linezolid).
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Celecoxib also reduces H. capsulatum burden by enhancing phagocytosis of alveolar
macrophages and decreasing levels of inflammatory cells and cytokines, thereby exhibiting
a protective role in pathogenesis of H. capsulatum

330

. Our study demonstrated that

celecoxib possesses activity against various multidrug-resistant Gram-positive pathogens,
including S. aureus, S. pneumonia, L. monocytogenes, B. anthracis, B. subtilis, and M.
smegmatis. However, we noticed that Gram-negative pathogens are not susceptible to
celecoxib, and the lack of activity was found to be due to the permeability barrier conferred
by the outer membrane. This was further confirmed by the fact that the antimicrobial
activity of celecoxib against Gram-negative bacteria was restored when the integrity of the
outer membrane was compromised using a sub-inhibitory concentration of colistin 338-340.
In addition, celecoxib also showed activity when an efflux pump such as acrAB was deleted
in E. coli. AcrAB has been known to contribute for resistant phenotype for various
antibiotics including ampicillin, chloramphenicol and rifampicin 228.. However, celecoxib
did not restore its activity in the presence of efflux pump inhibitor reserpine in any of the
Gram-negative bacteria tested in this study. This might be due to the variation in the efflux
systems in different bacterial strains. Taken together, in addition to the intrinsic physical
barrier outer membrane, celecoxib entry into Gram-negative bacteria is also influenced by
efflux pumps such as AcrAB. Our results indicate that the target of celecoxib is present in
both Gram-positive and Gram-negative bacteria and that celecoxib can be combined with
other approved drugs that cause leakage in the outer membrane, such as colistin, to
sensitize Gram-negative pathogens. Next, we investigated the activity of celecoxib against
clinical isolates of multidrug-resistant S. aureus. Celecoxib inhibited the growth of all
tested clinical isolates of MRSA, VISA, VRSA, linezolid-resistant S. aureus (NRS119)
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and mupirocin-resistant S. aureus (NRS107). MIC values determined in our study for
celecoxib against MRSA correlates with MIC values reported for celecoxib against F.
tularensis and S. aureus in previous published studies

80,331

.

Time kill kinetics of celecoxib against S. aureus revealed a unique biphasic killing
pattern. The bactericidal effect of celecoxib lasted for only a short time, after which gradual
regrowth of bacteria was noticed. This pattern was reported for azlocillin and tobramycin
against Pseudomonas aeruginosa

341,342

. The bactericidal activity and the extent of

regrowth in P. aeruginosa after incubation with azlocillin and tobramycin
concentration dependent manner

341,342

was

. However, the bactericidal activity (at 4 h) of

celecoxib at 8X MIC was found to be slightly higher than 4X MIC but the regrowth was
found to be similar at both the concentration after 24 h of incubation.

The mechanism of celecoxib’s broad-spectrum antibacterial activity remains
unidentified. In our study, we found that celecoxib inhibited the synthesis of DNA, RNA,
and protein at concentrations significantly below the MIC . Additionally, the disruption of
lipid synthesis was evident at higher MIC concentration, whereas no significant effect was
observed on the cell wall synthesis. These results indicate that perturbation of the lipid
synthesis by celecoxib might be a secondary effect due to RNA and protein synthesis
inhibition. The effect of celecoxib on multiple macromolecular synthesis pathways might
likely due to the disruption in general cellular energy metabolism or membrane
perturbation. Antimicrobial peptides such as pleurocidin-derived peptides at sub-lethal
concentration cause cell membrane damage leading to the inhibition of multiple
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macromolecular synthesis pathways

343

. Lactoferricin B, a cationic peptide which also

cause membrane permeabilization is believed to have effect on general energy metabolism
which results in inhibition of multiple pathways

344,345

. Celecoxib with initial rapid

bactericidal property (biphasic killing pattern) might possibly also lead to the disruption of
various macromolecular pathways. However, the cause for inhibition on multiple pathways
is not yet clear. Further, we also attempted to generate a S. aureus that is resistant to
celecoxib. No colonies resistant to celecoxib at three-, five-, or tenfold the MIC were
detected. In addition, serial passage of S. aureus with sub-inhibitory concentration of
celecoxib for twelve days did not resulted in colonies that were resistant to celecoxib.
Therefore, future studies are warranted to identify the precise molecular target of celecoxib.

In view of the broad spectrum antibacterial activity exhibited by celecoxib in vitro,
we decided to investigate the in vivo antibacterial activity of celecoxib in animal models of
MRSA infection. First we tested the efficacy in MRSA infected C. elegans. Whole animal
model including C. elegans, provides a great platform for validating the in vivo efficacy of
novel compounds 301,320. Our results indicates that celecoxib at 16 and 32 µg/ml, which are
concentrations without considerable toxicity to the host, significantly reduced the mean
bacterial load (by 71% and 85% respectively) when compared with a control group (P ≤
0.05). Celecoxib at 32 µg/ml had an effect on the mean bacterial count that was comparable
to that of linezolid (16 µg/ml). Next, we moved forward to validate celecoxib’s efficacy in
a mouse model of MRSA infection. However, a high MIC that cannot be achieved
systemically is a major impediment to the potential use of celecoxib as an antimicrobial
agent. While the use of celecoxib to treat systemic bacterial infections is not currently
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possible, local application of celecoxib for treating/preventing bacterial infections in
wounds is a novel application for this drug that holds considerable promise. Therefore we
decided to test the activity of celecoxib in a topical MRSA skin infection model. Celecoxib
1% and 2% significantly reduced the bacterial load in the wounds (by 72% and 87%,
respectively) when compared with a control group (P ≤ 0.05).

However, staphylococcal skin infections often induce excess host inflammatory
cytokines, which in turn aggravate the pathogenesis

256,293

Drugs with anti-inflammatory

properties, especially those that inhibit pro-inflammatory cytokines such as IL-6 and TNFα, would accelerate the healing of chronic wounds.

107,293,328,346,347

. Celecoxib, which is

known to have anti-inflammatory activity, would potentially be able to limit the
inflammatory process induced by MRSA infection. Therefore, we measured the
inflammatory cytokines in MRSA lesions treated with celecoxib. Topical treatment with
celecoxib 1% significantly (P ≤ 0.05) reduced levels of TNF-α and IL-1β, while celecoxib
2% significantly (P ≤ 0.05) reduced the levels of all the inflammatory cytokines measured
(IL-6, TNF-α, IL-1β and MCP-1). This ability of celecoxib to dampen the inflammatory
response might aid the healing of chronic wounds 102-107. Celecoxib’s recognized beneficial
role in the wound healing process, reducing scar formation without disrupting
reepithelization, is an added advantage for the treatment of bacterial skin infections 348.

With increased emergence of resistant strains of S. aureus to topical drugs of choice,
such as mupirocin and fusidic acid, combination therapies have recently been gaining
attention 204,259,260,268,269,349. We, therefore, investigated whether celecoxib has potential to
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be combined with antibiotics against multidrug-resistant S. aureus strains by using the Bliss
independence model

282

. Celecoxib was found to exhibit a synergistic relationship with

topical (mupirocin, fusidic acid, daptomycin and retapamulin) and systemic antimicrobials
(gentamicin, clindamycin, vancomycin and linezolid), against most of the tested multidrugresistant staphylococcal strains, including MRSA300, NRS119, NRS107 and VRSA5. This
finding provides a potential basis for the combination of celecoxib with conventional
antimicrobial drugs for the treatment staphylococcal skin infections and reducing the
likelihood of strains developing resistance to monotherapy.

Taken together, our results show that celecoxib exhibits several beneficial properties,
including broad spectrum antimicrobial activity against various multidrug resistant Grampositive

and

Gram-negative

pathogens,

synergistic

action

with

conventional

antimicrobials, and anti-inflammatory activity that reduces excess host inflammation
during infection. Celecoxib may, therefore, be a good candidate for repurposing for the
treatment of topical bacterial infections. This emerging approach might form a novel
alternative strategy in search of new antimicrobials.
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CHAPTER 3. DRUG REPURPOSING FOR FUNGAL INFECTIONS

3.1

Repurposing approach identifies auranofin with broad spectrum antifungal
activity that targets Mia40-Erv1 pathway

(S. Thangamani, M. Maland, H. Mohammad, P. Pascuzzi, L. Avramova, C. Koehler, T. R.
Hazbun and M. N. Seleem. Repurposing approach identifies auranofin with broad spectrum
antifungal activity that targets Mia40-Erv1 pathway, “Frontiers in Cellular and Infection
Microbiology”-Under Review.)

3.1.1

Introduction

Invasive fungal infections, particularly those caused by Candida and Cryptococcus, afflict
millions of patients annually resulting in more than 1,350,000 deaths despite the
introduction of new antifungal agent

350-354

. Unfortunately, current antifungal therapies

have limited effectiveness in treating invasive fungal infections and suffer from restrictions
in route of administration, spectrum of activity, and bioavailability in target tissues such as
the brain 354,355. Further compounding this problem, the development of new antifungal is
currently unable to keep pace with the urgent demand for safe and effective new drugs.
Hence, there is a pressing and urgent need for novel, inexpensive, and safe antifungal drugs
to combat these dangerous pathogens.
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The concept of drug repositioning has recently gained momentum and emerged as a viable
approach to expedite anti-infective drug development 210,356. For example, several reports
have demonstrated that auranofin, an orally bioavailable FDA-approved drug for treatment
of rheumatoid arthritis, exhibits potent antibacterial and antiparasitic activities
58,212,215,249,263,357,358

. This discovery led to the FDA granting auranofin Orphan Drug status

for treatment of amebiasis. Recent studies by Fuchs et al.359 and Stylianou et al.360 reported
that auranofin also possesses antifungal activity. However, the antifungal mechanism of
action and in vivo antifungal efficacy of auranofin remain unclear with several possible
targets reported. Thus, the objectives of our study were to determine the antifungal activity
of auranofin against clinical isolates of different fungal pathogens, to investigate the drug’s
antibiofilm activity, to deduce auranofin’s antifungal mechanism of action using an
unbiased chemogenomic approach, and to validate the drug’s in vivo antifungal efficacy in
a C. neoformans-infected Caenorhabditis elegans whole animal model.

3.1.2 Materials and Methods
Fungal strains and reagents
Fungal strains used in this study are presented in Table 1. Yeast peptone dextrose agar
(YPD) was purchased from BD Biosciences (San Jose, CA). Auranofin (Enzo Life
Sciences, Farmingdale, NY), fluconazole (Acros Organics, New Jersey), and flucytosine
(TCI chemicals, Tokyo, Japan) were purchased from commercial vendors. XTT-sodium
salt, menadione, RPMI powder, and MOPS were purchased from Sigma-Aldrich (St. Louis,
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MO). Concanavalin A–conjugated with FITC 488 dye was acquired from Thermo Fisher
Scientific Inc. (Waltham, MA).

Antifungal susceptibility testing
Antifungal susceptibility testing was carried out as per the National Committee for Clinical
Laboratory Standards M-27A3 (NCCLS) guidelines 361. Briefly, the inocula were prepared
from 24 h old cultures of Candida spp. or 48 h old cultures of Cryptococcus spp. in YPD
plates. Five colonies were then transferred to 5 mL of sterile 0.9% saline (PBS). The
suspensions were adjusted to McFarland standard 0.5 and then diluted 1:2000 in RPMI
1640 buffered to pH 7.0 with 0.165 M MOPS (RPMI-MOPS) to yield an inoculum of 5.0
× 102 to 2.5 × 103 CFU/mL. An aliquot (100 µL) of the resulting suspension was incubated
with serially diluted fluconazole, flucytosine, and auranofin for 24 h for Candida spp and
72 h for Cryptococcus spp. The minimum inhibitory concentration (MIC) of fluconazole
and flucytosine were determined as the prominent decrease (approximately 50%) in visible
growth compared to untreated controls, as per NCCLS guidelines. Similarly the MIC of
auranofin was determined as the lowest concentration resulting in 50% reduction in visible
growth. All experiments were carried out in triplicate wells.

Time kill assay
Fungal cultures of Candida albicans and Cryptococcus neoformans were diluted
approximately to 5 × 105 CFU/mL and treated with 5 × and 10 × MICs of auranofin and
fluconazole (in triplicate) in RPMI-MOPS, at 35°C. Samples were collected at indicated
time points and serially diluted in PBS and plated onto YPD plates. Plates were incubated
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at 35°C for 24-48 h prior to counting fungal colony forming units (CFU), as described
elsewhere 362.

XTT-reduction assay
C. albicans ATCC 10231 was grown in YPD broth at 35°C for 24 h. Cells were washed
with PBS and resuspended in RPMI-MOPS at 106 cells/mL 363,364. An aliquot (100 µL) of
cell suspension was transferred to wells in a 96-well tissue culture plate. After 48 h
incubation (at 37C), wells were washed with PBS and drugs (auranofin, fluconazole, and
flucytosine) were added at indicated concentrations. After 24 h of incubation, the
supernatant was removed and 100 µL of XTT/menadione solution was added to each well.
The plates were covered with aluminum foil and incubated at 37°C for 1 hour. Aliquots
(75 µL) were taken from each well and the absorbance (OD495) was measured using a
spectrophotometer. The antifungal activity of each drug was expressed as a percentage of
metabolic activity of treatment groups relative to the DMSO-treated control groups. The
experiment was performed using triplicate samples for each treatment regimen.

Confocal imaging of fungal biofilms
C. albicans ATCC 10231 was seeded on FBS-coated glass cover slips in 6-well tissueculture plates and grown in RPMI-MOPS medium with 0.2% glucose at 37°C 365. After 48
h, wells were washed with PBS and drugs (auranofin, fluconazole, and flucytosine) were
added at indicated concentrations. After 24 h of treatment, wells were washed with PBS
and stained with concanavalin A– conjugated with FITC 488 dye (25 µg/mL in PBS) for
45 minutes at 37°C. After incubation, the coverslips were washed three times with PBS
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and mounted on glass slides. Stained biofilms were observed using Leica confocal laser
scanning microscopy. Images were reconstructed using IMARIS software.

Chemogenomics profiling of Saccharomyces cerevisiae
Initial testing of Saccharomyces cerevisiae sensitivity to auranofin was performed with
the wild-type BY4743 diploid strain, the isogenic parent to the heterozygous diploid
deletion collection. BY4743 was grown in YPD in 96-well plates with 1% DMSO or
auranofin in concentrations ranging from 10 to 200 M to determine a suitable level of
growth inhibition. Auranofin (75 µM) was used for haploinsufficiency profiling because
it delayed growth by 30% compared to the no drug control half-maximal optical density
(OD). All experiments were performed at 30°C and cultures were shaken at 300 rpm. The
heterozygous deletion set was purchased in a pooled format (Thermo Fisher Scientific,
Waltham, MA). A frozen aliquot (200 µL) was thawed and used to inoculate 2 mL of YPD
and grown for 9 h to reach an OD600 of 4.0. The culture was diluted to an OD600 of 0.13
and either 1% DMSO or 75 µM auranofin was added (three replicates each, 1 mL) and
grown for 7 h. The cultures were grown again by diluting to an OD of 0.13 in 1 mL YPD
with DMSO or 60 µM auranofin and grown for 8 h. Cultures were harvested and genomic
DNA extracted using the YeaStar Genomic DNA kit (Zymo Research, Irvine, CA). The
UPTAGs were amplified by PCR with Phusion Hot Start II High-Fidelity DNA polymerase
at 0.02 U/µL (Thermo Fisher Scientific, Waltham, MA) using 0.5 ng/µL genomic DNA.
Primers are listed (Table S1). The PCR reactions were electrophoresed on an agarose gel
and the 267 bp product extracted using a QIAquick Gel Extraction Kit (Qiagen, Valencia,
CA). Purified DNA was measured using a Qubit instrument and samples were normalized
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and mixed together to a final concentration of 10 nM. Strains were grown and maintained
on media according to standard practices 366.

The pooled PCR products were sequenced using standard Illumina sequencing in a HiSeq
2500 instrument. The reads were separated based on a 5 base multiplex tag unique for each
experiment and an average of 5 million reads per replicate was obtained. The UPTAG
barcodes in each experimental sample were separated based on a reference database of
recharacterized barcode sequences 367.
The resulting strain counts were imported into R and analyzed with edgeR 368. Sequencing
library sizes were normalized using the default parameters. Only strains with one or more
counts in three or more samples were analyzed further. Differential representation of strains
was determined using the quantile-adjusted conditional maximum likelihood (qCML)
method. False discovery rates were determined to control for multiple testing.

Saccharomyces deletion strain haploinsufficiency validation
Overnight grown yeast cells were diluted (O.D600 ~ 0.03) and grown in the presence and
absence of auranofin, at indicated concentrations. Growth was monitored using a
spectrophotometer (OD600) at indicated time points and the results were expressed as
percent growth rate for each strain compared to the untreated control group. To assess
growth on solid medium, 5 µL of ten-fold diluted yeast cells were spotted onto YPD agar
containing DMSO or auranofin (6.25 µg/mL). Growth of yeast strains was monitored after
incubating the plates for 48 h, as described elsewhere 369.
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Oxygen consumption and membrane potential measurements
Mitochondria were purified from yeast cells grown on YPEG as described previously 370.
Oxygen consumption measurements with isolated mitochondria were performed using an
oxygen electrode (Hansatec) as described previously

371

. Membrane potential

measurements of purified mitochondria were performed with fluorescent 3, 3’dipropylthiadicarbocyanine iodide dye [DiSC3(5)]. 1% DMSO, carbonyl cyanide mchlorophenyl hydrazone (CCCP), MB-6, or MB-7 was added to mitochondria in import
buffer (0.6 M sorbitol, 2 mM KH2PO4, 60 mM KCl, 50 mM HEPES-KOH, 5 mM MgCl2,
2.5 mM EDTA,5 mM L-methionine, pH 7.1) for 10 min. Subsequently 0.2 μM DiSC3(5)
in import buffer was added, incubated for 5 min, and fluorescence was measured at
excitation and emission length of 620 nm and 670 nm, respectively.

Purification of mitochondria
Mitochondria were purified from wild-type yeast or yeast overexpressing Erv1 with a
hexahistidine tag ([a2up] Erv1) grown in YPEG as described previously

372,373

. Yeast

cultures were kept at 25°C with vigorous shaking during growth. Mitochondria
concentration was measured by BCA assay and stored at 25 mg/mL at -80°C. Mitochondria
with increased levels of Erv1 were purified from a strain in which Erv1 was overexpressed
from a 2-micron plasmid (Dabir et al., 2007).

Import of radiolabeled proteins into yeast mitochondria
Prior to import into purified mitochondria, [35S]-methionine and cysteine labeled proteins
were generated with TNT Quick Coupled Transcription/Translation kits (Promega) and
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plasmids carrying the genes of interest. Transcription of genes was driven by either a T7
or SP6 promoter. Import reactions were conducted as previously described

370,371

. After

frozen mitochondria aliquots were thawed and added to the import buffer at a final
concentration of 100 µg/mL, 1% DMSO or the small molecule was added as indicated. A
final concentration of 1% DMSO was used in all experiments. Following incubation at
25°C for 15 min, import reactions were initiated by the addition of 5-10 µl of translation
mix. Aliquots were removed at intervals during the reaction time course and import was
terminated with addition either of cold buffer or 25 µg/mL trypsin, or the combination. If
trypsin was added to digest non-imported precursor protein, soybean trypsin inhibitor was
subsequently added in excess after 15 min incubation on ice. After a final recovery of by
centrifugation (12,000 x g, 6 min), mitochondria were disrupted in Laemmli sample buffer.
Samples from import reaction time points were resolved by SDS-PAGE and visualized by
autoradiography. For experiments to investigate the Cmc1-Mia40 intermediate,
nonreducing conditions were used. The import reactions were stopped in the presence of
20 mM iodoacetamide and mitochondria disrupted in Laemmli sample buffer lacking βmercaptoethanol. The imported products were separated by nonreducing SDS-PAGE.

Caenorhabditis elegans (C. elegans) infection study
L4-stage worms of C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) were used to examine
the antifungal efficacy of auranofin as described elsewhere 226,374. Briefly, L4-stage worms
were infected with Cryptococcus neoformans NR-41292 for two hours at room temperature.
After infection, worms were washed with M9 buffer and treated either with DMSO or drugs
(auranofin, fluconazole, and flucytosine), at a concentration of 8 μg/mL. After 24 h, worms
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were washed with PBS and disrupted using silicon carbide particles

226

. The final

suspensions were plated onto YPD agar plates containing ampicillin (100 μg/mL),
streptomycin (100 μg/mL) and kanamycin (45 μg/mL) to determine the colony forming
unit (CFU) per worm 66.

Statistical analyses
Statistical analyses were done using GraphPad Prism 6.0 (GraphPad Software, La Jolla,
CA). P values were calculated via the Student t test and P values of ≤ 0.05 were deemed
significant.

3.1.3

Results and Discussion

Antifungal activity and killing kinetics of auranofin
Auranofin has a well-established pharmacological and toxicological profile that has
permitted it to be used for the treatment of rheumatoid arthritis for more than 30 years 47,48.
Independent of its antirheumatic effect, several studies have reported the anti-infective
properties of this drug against important parasitic and bacterial pathogens including
Schistosoma mansoni, Trypanosoma brucei, Plasmodium falciparum, Entamoeba
histolytica, Staphylococcus aureus and Streptococcus pneumoniae 58,212,215,249,263,357,358. In
this study, the antifungal activity of auranofin was tested against various clinical isolates
of Candida and Cryptococcus. Auranofin retains efficacy against clinically relevant drugresistant fungal strains including fluconazole-resistant C. albicans, C. glabrata, C.
tropicalis and C. parapsilosis with the minimum inhibitory concentration (MIC) ranging
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Table 3.1 MIC of auranofin and control antifungal drugs against Candida and Cryptococcus
strains
Strains

Description

C. albicans NR
29434

Bloodstream isolate from a person with a bloodstream
infection collected in Winnipeg, Manitoba, Canada, in
2000
Isolated from a man with bronchomycosis

C. albicans
ATCC 10231
C. albicans NR
29449
C. albicans NR
29435
C. albicans NR
29448
C. albicans NR
29437
C. albicans NR
29446
C. albicans NR
29453
C. albicans NR
29438
C. albicans
ATCC 26790
C. albicans
ATCC 24433
C. albicans
ATCC 14053
C. albicans
ATCC 90028
C. albicans NR
29366
C. albicans NR
29367
C. glabrata
ATCC MYA2950
C. glabrata
ATCC 66032
C. tropicalis
ATCC 13803
C. tropicalis
ATCC 1369
C. parapsilosis
ATCC 22019

Auranofin
(µg/ml)
8

Fluconazole
(µg/ml)
4

Flucytosine
(µg/ml)
0.125

2

2

0.25

Is a vaginal isolate from a person with vaginitis
collected in Ann Arbor, Michigan, USA, between
1990 and 1992
Is a bloodstream isolate from a person with a
bloodstream infection collected in Iowa City, Iowa,
USA, in 2000.
Is an isolate from a person with a bloodstream
infection, collected in Arizona, USA.
Is a bloodstream isolate from a person with a
bloodstream infection collected in Brussels, Belgium
in 2000
Is a bloodstream isolate from a person with a
bloodstream infection collected in Utah, USA.
Is an oral isolate from an HIV+ person collected in
Pretoria, South Africa
Is a bloodstream isolate from a person with a
bloodstream infection, collected in Tel-Hashomer,
Israel, in 2000.
Pulmonary candidiasis

8

2

4

1

4

0.0625

4

>64

0.0625

4

2

0.0625

16

>64

0.25

8

2

0.0625

16

2

0.0625

8

2

0.0625

Nail infection

8

4

1

Human blood, Bethesda, MD

8

4

0.125

Blood, Iowa

16

4

1

Human isolate collected in China

16

>64

0.0625

Human isolate collected in China.

16

>64

0.0625

-

8

4

0.0625

-

8

2

0.0625

-

16

2

0.125

-

4

1

0.25

4

1

0.25

Case of sprue, Puerto Rico
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Table 3.1 continued
C. neoformans
NR-41291
C. neoformans
NR-41292
C. neoformans
NR-41296
C. neoformans
NR-41295
C. neoformans
NR-41294
C. neoformans
NR-41297
C. neoformans
NR-41298
C. neoformans
NR-41299
C. neoformans
NR-41291
Cryptococcus
gattii CBS1930
Cryptococcus
gattii - R265
Cryptococcus
gattii - Alg40
Cryptococcus
gattii - Alg75
Cryptococcus
gattii - Alg81
Cryptococcus
gattii - Alg99
Cryptococcus
gattii - Alg114
Cryptococcus
gattii - Alg115
Cryptococcus
gattii - Alg127

Obtained from human cerebrospinal fluid in China in
July 2011.
Obtained from human cerebrospinal fluid in China in
February 2012.
Obtained from human cerebrospinal fluid in China in
February 2012.
Obtained from human cerebrospinal fluid in China in
February 2012.
Obtained from human cerebrospinal fluid in China in
June 2011.
Obtained from human cerebrospinal fluid in China in
February 2012.
Obtained from human cerebrospinal fluid in China in
February 2012.
Obtained from human cerebrospinal fluid in China in
August 2009.
Obtained from human cerebrospinal fluid in China in
July 2011.
Isolated from a goat in Aruba prior to the outbreak in
Vancouver, British Columbia, Canada.

4

1

0.5

0.5

1

0.5

1

2

0.5

4

2

0.5

0.5

4

2

1

8

4

1

4

2

4

4

2

1

4

1

0.5

2

2

Isolated from a human on Vancouver Island, Canada
during the outbreak that began in the late 1990's
Progeny of a genotypic cross between C. gattii strains
R265 and CBS1930.
Progeny of a genotypic cross between C. gattii strains
R265 and Alg40.
Progeny of a genotypic cross between C. gattii strains
R265 and Alg75.
Progeny of a genotypic cross between C. gattii strains
R265 and Alg81.
Progeny of a genotypic cross between C. gattii strains
R265 and Alg99.
Progeny of a genotypic cross between C. gattii strains
R265 and Alg114.
Progeny of a genotypic cross between C. gattii strains
R265 and Alg115.

1

1

1

0.5

2

0.5

8

8

8

4

8

4

4

8

4

8

8

4

8

8

4

4

4

4

from 1 to 16 µg/mL (Table 3.1). Auranofin also displayed potent activity against both C.
neoformans and Cryptococcus gattii inhibiting growth of these fungal species at
concentrations ranging from 0.5 to 8 µg/mL (Table 3.1).

A time-kill assay was employed to investigate the killing kinetics of auranofin against both
C. albicans and C. neoformans. Similar to fluconazole, auranofin (at 5 × MIC) exhibited
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fungistatic activity against C. albicans and C. neoformans (Figure 3.1). However, at 10 ×
MIC, auranofin (unlike fluconazole) completely kills C. neoformans after 48 h of
incubation (Figure 3.1).

Figure 3.1Killing kinetics of auranofin. An overnight culture of C. albicans ATCC 10231
and C. neoformans NR-41291 were treated with 5 × and 10 × MIC of auranofin and
fluconazole (in triplicate) in RPMI-MOPS and incubated at 35°C. Samples were collected
at indicated time points and plated onto YPD plates. Plates were incubated for 24-48 h
prior to counting the colony forming units (CFU).

Antibiofilm activity of auranofin
In addition to planktonic growth, fungi especially, Candida spp., are known to form
biofilms that are recalcitrant to treatment with antifungal agents. Fungal cells encased
within the biofilm are resistant to most clinically used antifungals, including azole drugs,
ultimately resulting in treatment failure 375-377.
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Figure 3.2 Effect of auranofin on Candida biofilms. (A) C. albicans ATCC 10231 biofilm
was treated with indicated concentrations of auranofin, fluconazole, and flucytosine for 24
h. The percent metabolic activity of fungal cells in biofilms, after treatment, was
determined using the XTT reduction assay. Results are presented as means ± SD (n = 3).
Statistical analysis was calculated using the two-tailed Student’s t test. P values of (** P
≤ 0.01) are considered as significant. Auranofin was compared both to controls and
antifungal drugs (**). (B) C. albicans ATCC 10231 biofilm was formed on FBS-coated
glass cover slips and treated with indicated drugs for 24 h and stained with concanavalin
A– conjugated with FITC dye and imaged by Leica confocal laser scanning microscopy.

Therefore, the antibiofilm activity of auranofin, against C. albicans, was evaluated using
the XTT reduction assay in order to measure the metabolic activity of fungal cells posttreatment. The metabolic activity of C. albicans was reduced by more than 70% with the
treatment of auranofin (Figure 3.2A). Fluconazole and flucytosine, were ineffective (less
than 10% reduction observed) at reducing the metabolic activity of C. albicans biofilm,
even at a concertation equivalent to 32 × MIC (Figure 3.2A).
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The effect of auranofin on reducing fungal biofilm density was further evaluated using
confocal microscopy. Fungal cells stained with ConA-conjugated with FITC revealed that
auranofin (8 × MIC) eradicates a considerable portion of Candida cells in comparison to
the control group (Figure 3.2B). However, treatment with fluconazole and flucytosine,
even at 32 × MIC, appear similar to control group (Figure 2B). These findings illustrate
that auranofin is a potential candidate for use in treatment of biofilm-related fungal
infections.

Chemogenomic profiling identifies Mia40 as a potential target of auranofin
After verifying auranofin’s antifungal activity, we proceeded to investigate the antifungal
mechanism of auranofin. Chemogenomic profiling was employed given it is a highlyspecific technique to investigate the target of unknown compounds

378-380

. This technique

uses drug-induced haploinsufficiency, where it causes a strain-specific fitness defect after
treatment with compounds, and thereby aids in identifying the drug target

378-383

.

Haploinsufficiency profiling (HIP) allows for the simultaneous assessment of the
sensitivity of the pooled genome-wide set of heterozygous deletion strains because each
strain is uniquely identified with a synthetic DNA barcode. The method is an unbiased
approach to survey the genome-wide strain set in order to identify the strains with the most
sensitivity to auranofin. We first identified the concentration that reduced wild-type growth
by 30% and used 75 M to profile the pooled heterozygous strains in biological samples.
PCR was used to amplify the unique UPTAG DNA barcodes located at the gene deletion
site and we tracked the barcode abundance with Illumina sequencing. The resulting counts
were normalized and visualized using EdgeR (Figure 3.3A).

We identified 85
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heterozygous deletion strains that were under-represented based on an FDR less than 0.1
when comparing auranofin treatment to DMSO. These 85 strains were analyzed to identify
associated gene ontology cellular component annotations and found to be enriched in
several categories including the mitochondrial intermembrane space and chromatin
components. Five heterozygous deletion strains within these categories (mia40, acn9,
coa4, rad18 and nsi1) were selected to validate sensitivity to auranofin using a variety
of growth assays (Figure 3.3A).

Growth of these five heterozygous deletion strains and the wild-type (BY4743) strain were
monitored in the presence of different concentrations of auranofin (6.25, 12.5 and 25
µg/mL) in a liquid growth assay. The result indicated that only three heterozygous deletion
strains (mia40, acn9, and coa4) exhibited drug-induced haploinsufficiency under these
conditions. The growth of these deletion strains was suppressed, even in the presence of
low concentrations of auranofin (6.25 µg/mL) (Figure 3B). However, auranofin does not
induce haploinsufficiency in the other two deletion strains (rad18 and nsi1) as growth
of these strains, in the presence of auranofin, mimics the pattern observed with the wildtype strain (Figure 3.3B). These two deletion strains were not affected possibly because of
the concentration used in our validation studies or because they may be false positives.
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Figure 3.3 Auranofin targets mitochondrial protein(s). (A) Chemogenomic profiling of S.
cerevisiae with treatment of auranofin. The strain abundance were normalized using EdgeR
and shown. (B) Growth curve of wild type (BY4743) and heterozygous deletion strains
(mia40, acn9, coa4, rad18 and nsi1) in the presence of indicated concentration of
auranofin in YPD broth were determined. (C) The percent growth of yeast cells (OD600
after 24 h) incubated with auranofin (6.25 µg/mL) in YPD broth was determined in relation
to the DMSO treatment. The results are presented as means ± SD (n = 3). Statistical
analysis was calculated using the two-tailed Student’s t test. P values of (* P ≤ 0.05) (** P
≤ 0.01) are considered as significant. (D) Yeast cells grown in YPD broth overnight were
serially diluted and spotted on solid YPD agar containing auranofin (6.25 µg/mL) or
DMSO and the CFU were shown. (E) Comparison of Lee et al.’s HIP results with our 85
strains are shown as a Venn diagram.
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For each strain, the growth of cells (OD600 after 24 h) incubated with auranofin (6.25 µg/mL)
was determined in relation to DMSO treatment. The growth of three heterozygous deletion
strains (mia40, acn9 and coa4) was drastically suppressed by more than 50% in the
presence of auranofin (6.25 µg/mL). However, the remaining two deletion strains (rad18
and nsi1) had a modest reduction in growth of approximately 10% compared to the wildtype strain (Figure 3.3C).

The growth of these five deletion strains was further confirmed by spotting serial dilutions
of cultures on solid agar. As shown in Figure 3.3D, growth of the wild-type and five
heterozygous deletion strains was normal in agar containing DMSO. However, the
heterozygous deletion strain, mia40 exhibited a nearly two-fold reduction in colony
forming units when spotted onto YPD agar containing auranofin (6.25 µg/mL).

A study conducted by Lee et al.

384

previously analyzed a heterozygous deletion pool

representing essential genes using haploinsufficiency profiling and identified 17 strains as
possibly sensitive to auranofin. Comparison of Lee et al.’s results with our 85 strains
showed that two strains, rho1 and mia40, overlapped in the data sets (Figure 3E). An
additional study by Gamberi et al. 369 specifically assessed sensitivity of haploid deletion
strains involved in mitochondrial function and found them to be differentially sensitive to
auranofin. Based on studies by Gamberi et al.

369

and Lee et al.

384

, we next moved to

examine sensitivity of the corresponding heterozygous deletion strains involved in
mitochondrial function and redox homeostasis that are possibly sensitive to auranofin.
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Figure 3.4 Effect of auranofin on deletion strains related to ROS production and
mitochondrial function. (A) The percent growth of wild type and heterozygous deletion
strains incubated with auranofin (6.25 µg/mL) in YPD broth (OD600 after 24 h) was
determined in relation to the DMSO treatment. The results are presented as means ± SD (n
= 3). Statistical analysis was calculated using the two-tailed Student’s t test. P values of
(* P ≤ 0.05) (** P ≤ 0.01) are considered as significant. (B) Yeast cells grown in YPD
broth overnight were spotted on solid YPD agar containing auranofin (6.25 µg/mL) or
DMSO. The colony forming units are shown.
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Heterozygous deletion strains including ndil, atp2, citl, sdh4, gsh1, gsh2, prx1,
trr1 erv1, toa2, arp7, ydl63w and yjl086cexperienced a significant growth
reduction when treated with auranofin (6.25µg/mL) relative to DMSO-treated cells (Figure
3.4A). These results are in agreement with Gamberi et al.’s 369 and Lee et al.’s 384 reports.
It should be noted that Gamberi et al. used haploid deletion strains which generally do not
inform on direct targets of a compound as opposed to the heterozygous deletion strains
used in our study. These results were confirmed using the YPD agar spotting assay.
Interestingly, heterozygous deletion strains involved in ROS response and redox
homeostasis (sdh4, gsh1, gsh2and prx1which had significant growth reduction in
liquid medium did not demonstrate considerable reduction in growth when spotted onto
YPD agar containing auranofin (6.25 µg/mL) (Figure 3.4B). Gamberi et.al. through various
experiments also demonstrated that auranofin does not elicit the production of ROS 369 but
some haploid deletion strains associated with ROS were sensitive suggesting they are
selectively important for resistance to auranofin. Taken together it appears that the ROS
response enzymes are not direct targets of auranofin but several of these enzymes do
mediate resistance to the inhibitory activity of auranofin.

As noted earlier, heterozygous deletion strains that encode genes required for
mitochondrial function (including ndil, atp2, citl and erv1), showed a considerable
decrease in colony count (almost one-fold log reduction) when spotted onto YPD agar
containing auranofin (6.25µg/mL) (Figure 3.4B). More notably, the pos5 strain does not
demonstrate any sensitivity to auranofin (Figure 4B). POS5 encodes a mitochondrial
NADH kinase required to respond to oxidative stress. This is in contrast to the haploid
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deletion version, which was demonstrated to have slight resistance to auranofin
Chemogenomic profiling by Lee et al.

369

369

.

also did not identify the pos5heterozygous

deletion strain as sensitive to auranofin. Interestingly, a deletion strain (erv1), which
forms a complex with Mia40, also showed considerable sensitivity to auranofin, which
coincides with Lee et al.’s findings

385

(Figure 3.4B). Taken altogether, our findings

support the notion that Mia40 is the probable antifungal target of auranofin.

The Mia40 (mitochondrial intermembrane space import and assembly protein 40) –Erv1
pathway is mainly involved in oxidation of several cysteine rich proteins that enter the
mitochondria from the cytoplasm 385,386. These proteins, present in the inner mitochondrial
space, are essential for cell viability and are functionally linked to the respiratory chain
385,387

. In addition, an erv1 mutant strain was shown to be deficient in respiration
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consistent with the metabolic shift from respiration to fermentation observed in auranofin
treated cells 369.

To further confirm the specific inhibition of the Mia40-Erv1 pathway by auranofin we
employed several biochemical experiments using purified yeast mitochondria similar to a
previous study that investigated the effect of several small molecule inhibitors of redoxregulated protein import into mitochondria 371. A possible indirect mechanism of inhibition
of mitochondrial function and the Mia40-Erv1 pathway is by the disruption of membrane
potential or diminished oxidative phosphorylation. Maintenance of membrane potential
was determined by mitochondrial uptake of DiSC3 (5) dye and subsequent quenching in
the presence of membrane potential. Auranofin had no effect on the membrane potential
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compared to DMSO whereas the uncoupling agent, CCCP, caused a 4-fold increase in
fluorescence indicating uncoupled mitochondria (Figure 3.5A).

The effect on

mitochondrial respiration was determined by measuring dissolved oxygen in a chamber
with purified mitochondria and respiration was initiated with NADH resulting in an oxygen
consumption rate (-0.45 O2 nmol/s) consistent with well-coupled mitochondria. The
addition of DMSO did not increase respiration rate and auranofin at a concentration of
34µg/mL only slightly increased the respiration rate (-0.64 O2 nmol/s) (Figure 3.5B). As a
control, the addition of CCCP resulted in a severe increase in consumption rate (-1.15 O2
nmol/s) suggestive of uncoupled mitochondria (Figure 3.5B). Overall, auranofin does not
have a generalized mode of action resulting in the disruption of membrane potential or
respiration and mitochondrial integrity is maintained in the presence of the compound.
To confirm that auranofin targets the Erv1/Mia40 pathway we measured the effect of
compound on the import of mitochondrial protein substrates compared to control
compounds previously identified as Erv1 inhibitors

371

. Radiolabeled precursor proteins

were incubated with mitochondria in the presence of small molecules or DMSO and the
reaction was terminated with protease and subsequently analyzed by gel electrophoresis.
Protein substrates from different import pathways were assessed including the Tim23
substrate, Su9-DHFR, and the Mia40 substrate, Cmc1. Auranofin at a lower concentration
of 6.8 µg/mL inhibits import of Su-DHFR to a 60% level and Cmc1 to a 25% level
compared to untreated samples (Figure 3.5C and 3.5D). These results indicate the
preferential activity of auranofin towards inhibiting Cmc1 import compared to Su9-DHFR,
which is expected because Cmc1 is directly imported by Mia40/Erv1.
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Figure 3.5 Auranofin does not impair general mitochondrial function but inhibits the import
of substrates of the Mia40 pathway. (A) Mitochondrial uptake and quenching of DiSC3(5)
dye when membrane potential is present. Dye fluorescence was measured as relative
fluorescence units (RFUs) in the presence of DMSO, auranofin and CCCP. (B) Respiration
of mitochondria was initiated by NADH followed by the addition of auranofin and CCCP.
Respiration levels measurements were performed using an oxygen electrode and rates
represent the consumption of O2 nmol/s. (C, D) Radiolabeled proteins Su9-DHFR and
Cmc1 were imported into mitochondria in the presence of varying concentrations of
auranofin and MB-7. (E) Non-reducing gel demonstrating the formation of the Cmc1Mia40 intermediate in the presence of auranofin, MB-6 and MB-7. (F) Auranofin inhibition
of protein import is dependent on in organello mitochondrial Erv1 expression level. Wildtype (WT) and Erv1 overexpressed (OE) mitochondria were treated with varying
concentrations of auranofin and the level of radiolabeled Cmc1 was detected. The asterisk
represents a large complex of unknown composition that is observed in most Mia40
precursor studies. Representative gels have been shown (n = 3).
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Strikingly, auranofin exhibits more potent activity than control compound, MB-7 with a
drastic difference in import efficiency observed between the compounds at 10 M
(6.8µg/mL for auranofin and 8.5µg/mL for MB-7; Figure 3.5D). Although auranofin does
inhibit Su9-DHFR import at high concentrations, these results demonstrate the compound
has specificity towards the Mia40 pathway and increased potency compared to previously
identified inhibitors from a large-scale chemical library screen 371. It is not surprising that
the import of Su9-DHFR is mildly inhibited because mitochondrial import pathways are
interconnected. Mia40 has previously been demonstrated to form an intermediate with
Cmc1 as part of the import process 389,390. The effect of compounds on the formation of a
disulfide intermediate between Mia40 and Cmc1 was monitored in organello. Auranofin
inhibits radiolabeled Cmc1 from interacting with Mia40 in a similar dose dependent
manner to MB-7 (Figure 3.5E). The addition of another control, MB-6, causes the
accumulation of the intermediate. In sum, auranofin inhibits the heterodimer formation of
the Mia40-Cmc1 intermediate and is a potent inhibitor of the Mia40 import pathway.

To further validate the Mia40 pathway as a target of auranofin, import of Cmc1 was
performed with mitochondria from WT and Erv1 overexpressing yeast.

Erv1

overexpression is expected to maintain the Mia40 pool in an oxidized state, which is
required for the interaction with substrate proteins 373,391 and hence should be more resistant
to auranofin inhibition. As predicted, the Erv1 overexpressing mitochondria were resistant
to auranofin (3.4 µg/mL) treatment as evidenced by the increased level of Cmc1 (60%)
import compared to WT (30%) mitochondria providing further confirmation of Mia40 as
a target (Figure 3.5F).
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It should also be taken into account the affinity of auranofin to human Mia40 protein. The
central part of the human homolog of Mia40 shares high sequence identity with most of its
eukaryotic analogues. However, Mia40 in yeast differs from its human homolog in one
major respect – yeast Mia40 lacks the N-terminal extension including a transmembrane
region

386

. Future studies are needed to examine the affinity and binding of auranofin to

Mia40 and in vivo studies will determine if Mia40 function is affected. It may be possible
that a therapeutic window exists because human Mia40 is not accessible or affected by
auranofin at the concentrations needed for antifungal activity.

Previous studies in bacteria and parasites proposed thioredoxin reductase (TrxR) to be the
target of auranofin
by Parsonage et al.

263,264

392

. However, a recent crystallographic study conducted

revealed that auranofin most likely does not bind to the cysteine

residues in TrxR of Entamoeba histolytica. As it pertains to yeast, Gamberi et al. used
homozygous deletion strains and demonstrated that deletion of the mitochondrial
thioredoxin reductase (TRR2) or glutathione reductase (GLR1) genes in S. cerevisiae do
not display resistance to auranofin 369. However, the effect of auranofin on the cytoplasmic
thioredoxin reductase (TRR1) gene was not explored in their study

369

. Results from our

investigation indicate that the heterozygous deletion strain (trr1) behaves similar to the
wild-type (Figure 4b). We therefore conclude that auranofin does not primarily target the
thioredoxin reductase in yeast or fungi, which is in agreement with a previous study 369.
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In vivo efficacy of auranofin in C. neoformans infected C. elegans model
To investigate if the in vitro antifungal activity of auranofin translates in vivo, the
antifungal efficacy of auranofin was examined in a C. neoformans-infected C.
elegans animal model. As shown in Figure 3.6, treatment of infected C. elegans with
fluconazole, flucytosine and auranofin, at 8 µg/mL, produced a significant reduction (P ≤
0.01) in mean fungal load when compared to the untreated control groups.

Figure 3.6 Efficacy of auranofin in C. neoformans-infected C. elegans. L4-stage worms
were infected with C. neoformans and treated with auranofin, fluconazole, and flucytosine,
at a concentration of 8 μg/mL. After 24 h, worms were lysed and plated onto YPD plates
to determine the CFU per worm. Each dot represents average fungal load in each worm per
well. The results are presented as means ± SD (n = 3). Statistical analysis was calculated
using the two-tailed Student’s t test. P value of (** P ≤ 0.01) are considered as significant.

Strikingly, C. elegans treated with auranofin (8 µg/mL) generated the largest reduction in
C. neoformans CFU (0.87±0.03 log10), followed by fluconazole (8 µg/mL) (0.82±0.03
log10) and flucytosine (8 µg/mL) (0.58±0.11 log10) (Figure 3.6). Altogether, results from
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our study suggest that auranofin, with its unique mechanism of action and potent in vivo
antifungal activity, warrants further investigation as an antifungal agent to combat drugresistant fungal infections.

3.2

Ebselen exerts antifungal activity by regulating glutathione (GSH) and
reactive oxygen species (ROS) production in fungal cells

(S. Thangamani, H. E. Eldesouky, H. Mohammad, P. Pascuzzi, L. Avramova, T. R. Hazbun
and M. N. Seleem. Ebselen exerts antifungal activity by regulating glutathione (GSH) and
reactive oxygen species (ROS) production in fungal cells. “BBA- General Subjects”-Under
Review.)

3.2.1
Ebselen

Introduction

(2-phenyl-1,2-benzisoselenazol-3(2H)-one)

is

an

organoselenium

compound that is known to possess anti-atherosclerotic, anti-inflammatory, antioxidative,
cytoprotective, anti-mutagenic and anti-lipoperoxidative properties

59-62

. Several studies

have demonstrated that ebselen, due to its highly electrophilic nature, interacts with
cysteine rich proteins (such as thioredoxin) and non-proteins (thiols)

60,393-399

. Ebselen

specifically interacts with free thiols such as glutathione (GSH) to form ebselen selenenyl
sulfide; this intermediate catalyzes reactive oxygen species (ROS) formation. Interestingly,
ebselen selenenyl sulfide can be reduced by GSH to form ebselen selenol. This particular
intermediate functions as a ROS scavenger, and thereby protects the cell from free radical
damage

60,394,395

. As a clinically safe molecule, ebselen has been investigated for the
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treatment of various ailments such as arthritis, stroke, cardiovascular disease and cancer
60,63-66

.

In addition to the beneficial properties of ebselen in mammalian cells, ebselen has also
been investigated for its antimicrobial activity against multidrug-resistant Staphylococcus
aureus and Enterococcus

67,68,211,226,400,401

. Recently, we demonstrated that ebselen exerts

its antibacterial activity through the inhibition of protein synthesis in bacteria

211,226

.

Ebselen has also been shown to possess potent antifungal activity, though different
molecular targets have been proposed

69,402,403

. Studies by Billack et.al and Chan et.al

demonstrated that ebselen inhibits the plasma membrane H(+)-ATPase pump (Pma1p) in
yeast 69,403. Azad et.al proposed that ebselen inhibits glutamate dehydrogenase (GDH3) and
induces ROS production in yeast

404

. A follow-up study by their research group also

proposed that ebselen activates the DNA damage response and alters nuclear proteins in
yeast 405. The studies above highlight that the antifungal mechanism of action of ebselen is
challenging to elucidate and currently remains unresolved.
Given the tremendous pressure imposed by the emergence of resistance to antifungal
agents currently utilized in the clinic, identifying new classes of antifungal drugs remains
an unmet challenge 355,356,406,407. However, the traditional pathway for drug discovery is an
arduous process that yields few approved new antimicrobials annually. An alternative
approach steadily gaining support is utilizing drug repurposing to identify promising new
anti-infective agents and expedite their regulatory approval 210,356.
Based upon the preliminary data presented in literature, ebselen is a promising drug to
repurpose as a novel antifungal agent. However, additional research is necessary to
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elucidate ebselen’s antifungal mechanism of action. Thus, the objectives of our study were
to examine ebselen’s spectrum of activity against an array of fungal clinical isolates, to
deduce ebselen’s antifungal mechanism of action, and to confirm the drug’s in vivo efficacy
in two Caenorhabditis elegans animal models of fungal infection.

3.2.2 Materials and Methods
Fungal strains and reagents
Candida and Cryptococcus strains used in this study are presented in Table 1. RPMI
powder, MOPS and L-reduced glutathione were purchased from Sigma-Aldrich (St. Louis,
MO). Yeast peptone dextrose agar (YPD) (BD Biosciences, San Jose, CA), fluconazole
(Acros Organics, New Jersey), flucytosine and ebselen (TCI chemicals, Tokyo, Japan)
were purchased from commercial vendors.

Antifungal susceptibility testing
Antifungal susceptibility testing was done as per the National Committee for Clinical
Laboratory Standards M-27A3 (NCCLS) guidelines

361

. Briefly, five colonies from 24-

hour old cultures of Candida spp. or 48-hour old cultures of Cryptococcus were transferred
to 5 ml of sterile 0.9% saline (PBS). After adjusting to reach a McFarland standard 0.5,
fungal suspensions were diluted 1:2000 in RPMI 1640 buffered to pH 7.0 with 0.165 M
MOPS (RPMI-MOPS). The drugs (ebselen, ebselen, fluconazole, flucytosine and
amphotericin) were serially diluted and the minimum inhibitory concentration (MIC) was
determined as follows: (i) For fluconazole and flucytosine, the MIC was classified as a
significant decrease (approximately 50%) in visible growth compared to untreated controls;
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(ii) For ebselen and amphotericin B, the MIC was categorized as the lowest concentration
that produced no visible fungal growth. All experiments were carried out in triplicate wells.

Time kill assay
Cultures of Candida albicans and Cryptococcus neoformans at a dilution of 5 × 105
CFU/ml were treated with 5 × MICs of ebselen, fluconazole, flucytosine and amphotericin
B (in triplicate) in RPMI-MOPS, at 35°C. At specific time points, aliquots were collected,
serially diluted in PBS, and plated onto YPD agar plates. After incubation at 35°C for 2448 hours the fungal colony forming units (CFU) were obtained, as described elsewhere 362.

Chemogenomics profiling of Saccharomyces cerevisiae
The initial testing of Saccharomyces cerevisiae response to ebselen was performed with
the wild type BY4743 diploid strain, the isogenic parent to the heterozygous diploid
deletion collection. BY4743 was grown in YPD in 96-well plates with 1% DMSO or
ebselen in concentrations ranging from 10 to 200 M to determine a suitable level of
growth inhibition. Ebselen (25 µM) was used for haploinsufficiency profiling because it
delayed growth by 30% compared to the no drug control half-maximal optical density (OD).
All experiments were performed at 30°C and cultures were shaken at 300 rpm. A frozen
aliquot (200 µL) of the heterozygous deletion pool (Thermo Fisher Scientific, Waltham,
MA) was thawed and used to inoculate 2 mL of YPD and grown for 9 hours to reach an
OD600 of 4.0. The culture was diluted to an OD600 of 0.13 and either 1% DMSO or 25 µM
ebselen was added (three replicates each) and grown for 7 hours. The cultures were grown
again by diluting to an OD600 of 0.13 in 1 mL YPD with DMSO or 25 µM ebselen and
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grown for 8 hours, harvested and genomic DNA extracted using the YeaStar Genomic
DNA kit (Zymo Research, Irvine, CA). The UPTAGs were amplified by PCR with Phusion
Hot Start II High-Fidelity DNA polymerase at 0.02 U/µL (Thermo Fisher Scientific,
Waltham, MA) using 0.5 ng/µL genomic DNA. The 267 bp PCR product was
electrophoresed on an agarose gel and the DNA extracted using a QIAquick Gel Extraction
Kit (Qiagen, Valencia, CA). Purified DNA was measured using a Qubit instrument and
samples were normalized and mixed to a final concentration of 10 nM. Strains were grown
and maintained on media using standard practices 366.

The pooled PCR products were sequenced using standard Illumina sequencing in a HiSeq
2500 instrument. The reads were separated based on a 5 base multiplex tag unique for each
experiment and an average of 5 million reads per replicate was obtained. The UPTAG
barcodes in each experimental sample were separated based on a reference database of
recharacterized barcode sequences 367.
The resulting strain counts were imported into R and analyzed with edgeR 368. Sequencing
library sizes were normalized using default parameters. Only strains with one or more
counts in three or more samples were analyzed further. Differential representation of strains
was determined using the quantile-adjusted conditional maximum likelihood (qCML)
method. False discovery rates were determined to control for multiple testing.

Saccharomyces deletion strain haploinsufficiency validation
Overnight grown saturated cultures of yeast cells were diluted to 1 to 10 and further to 1 to
5000 before treating with indicated concentration of ebselen. After 24 hours of incubation,

206
yeast growth was monitored using a spectrophotometer (OD600) and the results were
expressed as percent growth rate for each strain compared to the untreated control group,
as described elsewhere 369.

Determining fungal growth with L-reduced glutathione supplementation
In experiments with L-reduced glutathione supplementation, indicated concentration of
glutathione was added to the fungal cultures (with or without ebselen) and the percent
growth rate or MIC was determined as described above.

Glutathione assay
The assay was conducted as per the manufacturer’s instructions (Glutathione assay kit from
Cayman chemicals, Michigan, USA). Briefly, saturated cultures of wild type and deletion
strains of S. cerevisiae cells were diluted to 1:5 in YPD broth and treated with ebselen (20
µg/ml) for 2.5 hours. After treatment, tubes were centrifuged. The cells were subsequently
washed once with cold water and followed by 1 × GSH MES buffer (supplied by the
manufacturer). After washing, cells were re-suspended in 250 µL of 1 × GSH MES buffer
and sonicated for 45 seconds. Tubes were centrifuged and the supernatant was collected
for the assay. An aliquot (50 µL) of cell supernatant was added to each well in a 96-well
plate and then 150 µL of the assay cocktail, prepared per the manufacturer’s guidelines,
was added. After two minutes of incubation, the intensity of yellow color produced was
measured using a spectrophotometer (OD410). The results are expressed either as
absorbance per ml or percent glutathione production relative to untreated control groups.
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Measuring ROS production in yeast cells
The Image-iT™ LIVE Green Reactive Oxygen Species (ROS) detection kit (Molecular
Probes, Inc. Eugene, OR) was utilized and the ROS production was measured as per the
manufacturer’s instructions. Briefly, saturated cultures of wild type and deletion strains of
S. cerevisiae cells were diluted to 1:5 in YPD broth and treated with ebselen (20 µg/ml) for
2.5 hours. Then 10mM of 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate
(carboxy-H2DCFDA) dye was added at a dilution of 1:500. After 2 hours of incubation,
the cells were washed once with PBS and the intensity of fluorescence produced was
measured using spectrophotometer or imaged by Leica confocal laser scanning microscopy.

Caenorhabditis elegans (C. elegans) infection study
C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) was used to investigate the antifungal
efficacy of ebselen, as described elsewhere 226,374. Briefly, L4-stage worms were infected
either with Cryptococcus neoformans NR-41292 or Candida albicans ATCC 10232 for
two-three hours at room temperature. After infection, worms were washed with M9 buffer
and treated for 24 hours either with DMSO or drugs (ebselen, amphotericin B, fluconazole,
and flucytosine), at indicated concentrations. Post-treatment, worms were washed,
disrupted using silicon carbide particles

226

, and the resulting suspensions were serially

diluted and transferred to YPD agar plates containing ampicillin (100 μg/ml), streptomycin
(100 μg/ml) and kanamycin (45 μg/ml). Plates were incubated for 24-48 hours at 35°C
before the colony forming unit (CFU) per worm was determined 66.
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Statistical analyses
Statistical analyses were done using GraphPad Prism 6.0 (GraphPad Software, La Jolla,
CA). P values were calculated using the Student t test. P values ≤ 0.05 were deemed
significant.

3.2.3

Results

Antifungal activity and killing kinetics of ebselen
Ebselen’s antifungal activity was examined against numerous clinical isolates of
Candida and Cryptococcus. Ebselen inhibited isolates of Candida albicans, C. glabrata,
C. tropicalis and C. parapsilosis at concentrations ranging from 0.5 to 2 µg/ml (Table 3.2).
Ebselen retained its potent antifungal activity against Cryptococcus neoformans and
Cryptococcus gattii, as the drug inhibited growth of these fungal species at concentrations
ranging from 0.5 to 1 µg/ml (Table 3.2).

In order to investigate the killing kinetics of ebselen against both C. albicans and C.
neoformans, a time-kill assay was conducted. Unlike fluconazole and flucytosine, ebselen
(at 5 × MIC) completely eradicated C. albicans ATCC 10231 and C. neoformans NR41291 within two hours of treatment (Figure 3.7). Ebselen’s fungicidal activity was
superior to amphotericin which required at least four hours to completely eliminate fungal
cells (Figure 3.7).
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Table 3.2. MIC of ebselen and control antifungal drugs against Candida and Cryptococcus
strains

Strains
C. albicans NR 29434
C. albicans ATCC 10231
C. albicans NR 29449
C. albicans NR 29435
C. albicans NR 29448
C. albicans NR 29437
C. albicans NR 29446
C. albicans NR 29453
C. albicans NR 29438
C. albicans ATCC 26790
C. albicans ATCC 24433
C. albicans ATCC 14053
C. albicans ATCC 90028
C. albicans NR 29366
C. albicans NR 29367
C. glabrata ATCC MYA-2950
C. glabrata ATCC 66032
C. tropicalis ATCC 13803
C. tropicalis ATCC 1369
C. parapsilosis ATCC 22019
C. neoformans NR-41291
C. neoformans NR-41292
C. neoformans NR-41296
C. neoformans NR-41295
C. neoformans NR-41294
C. neoformans NR-41297
C. neoformans NR-41298
C. neoformans NR-41299
Cryptococcus gattii - CBS1930
Cryptococcus gattii - R265
Cryptococcus gattii - Alg40
Cryptococcus gattii - Alg75
Cryptococcus gattii - Alg81
Cryptococcus gattii - Alg99
Cryptococcus gattii - Alg114
Cryptococcus gattii - Alg115
Cryptococcus gattii - Alg127

Fluconazole
(µg/ml)
4
2
2
4
>64
2
>64
2
2
2
4
4
4
>64
>64
4
2
2
1
1
1
1
2
2
4
8
4
4
2
1
2
8
8
8
8
8
4

Flucytosine
(µg/ml)
0.125
0.25
4
0.0625
0.0625
0.0625
0.25
0.0625
0.0625
0.0625
1
0.125
1
0.0625
0.0625
0.0625
0.0625
0.125
0.25
0.25
0.5
0.5
0.5
0.5
2
4
2
2
2
1
0.5
8
4
4
4
4
4

Amphotericin
(µg/ml)
1
0.5

1
2

1
0.5
1
1
0.5
0.5
1
1
1
1

2
2
2
2
1
2
2
2
2
2

1
1
1

2
4
2
0.5
0.5

1
2
1
1
1
1
0.5
0.5
0.5
0.5
0.5
0.5
1

Ebselen
(µg/ml)

2
2
1
1
0.25
0.5
0.5
0.5
1
1
1

0.5
0.5
0.5

0.5
0.5
0.5

0.5
0.5
1
1
1
1

2
2
2
2
2
2
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Figure 3.7 Killing kinetics of ebselen. An overnight culture of C. albicans ATCC 10231
and C. neoformans NR-41291 were treated with 5 × of ebselen, fluconazole, flucytosine
and amphotericin (in triplicate) in RPMI-MOPS and incubated at 35°C. Samples were
collected at indicated time points and plated onto YPD plates. Plates were incubated for
24-48 h prior to counting the colony forming units (CFU).

Glutathione as a potential target of ebselen
After verifying ebselen’s potent antifungal activity, we proceeded to investigate the
antifungal mechanism of ebselen. Chemogenomic profiling, using drug-induced
haploinsufficiency, was utilized due to its nature as a highly-specific technique to deduce
the molecular mechanism of unknown compounds

378-380

. Haploinsufficiency profiling

(HIP) allows for the simultaneous assessment of the sensitivity of the pooled genome-wide
set of heterozygous deletion strains due to the fact that each strain possesses a unique
synthetic DNA barcode. The method is an unbiased approach to find strains exhibiting the
most sensitivity to ebselen. After determining the concentration that reduced wild-type
growth by 30%, we used 25 M of drug to profile the pooled heterozygous strains in the
biological samples. PCR was used to amplify the unique UPTAG DNA barcodes located
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at the gene deletion site and the barcode abundance was tracked using Illumina sequencing.
The resulting counts were normalized and visualized using EdgeR.

We identified 33 heterozygous deletion strains that were under-represented based on a
FDR less than 0.01, when comparing ebselen treatment to DMSO. These strains were
enriched for glutathione metabolic process (p-value = 0.0026). In addition, we also
included additional heterozygous deletion strains based on previous chemogenomic
profiling using heterozygous and homozygous diploid strains. pma1 which was the fourth
ranked strain from a heterozygous screen 384; glr, gsh1, gsh2 hits from a homozygous
screen 384; ubx4, gsh1 trp2, brp1, ecm38, ylr287c, cts1, cda2, imh1 from a
homozygous screen 380; and rad4 from a heterozygous screen 380.

The heterozygous strains including gsh1, gsh2, glr1, trr1, trr2 fks1,
ylr287c, ylr282c, guf1, yle296w, est2, rrf1 and ycr006c experienced a
significant reduction in growth when exposed to ebselen (Figure 3.8A). Importantly, two
heterozygous deletion strains (gsh1 and gsh2) encoding genes involved in glutathione
(GSH) synthesis were the most sensitive to ebselen. A haploid set of these two deletion
strains (gsh1 and gsh2) was also tested. These haploid deletion strains (gsh1 and gsh2)
were not resistant to ebselen and exhibited increased sensitivity to ebselen when compared
to the diploid strains (Figure 3.8B). The results indicate that ebselen most likely does not
directly target the proteins (Gsh1 and Gsh2) involved in glutathione synthesis but somehow
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Figure 3.8 Glutathione as a potential target of ebselen. (A and B) The percent growth of
yeast cells (OD600 after 24 h) incubated with ebselen (2µg/ml) in YPD broth was
determined in relation to the DMSO treatment. The results are presented as means ± SD (n
= 3). (C) Saturated cultures of yeast cells were diluted to 1:5 and grown for 2.5 h. The
cells were sonicated and amount of glutathione was determined using glutathione assay kit.
The absorbance measured using spectrophotometer indicates the glutathione production in
each strain. (D) Yeast cells were treated with ebselen (20µg/ml) for 2.5 h and the
glutathione concentration was measured as indicated above. The results are expressed as
percent glutathione production relative to untreated control groups. Statistical analysis was
calculated using the two-tailed Student’s t test. P values of (* P ≤ 0.05) (** P ≤ 0.01) are
considered as significant.
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directly target the proteins (Gsh1 and Gsh2) involved in glutathione synthesis Based on the
fact that ebselen binds directly to GSH and depletes GSH levels, leading to apoptosis in
mammalian cells 398,408, we hypothesized ebselen exhibits a similar mode of action in yeast.
Glutathione levels in wild type (BY4743 and BY4741), heterozygous and homozygous
deletion strains (gsh1 and gsh2) were quantified using a glutathione assay kit. Results
indicate that all deletion strains experienced a significant reduction in GSH levels
compared to their respective wild-type strains (Figure 3.8C). Homozygous deletion strains
have a very low presence of GSH compared to their heterozygous strain counterpart (Figure
3.8C). However, treatment of homozygous deletion strains with ebselen further reduced
GSH levels (approximately by 40%) compared to untreated control groups. On the other
hand, the wild type and heterozygous deletion strains (gsh1 and gsh2) showed no
considerable decrease in GSH levels when treated with ebselen at this concentration
(Figure 3.8D). These results suggest that ebselen depletes intracellular glutathione levels
in yeast cells.

Depletion of glutathione by ebselen leads to increased ROS production
Glutathione plays a central role in maintaining redox-homeostasis in yeast

409,410

.

Significant decreases in GSH levels might lead to dysregulation of redox homeostasis and
in turn increase ROS production 398,408-410. Given that ebselen was shown to deplete GSH
levels in yeast cells, we investigated the effect of ebselen on ROS production. Basal level
of ROS production in wild-type and GSH deletion strains were quantified. As expected,
homozygous deletion strains (gsh1 and gsh2 displayed a considerable increase in ROS
levels compared to both the wild-type and heterozygous deletion strains (Figure 3.9A).
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Figure 3.9 Depletion of glutathione by ebselen leads to ROS production in yeast cells.
(A)Wild type and deletion strains of S. cerevisiae cells were grown in the presence of
carboxy-H2DCFDA dye and the intensity of fluorescence produced was measured using
spectrophotometer. (B and C) Yeast cells were grown in the presence of ebselen
(20µg/ml) for 2.5 h and incubated with carboxy-H2DCFDA dye to determine the
glutathione production by spectrophotometer or Leica confocal laser scanning
microscopy. The results are expressed as percent glutathione in ebselen treated cells in
relative to untreated control groups (B). Green fluorescence indicates the ROS production
in yeast cells (C). Statistical analysis was calculated using the two-tailed Student’s t test.
P values of (* P ≤ 0.05) (** P ≤ 0.01) are considered as significant.
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However, when exposed to ebselen treatment, all strains (except the gsh2 heterozygous
deletion strain) experienced a significant increase in ROS production (Figure 3.9B). As
expected, gsh1 and gsh2homozygous deletion strains exhibited the largest increase in
ROS production (almost two-fold increase) compared to untreated control groups (Figure
3.9B). These results were confirmed using confocal microscopy. As presented in Figure
3C, ROS production was prominently noticed only in the gsh1 and gsh2 homozygous
deletion strains. Collectively, the results support the notion that ebselen exerts its antifungal
activity by causing a sharp decrease in GSH levels that subsequently leads to increased
ROS production in yeast cells.

Supplementation of L-reduced GSH restored the cell growth
Based upon the above result, we hypothesized that GSH supplementation would
reverse the inhibitory effect in yeast caused by ebselen. As expected, supplementation with
L-reduced glutathione restored cell growth and reversed the inhibition caused by ebselen,
in a concentration-dependent manner (Figure 3.10). GSH, at 25 µg/ml, completely restored
the cell growth (Figure 3.10). In addition, the effect of GSH supplementation on
susceptibility of Candida and Cryptococcus strains to ebselen were also examined.
Interestingly, with GSH supplementation (0.25 mg/ml), all tested fungal strains including
C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. neoformans and C. gattii
become resistant to ebselen (MIC >128 µg/ml) (Table 3.3). On the other hand, the MIC of
control antifungal drugs (fluconazole and flucytosine amphotericin) was not altered with
GSH supplementation (Table 3.3). These results suggest a mode of action of ebselen that
is specifically reversed by elevated GSH levels.
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Figure 3.10 Supplementation of L-reduced glutathione restored the cell growth. Wild
type and deletion strains of S. cerevisiae cells were grown in the absence (or) presence of
indicated concentration of ebselen and glutathione and the percent growth rate (OD600
after 24 h) was determined by using spectrophotometer. Statistical analysis was
calculated using the two-tailed Student’s t test. P values of (* P ≤ 0.05) (** P ≤ 0.01) are
considered as significant.

Table 3.3 MIC of ebselen and control antifungal drugs against Candida and Cryptococcus strains
with L-reduced glutathione supplementation
Strains

Fluconazole
(µg/ml)
GSH (-)
GSH (+)
2
2
2
1
1
1
2
2
1
1
4
4
0.5
0.5
1
1
2
2
8
8
4
4

Flucytosine
(µg/ml)
GSH (-)
GSH (+)
0.25
0.25
0.0625
0.0625
0.25
0.25
0.125
0.125
0.25
0.25
0.0625
0.0625
0.0625
0.0625
1
1
2
2
4
4
1
2

Amphotericin
(µg/ml)
GSH (-)
GSH (+)
0.5
0.5
1
1
1
1
1
1
1
1
1
1
2
2
0.5
0.5
0.5
0.5
0.5
0.5
1
1

Ebselen
(µg/ml)
GSH (-)
GSH (+)
2
>128
1
>128
2
>128
2
>128
1
>128
0.5
>128
1
>128
0.5
>128
0.5
>128
1
>128
1
>128

C. albicans ATCC 10231
C. albicans - 18E
C. tropicalis ATCC 1369
C. tropicalis ATCC 13803
C. parapsilosis ATCC 22019
C. glabrata ATCC MYA-2950
C. glabrata LRA 85.10.75
C. gattii - R265
C. gattii - CBS1930
C. neoformans NR-41297
C. neoformans NR-41299
(-) indicates no supplementation and (+) indicates supplementation of L-reduced GSH (0.25mg/ml) to the
growth medium.
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In vivo efficacy of ebselen in infected C. elegans model
To investigate if the in vitro antifungal activity of ebselen translates in vivo, the
antifungal efficacy of ebselen was tested in a C. albicans and C. neoformans-infected C.
elegans animal model. As shown in Figure 3.11, treatment of infected C. elegans with
amphotericin, fluconazole, flucytosine and ebselen at 4 and 8 µg/ml, produced a significant
reduction (P ≤ 0.05) in mean fungal load when compared to the untreated control groups.
C. elegans treated with ebselen (8 µg/ml) completely eradicated C. albicans,.
Amphotericin (8 µg/ml) produced a 1.53±0.08 log10 CFU reduction which was nearly
identical to ebselen at 4 µg/ml (1.52±0.14 log10). Fluconazole, at 8 µg/ml, reduced the
burden of C. albicans by 1.36±0.07 log10 followed by amphotericin (4 µg/ml) (1.05±0.16
log10), flucytosine (8 µg/ml) (0.79±0.09 log10), flucytosine (4 µg/ml) (0.62±0.08 log10) and
fluconazole (4 µg/ml) (0.55±0.09 log10).

Figure 3.11 Efficacy of ebselen in C. albicans (or) C. neoformans-infected C. elegans. L4stage worms were infected with C. albicans or C. neoformans and treated with ebselen,
fluconazole, flucytosine and amphotericin at a concentrations of 4 and 8 μg/ml. After 24 h,
worms were lysed and plated onto YPD plates to determine the CFU per worm. Each dot
represents average fungal load in each worm per well. The results are presented as means
± SD (n = 3). Statistical analysis was calculated using the two-tailed Student’s t test. P
value of (** P ≤ 0.01) are considered as significant.

218
Treatment of C. neoformans-infected C. elegans with ebselen (8 µg/ml) also generated the
highest reduction in CFU count (2.31±0.02 log10), followed by amphotericin (8 µg/ml)
(1.98±0.13 log10), (1.97±0.09 log10), ebselen at 4 µg/ml (1.97±0.09 log10), amphotericin (4
µg/ml) (1.46±0.03 log10), fluconazole (8 µg/ml) (1.32±0.04log10), flucytosine (8 µg/ml)
(0.75±0.02 log10), fluconazole (4 µg/ml) (0.66±0.02 log10) and flucytosine (4 µg/ml)
(0.58±0.11 log10).

3.2.4
Fungal

infections

are

a

Discussion

significant

healthcare

immunocompromised individuals, such as HIV patients

challenge

411,412

particularly in

. Candida albicans is the

fourth leading cause of bloodstream infections in the United States and has been associated
with a high mortality rate (50%)

413,414

. In addition to infections caused by C. albicans,

Cryptococci, particularly C. gattii, are a major source of infections in humans.
Cryptococcal meningitis is a significant cause of mortality in HIV patients 412. The immune
system in these immunocompromised patients is not capable of eradicating these fungal
pathogens. Thus treatment is highly dependent on antifungal drugs successfully resolving
the fungal infection

356

. Unfortunately, recent clinical reports indicate current antifungal

therapies are not effective in treating invasive fungal infections

355

. Further compounding

this problem, the number of antifungal drug classes currently available to clinicians is
limited. This issue is exacerbated by the fact that resistance to antifungal agents is
increasing and many current antifungal agents exhibit unusual toxicities thus further
restricting their use

355,356,406,407

. This highlights the pressing need to identify new

antifungal drugs to combat these dangerous pathogens. The traditional route of antifungal
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innovation and regulatory approval is a time-consuming, expensive venture. This has led
researchers to explore alternative approaches, such as drug repurposing, to expedite antiinfective drug development 210,356.

Ebselen is an organoselenium compound that is currently undergoing clinical trials
for the prevention and treatment of cardiovascular disease, arthritis, stroke, atherosclerosis,
and cancer

60,63-66

. In an intensive search for non-antifungal drugs exhibiting antifungal

activity, we and others 69,402,403 demonstrated that ebselen possesses potent broad-spectrum
fungicidal activity against Candida and Cryptococcus spp with the MIC values ranging
from 0.5 to 2 µg/ml. Although, its antifungal activity has been reported before, the
antifungal mechanism of action and in vivo efficacy of ebselen remains unclear with several
potential targets proposed

68,69,402,403

. In the present study, we demonstrated that ebselen

reduces GSH concentration in yeast cells leading to dysregulation of redox homeostasis.
These results correlate with studies conducted by Yang et.al and Shi et.al that reported
ebselen depletes GSH levels in mammalian cells, ultimately leading to apoptosis 398,408.

Although, ebselen has been shown to have an antioxidant effect and protects cells
from free radical damage, it has also been shown to cause apoptosis by reducing thiol levels
in mammalian cells 398,408. The present study indicates that ebselen also exhibits a similar
mode of action in yeast cells. Decreased GSH levels subsequently leads to increased ROS
production thereby placing cells under oxidative stress. This finding is in agreement with
a recent study by Ngo et. al that demonstrated ebselen treatment induces ROS in Candida
albicans

402

. In addition, Azad et. al proposed that ebselen increases ROS levels in yeast
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by inhibiting the Gdh3 enzyme involved in glutathione synthesis

404

. However, we found

that gdh3 heterozygous and haploid deletion strains were not susceptible to ebselen
compared to both the gsh1 and gsh2 deletion strains. Studies conducted by Billack et.
al and Chan et. al proposed that the plasma membrane H(+)-ATPase pump (Pma1) is the
potential target of ebselen in yeast

69,403

. However, we also confirmed that the pma1

heterozygous deletion strain does not experience significant growth impairment when
exposed to ebselen relative to the gsh1 and gsh2 deletion strains. Many of the proposed
targets for ebselen have been demonstrated via biochemical based assays in which it is
difficult to assess the specificity of ebselen for the protein target compared to other targets
especially because of the molecules reactivity to cysteines. Collectively, results from our
study demonstrate that ebselen reduces intracellular GSH concentration leading to
dysregulation of redox homeostasis and that deficiency in glutathione biosynthesis
exacerbates this mode of action.

Glutathione is an essential metabolite required to protect yeast from oxidative stress
409,410,415-418

. S. cerevisiae lacking c-glutamyl cysteine synthase (Gsh1), the first enzyme in

glutathione biosynthesis leads to glutathione autotrophy in which the cells dependent on
exogenous GSH for its growth and survival

419,420

. In the absence of endogenous GSH,

yeast has the ability to uptake GSH from an environment through high-affinity glutathione
transporters such as Hgt1 419-421. In the present study, we also demonstrated that gsh1 and
gsh2 homozygous deletion strains has relatively low amount of basal GSH when
compared to wild type and the counterpart heterozygous deletion strains. The GSH
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observed in the gsh1 and gsh2homozygous deletion strains is likely derived from
growth medium. The presence of low amount of GSH in these deletion strains was further
depleted by ebselen treatment and in turn places cells in oxidative stress. Importance and
essentiality of GSH has also been demonstrated in other fungi species including Candida
416,421

, suggesting that glutathione might form an attractive novel target for the development

of new antifungal drugs

422-424

. Future studies are required to delineate the interaction

between ebselen and yeast GSH, and also the affinity of ebselen towards mammalian GSH.

Chemogenomic profiling was employed in this study, and it identified 33
heterozygous deletion strains sensitive to ebselen that were under-represented based on an
FDR less than 0.01. However, the hits recovered did not include the GSH1 or GSH2 genes.
It is also interesting to note that these strains were also not identified as hits in other
heterozygous chemogenomic profiling screens employed by two other groups

380,384

.

Potential hits obtained using this technique greatly depend on (i) the concentration of the
drug/compound used to test the deletion pool (ii) Many technical factors such as the PCR
quality and number of reads. These factors should be taken into consideration when
utilizing chemogenomic profiling to identify the mode of action of unknown compounds.

The final segment of this study investigated the in vivo antifungal efficacy of ebselen
in a C. albicans and C. neoformans-infected C. elegans animal model. Ebselen, at 8 µg/ml,
completely eradicated the C. albicans load and produced a more than two- log10 reduction
in C. neoformans CFU load. Ebselen’s antifungal activity was found to be superior to
currently approved antifungal drugs including amphotericin, fluconazole and flucytosine
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in reducing the fungal load in the C. elegans animal model. These results lay a strong
foundation for future studies to test the antifungal efficacy of ebselen in appropriate mice
models of fungal infection. Ebselen is also known to be capable of crossing the blood brain
barrier 66. This quality provides an added advantage to investigate the potential use of this
drug for the treatment of Cryptococcal meningitis infections particularly in HIV patients
66,412

.
In conclusion, the present study confirms ebselen, with its unique mechanism of

action and potent in vivo antifungal activity, is a promising clinical molecule that
necessitates further investigation for repurposing as a novel antifungal agent.
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